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There is a theory which states that if ever anyone discovers exactly what the
Universe is for and why it is here, it will instantly disappear and be
replaced by something even more bizarre and inexplicable.
There is another theory which states that this has already happened.
– Douglas Adams (The Restaurant at the End of the Universe)
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A B S T R A C T
For centuries evolution has been investigated with an "end-point" ap-
proach, through comparisons between species or fossil records. How-
ever, to understand processes in general, including evolution, it is
highly valuable to observe the dynamics as they unfold, in "real-
time".
This is possible through laboratory experiments, with a high degree
of control and rigour. But to truly understand evolution and the com-
plex mechanisms it deploys, it is necessary to combine the laboratory
learnings with investigations of natural systems. –Though, this can
be tricky. Because of the heterogeneity and constant change of nat-
ural environments, the primary obstacle is re-sampling of the same
population over time, especially if the population is small.
Nevertheless, it has been accomplished: Chronic airway infections of
cystic fibrosis (CF) patients have offered a unique view into the ad-
aptation and evolution of Pseudomonas aeruginosa to this natural envir-
onment, spanning thousands of bacterial generations. Because of the
prolonged and persistent infections, they provide a valuable model
system for the investigation of evolutionary mechanisms.
The main focus of this thesis has been to show the link between evol-
utionary studies in the CF model system and general evolutionary
theories, many of which have been developed from observations of
other organisms.
This comparison has initially been sought by showing the plausibility
of using comprehensive collections of longitudinally sampled single
isolates, for their use in evolutionary studies (Study 1). This was done
by comparing five metagenomes with single isolates from four CF
patients, and identifying significant genetic links found within the
patient specific P. aeruginosa populations. This evident genetic link
was even found for two populations, where a recent patient-to-patient
transmission had occurred.
Secondly a comprehensive collection of 474 longitudinal single P. aer-
uginosa isolates from 34 young Danish CF patients was investigated
by whole genome sequencing (Study 2). This was done to reconstruct
the recent evolutionary history, and identify genes targeted in the
initial adaptation to the CF airways. From this analysis we found
common clonal lineages among the patients, evidence of patient-to-
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patient transmission, historic contingencies, and convergent evolution
of 52 candidate pathoadaptive genes.
By further genome sequencing 26 P. aeruginosa isolates from four
Italian CF patients (Study 3), and 35 P. aeruginosa isolates from 12
primary ciliary dyskinesia (PCD) patients (Study 4), we were able
to find genetic and phenotypic links across countries and diseases.
All three studies (not including the metagenome study) had common
clonal lineages and clear overlaps of genetic adaptational patterns.
However, the genetic overlap between CF and PCD isolates did not ex-
tend to a phenotypic overlap, which indicates that the mucus, which
is different in CF patients compared to PCD patients, is a significant
selective factor for the evolution and adaptation of P. aeruginosa to
these environments.
Independently and together the studies presented in this thesis provide
new knowledge of adaptation and evolution in both CF and PCD air-
ways. With further characterisation of genetic and phenotypic adapt-
ations it should be possible to translate these results into clinically
relevant information, leading to better epidemiological predictions,
valuable information with regards to treatment strategies, and per-
haps extrapolation of this knowledge to other infection scenarios.
OVER ALL: Through the convergence of genetic and phenotypic ad-
aptations observed in CF studies and by linking processes of evolu-
tion to these observations, this thesis shows that collections of longit-
udinal P. aeruginosa isolates from CF patients provide a valuable basis
for the study of adaptation and evolution in natural environments.
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D A N S K R E S U M É
I århundreder har man undersøgt evolution ved at bruge en "end-
point" fremgangsmåde. Det vil sige, at man primært har lavet sam-
menligninger imellem arter og ved lejlighed fossiler. Men for at kunne
forstå processer generelt, inklusiv evolution, er det uvurderligt at
kunne undersøge processen undervejs og derved observere den "live".
Dette er muligt gennem laboratorieeksperimenter på grund af den
høje grad af kontrol og klarhed. Men for at få en sand forståelse af
evolution og de komplekse mekanismer det indebærer, er det nød-
vendigt at kombinere laboratorieforsøg med undersøgelser af natur-
lige miljøer.
På grund af heterogeneciteten og den konstante forandring af natur-
lige miljøer er den primære forhindring i dette tilfælde observationen
af den samme population over tid, specielt hvis populationen er lille.
Ikke desto mindre har det vist sig at være muligt: Kroniske luftvejsin-
fektioner hos cystisk fibrose (CF) patienter har vist sig at give et
enestående indblik i adaptation og evolution af Pseudomonas aeru-
ginosa til dette naturlige miljø. Det har tilmed været muligt at følge
denne proces over tusinder af bakterielle generationer. På grund af
den langvarige og persisterende kolonisering og infektion af disse
patienter, er CF infektionssystemet en værdifuld model til undersø-
gelser af evolutionære processer.
Det primære fokus for denne afhandling har været at vise links imel-
lem evolutionære studier fra CF modelsystemer og generelle evolu-
tionsteorier, hvoraf de fleste oprindeligt blev udviklet via observa-
tioner fra andre organismer.
Denne sammenligning blev i første omgang forsøgt ved at påvise mu-
ligheden for at bruge omfattende longitudinelle isolat samlinger til
studier af evolution (Studie 1). Dette blev opnået ved sammenligning
af fem sputummetagenomer med longitudinelle enkeltisolater fra fire
CF patienter og identifikationen af klare genetiske links indenfor den
enkelte patients specifikke P. aeruginosa population. Dette genetiske
link mellem enkelte isolater og metagenomer blev tilmed påvist for
to populationer, hvor en umiddelbar patient-til-patient transmission
havde foregået og derved øget ligheden imellem de to populationer
signifikant, i forhold til populationerne fra de andre patienter.
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Efterfølgende blev en omfattende samling af 474 longitudinelle P. aer-
uginosa isolater udsat for hel-genom sekvensering (Studie 2). Disse
isolater stammede fra 34 unge Danske CF patienter. Denne samling
blev analyseret for at rekonstruere den umiddelbare evolutionære his-
torie og identificere gener, der var vigtige for den indledende adapta-
tion til CF luftveje. Fra denne analyse identificerede vi fælles klon-
typer mellem patienter, beviser for patient-til-patient transmission,
historiske sammenhænge mellem mutationer og konvergerende evol-
ution af 52 kandidat pathoadaptive gener.
Yderligere sekvensering, af 26 P. aeruginosa isolater fra fire Italienske
CF patienter (Studie 3) og 35 P. aeruginosa isolater fra 12 primær cilie
dyskinesi (PCD) patienter (Studie 4), gjorde os i stand til at finde ge-
netiske og fænotypiske links på tværs af landegrænser og sygdomme.
Alle tre studier (ikke inkluderende metagenom studiet) havde fælles
klontyper og klare overlap af adaptive mutationer. Men det genet-
iske overlap imellem CF og PCD isolater kunne ikke udvides til at
inkludere fænotypiske overlapninger, hvilket indikerer, at det slim,
der findes i luftvejene, og som er markant anderledes for CF patienter,
er en signifikant selektionsfaktor for evolutionen og adaptationen af
P. aeruginosa i disse miljøer.
Uafhængigt af hinanden, men også i kombination giver de studier
præsenteret i denne afhandling ny og udvidet viden omkring adapt-
ation og evolution til både CF og PCD luftveje. Ved yderligere karak-
terisering af genetiske og fænotypiske adaptationer burde det være
muligt at oversætte disse resultater til klinisk relevant information,
der kan lede til vigtig viden med hensyn til behandlingsstrategier og
muligvis også ekstrapolation til andre infektionsscenarier.
OVERORDNET: Igennem den konvergerende genetiske og fænotyp-
iske adaptation, som er observeret i CF studier og ved at linke dette
til evolutionære processer viser denne afhandling at samlinger af lon-
gitudinelle P. aeruginosa isolater fra CF patienter giver en værdifuld
basis for studier af adaptation og evolution i naturlige miljøer.
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1
O V E RV I E W A N D S T R U C T U R E O F T H E S I S
1.1 overview
This thesis is meant to give a general description of cystic fibrosis (CF)
as a model system, where continuous sampling of bacterial popula-
tions can be used for the investigations of adaptation and evolution
to new environments.
Together with laboratory experiments, this model system makes it
possible to identify the impacts of different evolutionary mechanisms
and processes in a natural environment. This is important both in clin-
ical settings and in industrial settings, for the understanding and de-
velopment of improved production strains and treatment strategies.
1.2 structure of thesis
This thesis is organised in four chapters:
Chapter 1 (the current chapter) is a general introduction to the thesis
as a whole.
Chapter 2 includes a theoretical background to evolutionary processes
and link these to previous findings from studies of CF, as well as the
major findings of the papers included in this thesis. This is done by
including short descriptions of the papers (Study 1 to 4), when neces-
sary.
Chapter 3 includes the overall conclusions and future perspectives.
Chapter 4 encloses the full-length research articles included in this
thesis.
1

2
C Y S T I C F I B R O S I S A S A M O D E L S Y S T E M
2.1 introduction
Evolution is a process that has shaped the world and the remarkable
diversity we see around us, and the ability to understand this process
will take us closer to understanding life as we see it today. This under-
standing includes the bigger questions of how life has evolved, but
also the smaller, more pressing questions, of resistance development
in microorganisms and how to develop the best production strain for
a given product, which could be an antibiotic.
For centuries evolution has been investigated by comparative studies
of living organisms, by investigating differences between species ori-
ginating from the same ancestor, including comparisons with fossil
records. The common denominator being the "end-point" approach
focusing on fundamental differences or similarities between species,
not as they evolve but as they have evolved [1, 2]. However, to under-
stand processes in general, including evolution, it is highly valuable
to observe the dynamics as they unfold, on account of the degree of
detail that cannot be found by "end-point" comparisons[3].
With their manageable genomic complexity and fast growth, bacteria
make ideal model organisms and because of the advent of modern
technologies we are now capable of observing and investigating evol-
ution as it is unfolding in "real-time", both phenotypically and geno-
typically. This entails investigations of processes of speciation, where
invasion of new niches bring about alternate selective pressures for-
cing the bacterial organisms to adapt and evolve through natural se-
lection.
To explain, NATURAL SELECTION acts on variation within a pop-
ulation by increasing the abundance of organisms with the highest
reproductive success, also called FITNESS, in a given environment of
specific SELECTIVE PRESSURES. In other words, when an organism
is subjected to a selective pressure (e.g. antibiotics) it needs to adapt
(e.g. antibiotic resistance), and this is done through the force of nat-
ural selection[3, 4].
By the use of bacterial populations it is possible to observe the nature
and mechanisms of interactions between an organism and its sur-
roundings, which forms the basis of adaptation and evolution. How-
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ever, in most natural environments, if not all, the complexity of evolu-
tion and the difficulties of re-sampling the same population over time
obscure the patterns of interaction. But without the complexity, posed
by natural environments, the interplay and the complete picture can-
not be achieved[3].
There is one natural environment where the study of evolution in
"real time" has been found possible: cystic fibrosis (CF) airway infec-
tions. By investigating airway infections of patients with CF it has
been possible to follow the same clonal lineage over a time period of
approximately 35 years[5].
However, the complexity of natural systems, such as the CF airway
infections, results in difficulties of data interpretation. To abate this,
it is necessary to combine these learnings with those gained from
controlled and rigorous laboratory studies. Through this fusion of
knowledge it is possible to deduce theories concerning the intricate
interplays of evolutionary processes, important for the understanding
of life as we see it today.
When investigating evolution through bacterial populations it is im-
portant to be aware that not all mechanisms can be directly translated
to all other organisms. Primarily because the mechanisms of speci-
ation, diversity maintenance, and diversity generation in organisms
with sexual reproduction can be markedly different from asexual or-
ganisms, such as bacteria[6, 7, 8].
Nevertheless, in many cases this extrapolation is possible, which will
be illustrated by connecting investigations of bacterial populations
from CF infections, with general evolution theories, – which in most
cases have been developed from observations of other organisms.
Through the same connections the possibility of using CF infections
as model systems for the investigation of evolutionary processes will
also be evident.
2.2 laboratory evolution
Laboratory evolution studies, which posses a high degree of con-
trol and rigour, are one aspect of the investigation of evolution. This
is achieved by the simple set-up, where a population, or multiple
populations is established from a common ancestor, which can then
be propagated either by serial transfers or in chemostats (Figure 1).
Both the ancestor as well as subsequent serially collected samples
are stored as time passes (in most cases at -80◦C) as a "fossil record".
The stored samples can then be utilised in additional experiments
2.2 laboratory evolution 5
of how evolution and adaptation has progressed, by phenotypic and
genotypic analyses. For quantitative measurements of evolution, fit-
ness can be assessed by competition assays between ancestors and
evolved lines[3]. With fitness, in this case, being the ability to pro-
duce descendants or survive under a specific selective pressure, such
as the presence of antibiotics. The most important aspect of fitness
measurements is to measure it in the environment where the organ-
isms were initially evolved[9, 3].
All in all, this active investigation gives a more detailed understand-
ing of the process of evolution than passively comparing traits between
extinct and present day organisms.
Time
Transfer of cells Media supply
Spent media
A) Serial transfer B) Chemostat
Figure 1: Serial Transfer and Chemostats. A) In a serial transfer experiment
a bacterial isolate is cultured, and part of this culture is later trans-
ferred to fresh medium when appropriate. B) In a chemostat, fresh
medium is continuously added to the system and liquid culture is
continuously removed to keep the volume constant. It is possible
to control the growth rate by changing the rate of media flowing
into the system, giving additional control as compared to the serial
transfer.
The longest running laboratory evolution experiment was set up in
1988 with Escherichia coli as the study organism and it has been run-
ning ever since, corresponding to more than 60,000 bacterial genera-
tions[3, 10]. This is carried out in a controlled environment of serial
transfers of 12 lineages originating from the same ancestor.
This use of low-complexity laboratory environments surpass the prob-
lems found when investigating evolution in natural systems, which
are much more complex.
However, in nature, we rarely find organisms as isolated pure cul-
tures or in meticulously controlled environments, making the find-
ings of laboratory experiments difficult to extrapolate. Therefore, to
fully understand evolution it is necessary to pair the laboratory find-
ings with findings from natural systems. Because only in natural and
complex environments are the intricate interplays between the evolu-
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tionary mechanisms fully present.
2.3 evolution in natural environments
Continuous sampling of a single or a few clonal lineages from natural
populations is generally difficult, - if not impossible. Either because of
temporal fluctuations and physical disturbances or because the pop-
ulation of interest is small.
Despite these difficulties of re-sampling, one natural system has proven
to be useful: By investigating airway infections of patients with CF, it
has been possible to re-sample the same bacterial lineage of Pseudo-
monas aeruginosa, also called clone type DK2, over a time period ac-
counting for more than 200,000 bacterial generations[5].
CF is an autosomal recessive disease, which is caused by mutations in
the Cystic Fibrosis Trans-membrane Conductance Regulator (CFTR)
gene, encoding a Chloride-ion channel[11]. The mutation of the Cl-
channel causes it to malfunction to a higher or lower degree[12] res-
ulting in a thick dehydrated mucus on all mucociliary surfaces in
the body. Among other things, this leads to an impaired mucociliary
clearance of the upper airways and thence an elevated risk of airway
infections[13, 14]. In congruence with this, CF patients are continu-
ously colonised and infected by a multitude of microbes, with the
most prevalent being Staphylococcus aureus and Haemophilus influenzae
in childhood and P. aeruginosa in adulthood (Figure 2)[15, 16].
Because of this high rate of bacterial infections CF patients are treated
with large amounts of antibiotics[17], resulting in increased resistance
development of the infecting species.
This thesis will primarily be focused on P. aeruginosa, since this is
the organism found to cause colonisation and chronic infection in the
majority of CF patients (Figure 2); It has a prevalence among the 26+
years old CF patients of >70% [15, 16], thus providing a broad basis
for evolutionary studies. Furthermore it is able to cause colonisation
and infection in a variety of other settings, such as chronic wounds
and general nosocomial infections[18, 19]. Also, it has the ability to
rapidly gain resistance towards multiple antibiotics[20], causing in-
creased morbidity and mortality for infected patients[19]. Thereby
making P. aeruginosa highly relevant for infection studies, as well.
2.3 evolution in natural environments 7
Non-infected
Pseudomonas aeruginosa
Total number of patients
0
5
10
15
20
25
30
35
40
45
0-5 5-10
10-15
15-20
20-25
25-30
30-35
35-40
40-45
45-50
50-55
55-60
Age of patients (years)
N
um
be
r o
f p
at
ie
nt
s
Figure 2: Chronic Infection of CF Airways by Pseudomonas aeruginosa in
2008. Number of CF paients in the Danish CF clinic who were
registered as chronically infected with P. aeruginosa (blue) or not
infected with a Gram-negative bacterium (white with black out-
line). Chronic infections by other Gram-negative species are not
shown. Data provided by Tacjana Pressler, DMSc, Copenhagen CF
database, 2008.
2.3.1 CF and Laboratory Experiments
When using an environment as the CF airways as a model system for
evolution, it is valuable to make further investigations in controlled
environments such as laboratory experiments. However, an optimal
approach is to replicate the environment, where the evolution initially
took place as much as possible, which can be difficult in the case of
the CF model system[9].
In many studies of CF infections the phenotypic analyses are carried
out in regular laboratory media[21, 22, 23, 24], with little resemb-
lance to the mucus of the CF airway environmen t[9, 25, 26]. Not
surprisingly, these differences in media composition and physical
factors have been found to have a significant impact on phenotypic
traits[9, 27, 28, 29].
However, we are slowly approaching a medium closely resembling
the nutritional and physical aspects of CF sputum, called artificial
sputum medium (ASM)[25, 26], showing similar phenotypic results
for P. aeruginosa as found when using CF sputum as medium.
The introduction of ASM to the laboratory enables us to approach an
experimental set-up more closely resembling the environment found
in the CF sputum[26], and should further increase our knowledge
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of the actual phenotypic adaptations found in the airways of CF pa-
tients.
2.3.2 Environmental Heterogeneity
The human airways are spatially heterogeneous, and can be roughly
divided into the lower and upper airways, with the upper airways
including the paranasal sinuses.
The sinuses are small air filled cavities situated in the cranium, with
a different immune response and reduced antibiotic concentrations,
compared to the lower airways. This is why they are considered
to be a protected niche for bacteria, during airway infections of CF
patients[30]. This will be addressed later in section 2.6 on page 19.
This spatial heterogeneity is predicted to result in adaptive radiation[4].
ADAPTIVE RADIATION is the adaptation of different sub-populations
to different vacant niches. These could be the lungs or the sinuses of
the human airways, where the different sub-populations become bet-
ter equipped to proliferate in one environment (niche) compared to
another.
Adaptive radiation has been shown in laboratory experiments in-
volving Pseudomonas fluorescens in static cultures, where the stratific-
ation of the liquid media selected for three different phenotypic sub-
populations[31]. It has also been shown for P. aeruginosa populations
in CF, both by Markussen (2014)[21] and Jorth (2015)[32].
However, in an environment such as the CF airways, we have both
chemical and physical temporal disturbances working against ad-
aptive radiation, such as antibiotic treatments, physiotherapy, and
perturbations. This results in a population that, theoretically, would
evolve into GENERALISTS with a higher average fitness, instead of
NICHE SPECIALISTS with a temporarily optimal fitness[4], Figure 3.
Despite what the theory dictates, the heterogeneity of bacterial pop-
ulations in CF airway infections is evident from several studies of
longitudinal single isolates, showing the presence of multiple contem-
porary sublineages. As an example, the phylogenetic reconstruction
of 55 DK2 isolates from 21 Danish CF patients showed evidence of
the following scenarios: Stable existence of a single clonal sublineage;
stable coexistence of multiple independent sublineages, possibly due
to niche differentiation; and sequential dominance of competing sub-
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Figure 3: Niche Specialisation. Relative fitness for three populations, one
which is adapted and specialised to environment A (blue), one
which is adapted and specialised to environment B (green), and a
generalist (grey), with a high average fitness.
lineages within the same patient[33].
NICHE DIFFERENTIATION is a process where natural selection drives
organisms into different niches, either spatially or nutritionally. In
other words, this process makes co-existence of different sublineages
possible, by forcing them to use different resources and thereby hinder-
ing a diversity collapse caused by niche exclusion[34]. NICHE EX-
CLUSION is a process that results in a single genotype occupying the
single niche provided by a perfectly homogeneous environment[35].
Niche differentiation is a process with which sympatric speciation can
occur. SYMPATRIC SPECIATION is more commonly used to describe
a specific speciation mechanism for sexually reproducing organisms,
where different species evolve in overlapping or even identical ecolo-
gical niches. In the example of DK2[33] it can be transferred to the
generation of sub-speciation events seen in bacterial populations in
CF.
The study of DK2 was based on longitudinally collected single isol-
ates, compromising the depth with which population diversity could
be examined. Examples where this has been investigated further, evid-
ence of heterogeneous populations has been found for P. aeruginosa[36,
21, 37] and Burkholderia dolosa[38]. This will be discussed further in
Section 2.4.3 on page 15.
Other mechanisms of diversity maintenance is the trade-offs that ac-
company the process of niche specialisation. This includes: MUTA-
TION ACCUMULATION, where neutral mutations, that have accu-
mulated in one environment, result in decreased fitness in another,
and ANTAGONISTIC PLEITROPY, where a mutation creating a be-
nefit in one environment is deleterious in another[3, 39]. In the case
of mutation accumulation, an example could be the accumulation of
mutations in genes involved in metabolic mechanisms. The possible
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down regulation or destruction of some of these mechanisms might
not cause decreased fitness in one environment, where alternative
nutrients are present. But if the mutated organism is moved to an en-
vironment, where these mechanisms are necessary the accumulated
mutations will be detrimental[39].
The difficulty of separating mutation accumulation from antagonistic
pleitropy has been demonstrated for E. coli populations by Cooper
(2000)[39]. Evidence of both mechanisms was found, but the decay of
the catabolic mechanisms was often adaptive and could therefore not
be solely attributed to random mutation accumulation. This caused
them to attribute the functional decay to antagonistic pleitropy.
It is possible that mutation accumulation might be a significant factor
when looking at populations with increased mutation rates, so called
hypermutators, where deleterious and neutral mutations accumulate
at a much higher rate than the adaptive beneficial mutations[40]. How-
ever, in the same E. coli study as mentioned above[39], no indication
of this was found, when comparing populations with normal muta-
tion rates and populations with increased mutation rates. It is argued
that overall, the selective pressures and bottlenecks implicit in the
study design had too high an impact for non-adaptive evolution to
occur.
To my knowledge, there are no studies of CF bacterial populations
where mutation accumulation has been found to be the primary cause
of trade-off. This is probably because the CF airways pose a highly
selective environment, where adaptive evolution is the front runner
rather than random mutation accumulation, as shown above for the
E. coli populations.
2.4 evolution and adaptation in cf
In the moment a bacterium is moved from one environment to an-
other, that being from soil to water, or from an external environment
to the CF airways, adaptation is a necessity (Figure 4 A).
The adaptation to a new environment is guided by the selective pres-
sures found in the environment (Figure 4 B) and natural selection,
and it is through this process the transmission from being the cause
of an intermittent colonisation to a chronic infection happens[41].
In general, adaptation can take two forms: phenotypic acclimation
and genetic adaptation. PHENOTYPIC ACCLIMATION is based on
alterations in gene regulatory mechanisms caused by environmental
cues, such as toxins or nutrients, resulting in a phenotypic change
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Figure 4: Adaptation to a New Environment. A) Transition from environ-
ment X to environment Y. B) Factors found in most environments
to have an influence on adaptation and evolution.
without genotypic alterations. On the other hand, GENETIC ADAPT-
ATION is facilitated by either acquisition of new genetic material
from the environment, so called HORIZONTAL GENE TRANSFER
(HGT), or changes to the pre-existing genetic content by mutation[42].
Phenotypic acclimation is probably one of the initial adaptive mech-
anisms, which together with genetic adaptation causes a rapid initial
boost of phenotypic adaptation, as has been found in both laboratory
experiments with E. coli[39] and in CF for P. aeruginosa[5]. This will
be discussed in more detail in section: 2.6, subsection: 2.6.1 on page
22.
2.4.1 Genetic Adaptation and Complex Evolutionary Trajectories
In many cases, genetic adaptation has been found to cause increased
antibiotic resistance[43, 44, 45, 46, 47, 48, 49].
Antibiotic resistance development is a well researched subject, espe-
cially in CF context because of the intense antibiotic treatment and
the difficulties of eradication of P. aeruginosa[17]. Furthermore, antibi-
otic resistance is in general of great importance today because of the
emerging threats of multi resistance, not only in P. aeruginosa, but in
many other species as well. Therefore, we either need new drugs or
we need to understand the evolution of resistance development, in or-
der to improve treatment regimes and avoid resistance development
when possible, and preferably both[50].
A specific example, where resistance development was linked to the
introduction of a new drug was found by Marvig (2012)[43]. They
were able to link the introduction of the antibiotic Azithromycin to
the CF clinic in 2001, with the appearance of resistance generating
mutations in the 23S rRNA of clinical isolates of P. aeruginosa from
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CF patients.
Other cases of antibiotic resistance have also been found and linked
to mutations in specific genes such as: gyrA and fluoroquinolone res-
istance, nfxC and quinolone resistance, and nalD, mexA, mexB, mexR
and multi drug resistance[44, 45, 46, 47], etc.[48, 49].
In some cases multiple mutations are required for the development
of resistance, some of which are deleterious when acting alone. Only
when other mutations arise do they together result in a beneficial
effect of resistance, subsiding the initial negative effects. One such
example was found by Jochumsen (2013)[51]. They investigated the
evolution of colistin resistance in P. aeruginosa and found an intricate
web of molecular trajectories affected by antagonistic pleiotropy and
EPISTATIC INTERACTIONS, i.e. non-additive effects caused by ge-
netic interactions.
Another example of epistatic interactions has been shown by Damkiær
(2013)[29] where mutations in four genes were found to be mutated
in clinical isolates (mucA, algU, rpoN, and lasR). By reconstructing the
mutated genes in the laboratory P. aeruginosa strain PAO1, they were
able to show that mutations in either of the four genes alone or in
combinations of up to three genes had no impact on resistance to-
wards the two CF relevant antibiotics: ceftazidime and tobramycin.
However, when all four genes were mutated in concert, they resulted
in a significant increase of resistance to both antibiotics.
These complex trajectories can include points of temporarily lowered
fitness compared to the ancestor, which was specifically shown in Jo-
chumsen (2013)[51], where antibiotic resistance was used as a fitness
indicator.
It is not uncommon in a complex environment that to go from one fit-
ness peak to another it is necessary to cross a valley of lowered fitness
(Figure 5). However the retainment of mutations with a deleterious
effect is only possible in natural systems in two scenarios: One highly
dependent on genetic drift and a large population size, and another
relying on increased mutation rates[52, 40].
GENETIC DRIFT is the random change in frequency of genetic vari-
ants in a population over time. When natural selection is absent a
genetic variant will, by chance events, go to fixation whereas other
variants will be lost. The effect of genetic drift is dependent on pop-
ulation size, which can be exemplified by a coin toss: The chance of
getting either heads or tails is equal, i.e. 0.5 for each. As the coin is
tossed an infinite number of times the frequency with which you will
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Figure 5: Adaptive Peaks in a Fitness Landscape. Demonstration of a popu-
lation (circle) adapting to the different peaks of a fitness landscape.
Peaks (A and B) represent optimal genotypes/phenotypes in a spe-
cific environment. To go from the current adaptive peak (A, and
blue circle) the population has to cross a valley of lowered fitness
(dotted line and arrow) to reach the higher fitness of the adaptive
peak B (green circle). The axes X and Z are different genotypic
or phenotypic dimensions that the population can move within to
go towards different adaptive peaks, resulting in different relative
fitness.
get heads will go towards 0.5. But, it is not unreasonable to think that
if you only toss the coin 10 times you could end up with seven heads
and three tails[52].
This entails that in the beginning of a colonisation, where the pop-
ulation is small, the chances of a non-beneficial mutation "sticking
around" via genetic drift is low. On the other hand, in later stages,
when the population is increasingly larger, rare mutations face a
lower risk of being lost (the coin toss frequecy is close to 0.5) as a
result of genetic drift and might therefore be able to "stick around"
in the population long enough for another beneficial mutation to
arise. An example of this could be the retention of mutations causing
lowered fitness as compared to the ancestor, as found by Jochumsen
(2013)[51].
Another way to get multiple rare mutations and traversing valleys of
lowered fitness is by increasing the rate with which the population
mutates. By increasing the mutation rate a higher number of muta-
tions over a shorter period of time will automatically increase the
chance of gaining rare mutations as well as the chance of gaining a
subsequent beneficial mutation in time, – before the first mutation is
lost from the population[40].
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2.4.2 Speeding up Evolution
P. aeruginosa in CF, has been shown to have a mutation rate between
1.3 and 3.0 SNPs/year[21, 33, 53], for regular "non-mutator" popula-
tions. This rate can of course vary based on physiological factors such
as mutagens or stress, and stress can be caused by the presence of an-
tibiotics, which there is a lot of in the CF environment.
In hypermutator isolates sampled from two CF patients the mutation
rate has been shown to be 50 and 106 SNPs/year[36], and in a sim-
ulation it has been shown that mutation rates up to 1000-fold higher
than regular mutation rates in E. coli accelerate the adaptation rate
significantly, without the mutation accumulation being detrimental
for the population. The high mutation rate increases the number of
beneficial mutations accumulating over time. However, neutral or de-
leterious mutations are accumulating in a much higher rate, thereby
increasing the genetic load of the population at the same time[40].
Despite the increased genetic load, hypermutators have been found in
a high number of CF patients with chronic P. aeruginosa infections[54,
55]. This resilience of hypermutator populations is probably caused
by hitch-hiking, where the negative effects of the many deleterious or
neutral mutations are balanced out by beneficial mutations[40].
More specifically, HITCH-HIKING is caused by the genetic link between
genes or mutations causing them to be co-selected as a "linkage-
group". In asexual populations, such as bacterial populations, the en-
tire genome acts as a single linkage-group increasing the possibility
of two mutations or genes to be co-selected, and thereby the possibil-
ity that one can hitch-hike with the other[3].
On several occasions hypermutation has been shown to cause in-
creased antibiotic resistance in CF associated bacterial populations[54,
55, 56, 57], linking hypermutator generation to the antibiotic selec-
tion pressures found in CF patients. But as indicated by Fothergill
(2007)[22], hypermutators do not always show increased antibiotic
resistance, which is why antibiotic pressure cannot be the only driver
of the generation of hypermutators.
Other factors that have been acknowledged as driving the persist-
ence and occurrence of hypermutators are: oxidative stress[54], and
the need for genotypic diversity, where increased mutation rates can
increase the rate at which adaptive radiation can happen[36, 56].
The antibiotic pressure, the need to diversify, and a hypothesised
small size of the bacterial populations in the initial colonisation period
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is probably the reason why we identified hypermutators in young
Danish CF patients (Study 2).
2.4.3 Diversity and Resilience
Diversity of a population will theoretically increase productivity and
stability in an environment with temporal fluctuations, such as the CF
airways. This principle is known as the INSURANCE HYPOTHESIS[58],
and is supported by findings of a higher degree of resilience and
productivity in highly diverse communities as compared to low di-
verse communities[59, 60]. This has been experimentally tested for
biofilm populations of P. aeruginosa laboratory strains as well as CF
derived strains, where increased diversity resulted in higher resili-
ence towards physiological stress[61].
This mechanism is also known as BET-HEDGING, which is described
as a stochastic switch between phenotypes with the aim of increasing
overall fitness in multiple temporarily variable environments[62]. Un-
der this name, the mechanism has been supported by experimental
findings for P. flourescens, where a temporally alternating environ-
ment (static or shaken), resulted in mutations which in turn caused a
phenotypic switch to increase the overall fitness of the population[63].
In this context, Lieberman (2014)[38] found that the population struc-
ture of Burkholderia dolosa in CF airways evolved according to a "di-
verse community model", with a high degree of diversity rather than
a "dominant lineage model", where little diversity is seen. This find-
ing, together with the evident resilience and persistence of P. aeru-
ginosa in CF[36, 64, 21, 33, 23] despite heavy antibiotic treatment
strategies[17], further supports the theory of persistence and resili-
ence through diversity.
2.5 population heterogeneity
The heterogeneity of the CF airways together with the theory of in-
surance effects and bet-hedging makes it highly plausible that the bac-
terial populations in the CF airways are heterogeneous and diverse[65].
This is also underlined by results from several studies, through which
it has become increasingly obvious, that the populations correlated
with CF infections are diverse[21, 36, 66, 67]. Correlating in a higher
degree with the diverse community model than the dominant lineage
model[38], as described above.
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2.5.1 Diverse Populations and Collections of Single Isolates
In broad terms, diversity is upheld by a combination of ecological
specialisation (i.e. antagonistic pleiotropy) and spatial segregation or
spatial heterogeneity[4].
SPATIAL SEGREGATION is when physical barriers separate sub-pop-
ulations and thereby hinders a collapse of diversity of the population
as a whole. This is also a term found to describe speciation events
of ALLOPATRIC SPECIATION, which to some degree can be trans-
ferred to the generation of sub-speciation events seen in bacterial pop-
ulations of CF. In chronically infected CF patients spatial segregation
has been found to maintain diversity by maintaining the infecting
population in different compartments of the airways[21, 32]. It is also
possible that this mechanism of allopatric speciation or spatial segreg-
ation was the initiator of the population segregation and sub-lineage
formation.
The degree of spatial heterogeneity found in CF airways and the di-
versity found in the above mentioned studies, raise the question: Can
we investigate the evolution and adaptation of diverse bacterial pop-
ulations using collections of longitudinal single isolates?
Study 1:
Investigations of inter- and intra-clonal diversity of
Pseudomonas aeruginosa populations in cystic fibrosis
patients
Chapter 4 Section 4.1
To investigate this question we sequenced five metagenomes
from sputum samples of four young CF patients, from
whom we also had previous genome sequenced longitudin-
ally collected single isolates.
We were able to link the clone type and the SNP profile
of the single isolates to that of the metagenome(s) for each
individual patient, even in the case where two patients were
colonised by the same clone type as a result of patient-to-
patient transmission.
We also analysed a patient with a hypermutator population
by sampling two metagenomes with an interval of two
weeks. From this we were able to show that even though the
metagenomic approach increases the amount of information
gained per sample it is still important, as it is for the single
isolate approach, to have a comprehensive collection when
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investigating evolution and population dynamics.
In the end we were able to conclude that the information
gained by comprehensive collections of longitudinal single
isolates is sufficient for the analysis of adaptation and evolu-
tion of P. aeruginosa to the CF airways.
As a further verification of the use of single isolates, it is important
to note that some of the studies showing great diversity of the bac-
terial populations in CF were initially based on collections of single
isolates[21, 36]. Indicating that it is possible to disclose diversity, as
long as the collection of single isolates is comprehensive. By compre-
hensive, it is meant that, at the least, different compartments should
be sampled and different sampling techniques should be used.
The two major studies showing spatial segregation of sub-populati-
ons are Markussen (2014)[21] and Jorth (2015)[32]. This segregation
specifically hinders the use of single isolates for evolution studies, be-
cause all sub-populations are segregated and will not be identified
by single isolate sampling. However, it should be noted that the di-
versity found in Markussen was initially identified by comprehensive
sampling of single isolates from different sites of the airways (sinuses
and lungs). It is also important to note the progressed state of the
infection of the patients in both studies. Especially in Jorth (2015)[32],
where the study is based on transplanted lungs. It is highly pos-
sible that the spatial segregation found to be important for diversity
maintenance in these two studies primarily is a factor in progressed
chronic infections. This segregation of sub-populations might not be
relevant for the investigation of bacterial populations in CF patients
at other colonisation/infection stages.
In younger, intermittently colonised patients or in patients with a less
advanced chronic infection, mixing between airway compartments
have been identified. Here the same genotypes and phenotypes were
found in both the upper- and the lower-airways[30, 68, 69]. In these
cases an alternative process of diversity maintenance could be clonal
interference, which has been shown to occur and maintain diversity
in populations of E. coli in a well mixed environment[70].
CLONAL INTERFERENCE is when multiple beneficial mutations oc-
cur in a population, at the same time, and thereby limit the spread
of each other in the population. This competition between mutations
will increase the time of fixation for any one of the mutations and
thus slow down the overall rate of evolution and thereby maintain
diversity[71].
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Another way to maintain or create diversity is by negative-frequency-
dependent selection. As with clonal interference, this has also been
found in a homogeneous laboratory environment for E. coli[72]. Here,
negative-frequency-dependent selection was shown to play a role in
the maintenance of the mutationally derived diversity of the popula-
tion.
2.5.2 Frequency Dependent Selection and Cheater-Cooperator Dynamics
NEGATIVE-FREQUENCY-DEPEDENT SELECTION is when a sub-
lineage’s fitness, in this case the ability to proliferate, is high when
rare and low when abundant. An example, and what was found to
be one of the drivers in the E. coli study[72], is cross-feeding: Here
one sub-lineage (A) is dependent on substrates produced by another
sub-lineage (B), so when A becomes abundant it out-competes B to a
degree where B is incapable of producing enough substrate to sustain
A. The frequency of A then decreases whereas B increases, until B is
abundant enough to sustain A once more, Figure 6.
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Figure 6: Negative-Frequency-Dependent Selection. A caricature of
Negative-frequency-dependent selection, based on cross-feeding
from sub-lineage B to sub-lineage A.
Cross feeding has also been indicated in P. aeruginosa populations
from CF. Where Qin (2012)[73] found 19 of 27 collected isolates to be
auxotrophic for at least one amino acid (argenine, lysine, methionine,
alanine, and tryptophan), and all but one isolate could be complemen-
ted by at least one of the prototrophic isolates from the same patient.
Auxotrophy has also been shown for Burkholderia cepacia[74] and S.
aureus[75] in CF, but as hypothesised by Barth (1995)[74] the auxo-
trophy might just be supported by the nutrient rich sputum found in
CF, rather than cross-feeding.
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Another type of frequency dependent selection can be found in the
area of social microbiology of cheaters and cooperators.
Cooperators produce some kind of common good, for example iron
scavenging agents, so called siderophores, that can facilitate the cap-
ture and uptake of iron in an environment with limited free iron, such
as the CF airways. The cheaters are then isolates that do not have the
cost of producing these agents, but lives through the siderophores
produced by the cooperators. This diversity maintaining dynamic is
however different from the negative-frequency-dependent selection,
in that it is not maintained indefinitely. In most cases, the fitness of
the cheaters will out-compete the cooperators, and the diversity will
collapse.
In theory cheaters will have a fitness corresponding to a negative
function of their frequency, and thereby be submitted to frequency de-
pendent selection[76]. This dynamic has to my knowledge not been
proven directly in CF airways. However, the frequency dependence
of cheaters have been shown in mouse burn wound and chronic
wound infection models[77], and the presence of cheaters and cooper-
ators in young CF patients has recently been identified by Andersen
(2015)[78]. Here siderophore cheats were identified to uptake iron by
a receptor and only when cooperators were lost form the populations
did the cheaters loose their receptors, possibly causing a diversity
maintaining cheater-cooperator dynamic to break down.
One reason that frequency dynamics are difficult to observe is that
it is necessary to have multiple isolates from each sample, to map
the oscillations of the different sub-populations, and many studies
of the general bacterial evolution in CF are based on single isolate
collections[23, 33, 64, 78].
2.6 clonal persistence and adaptation
As stated earlier, to follow the process of evolution and adaptation, it
is valuable to be able to follow the same clonal lineage over time.
This is possible in CF infections because of a persistent clonal infec-
tion, enabling us to investigate the accumulation of mutations over
the time of infection. It is important to note that even though we
are talking about single clonal infections this does not preclude the
evolution of intra-clonal diversity, and the diversity discussion from
previously is equally applicable to single clone type and multi clone
type infections. Furthermore, it will be evident from the following
section that in CF we are in general talking about single clone type
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infection scenarios.
Persistence of infection is specifically evident from the chronic infec-
tions shown for two Danish clonal lineages: DK1 and DK2, causing
prolonged chronic infections for up to 32 and 35 years, respectively[21,
33]. This persistence of infection has also been shown by Smith (2006)[64]
for a period of 8 years, by Cramer (2011)[23] for periods of 20 and 23
years in two German patients, and by Feliziani (2014)[36] for 6 and 20
years in an Argentinian and Danish patient, respectively.
The persistence of infection, despite the continuous antibiotic treat-
ments, can be a result of three mechanisms: (1) transmission events
between patients, (2) the presence of an internal protected reservoir
within the patient, such as the sinuses, or (3) continous exposure to
an environmental or hospital source[79, 80, 81, 82].
The first notion, of transmission, has been shown to happen on sev-
eral occasions and was the instigating factor for the DK1 and DK2
spread among Danish CF patients[83, 84, 85, 86]. This patient-to-patient
transmission will be discussed later in Section 2.8, on page 29.
The second notion, of an internal and protected reservoir, has been
verified by studies of bacterial populations in the sinuses of CF pa-
tients. The sinuses are physically different from the lower airways
with regards to sub-MIC antibiotic concentration (MIC: Minimum In-
hibitory Concentration) and decreased immune system activity (IgA
instead of IgG) as compared to the lungs. These factors make it highly
likely that the sinuses can act as a protected niche, seeding the lower
airways with adapted bacteria after or during antibiotic treatments[30,
68, 69, 87]. The main proof for the directionality of seeding from the
sinuses to the lower airways is the fact that, despite employment
of intense antibiotic treatment strategies, seemingly eradicating the
lower airway bacterial infection[88, 17], infections keep re-occurring
and persisting.
The third notion, of environmental sources, is thought to be the primary
cause of the initial colonisation for Danich CF patients, and is also in-
dicated by the findings of Study 2 in this thesis.
The general notion of the course of colonisation and infection in CF
patients is as follows: An initial intermittent colonisation period with
continued re-infections by environmental isolates. This period will ex-
tend through months or years, depending on the treatment and the
adaptive state of the infecting bacteria[17, 89]. However, at some point
the intermittent phase of colonisation will inevitably transition to a
chronic infection, at which point there is little chance of eradication,
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– if any[17] (Figure 7 A).
This persistence of the same clonal lineage in chronic CF patients is
what makes it possible to follow the long term, within-patient, ad-
aptation to the chronic CF environment. Contradictory to this is the
hypothesised continuous re-colonisation by new environmental isol-
ates in young CF patients. This would make it impossible to study the
within-patient adaptation, because this adaptation would not exist.
Despite this notion of an initial phase of re-colonisations, the clonal
persistence found in chronic CF patients has recently been identified
in young Danish CF patients: A majority of 41 patients were shown
to harbour the same clone type from the first culture of P. aeruginosa
and until conclusion of the study [90].
A) Phases of Infection
B) Infection Patterns
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Figure 7: Phases of infection and infection patterns. Colours and shades
of grey denote different clonal lineages. (A) The phases of infec-
tion, with an intermittent colonisation with environmental, unique
clonal lineages and a subsequent chronic infection. (B) Four pat-
terns of infection as is observed in the Danish CF children col-
lection (Study 2). All four patterns are replicas of actual patterns
found in four patients.
There are two current definitions of a chronic infection: (1) The Leeds
criteria[91], where >50% of at least four samples collected over a year
must be culture positive. (2) The Copenhagen criteria[92] where con-
secutive culture positive samples over a period of at least six months
and/or an increased antibody response is required.
Currently, young Danish CF patients seem to harbour the same clonal
lineage through many years, without being considered chronic un-
der the above mentioned criteria. In this patient population we have
identified four infection patterns (Figure 7 B), where the patterns of
recurrent cultures of the same clonal lineage are seen in >75% of 41
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patients[90], Figure 7 B patterns 1 and 2.
These results suggest that by the time the first culturing of P. aeru-
ginosa is identified in the clinic, the patient has already transitioned
from no colonisation to a chronic colonisation. However, in most cases
this does not result in changes in the clinical conditions of the patients
(personal communication with DMSc Helle Krogh Johansen).
These findings call for a re-evaluation of the current definitions of
intermittent colonisation and chronic infection, as well as treatment
regimes applied to a "first-time" infection of P. aeruginosa.
2.6.1 Initial Infections and Pathoadaptation
The rapid foothold, that the initial colonising lineage seems to take, is
in clear accordance with the initial boost of phenotypic-adaptational
changes that appears, when Bacteria move from one environment to
another. This effect has been shown for E. coli in laboratory exper-
iments[39], where a significant increase in fitness over the initial 20,000
generations was shown. It has also been shown for the phenotypic ad-
aptation of P. aeruginosa collected from CF airways in the initial 50,000
generations[5] (Figure 8).
Study 2:
Convergent evolution and adaptation of Pseudomonas
aeruginosa within patients with cystic fibrosis
Chapter 4 Section 4.2
To investigate the initial phase of rapid adaptation we
investigated the molecular evolution of 474 longitudinally
collected single isolates from the airways of 34 young Danish
CF patients, with an initial colonisation of P. aeruginosa.
We were able to identify 53 distinct clone types with inter
clonal differences of >10,000 SNPs and intra clonal differ-
ences averaging on 122 SNPs (median = 9 SNPs). Of the 53
clone types ten were found to be harboured by multiple
patients and of these, three were linked by epidemiological
evidence of patient-to-patient transmission.
We identified 52 genes showing convergent molecular evol-
ution among the clone types, and they corresponded to
gene functions such as remodelling of regulatory networks
and central metabolism, antibiotic resistance and virulence
factors. Further results are shown on page 26.
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Figure 8: The Initial Phenotypic Adaptational Boost. Metabolic changes
over 200,000 generations of P. aeruginosa evolution in the CF air-
ways (PC1=63% of the total variation among isolates’ metabolic
capabilities). From Yang (2011)[5].
The 52 genes found in Study 2 are referred to in the paper as candid-
ate "pathoadaptive".
PATHOADAPTATION was first used in 1999 by Sokurenko [41], to
describe the adaptation of a micro-organism to a host environment
through mutation of inherent genetic material. It does not include
acquisition of virulence factors through HGT, but it includes both de-
struction and alteration of pre-existing functions.
In the context of CF, it has come to represent alterations significant to
the adaptation to the airways, enabling the bacteria to become more
resilient and persistent in the host environment.
We were able to link some of the clone types and pathoadaptive genes
found in Study 2 to P. aeruginosa isolates from Italian CF patients
(Study 3).
Study 3:
Within-host microevolution of Pseudomonas aeruginosa
in Italian cystic fibrosis patients
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For four Italian patients we tracked the adaptation and
evolution over 19 years by sequencing and phenotypically
analysing 26 P. aeruginosa isolates.
We were able to correlate genetic mutations with phenotypic
changes and identify shared clone types between Italy and
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Denmark, and show that clonal isolates within a country
can be more distantly related than clonal isolates between
countries.
In the investigation of pathoadaptive genes, we found an
11-fold enrichment of mutations in the 52 genes previously
identified as pathoadaptive in Study 2 (P(X > 34) pois(λ =
3.34) = 7.8x10 − 22). Furthermore we found a signature of
positive selection in these 52 genes, dN/dS > 5 (p=0.007) as
compared to all other genes, dN/dS = 0.7. Overall, we iden-
tified a significant pattern of negative selection for two of
the five clonal lineages (dN/dS = 0.7 and 0.3), whereas the
others showed no significant pattern of positive or negative
selection.
General conclusions of the extent to which natural selection has been
the primary driving force of fixation of mutations, can be inferred by
measuring relative rates of non-synonymous (dN) and synonymous
(dS) mutations.
NON-SYNONYMOUS mutations have a direct impact on the mutated
gene and can be contributed to missense and nonsense mutations,
causing alterations of the amino acid sequence of encoded proteins,
whereas SYNONYMOUS mutations do not cause these alterations of
the amino acid sequence[71].
The dN/dS ratio is used to measure the degree with which natural
selection is acting on the protein coding genome. POSITIVE SELEC-
TION implies a ratio greater than one and indicates selection for muta-
tion, whereas NEGATIVE SELECTION results in a ratio lower than
one, and thus a selection for the removal of mutations, which is why
it is also known as PURIFYING SELECTION.
Over the entire genome it is possible to have both positive and negat-
ive selection occurring at the same time[71]. This is the case in Study
3, where the general pattern of selection is either not significant for
positive or negative selection or significant for negative selection. At
the same time the selection pattern was found to be significant for
positive selection in the 52 pathoadaptive genes previously identified
in Study 2.
In general there are studies supporting both positive[64] and negat-
ive[79] selection as the driver of genomic evolution. In the end it is
probably a combination of both, working at different positions on the
genome, as was also indicated by Study 3.
2.6 clonal persistence and adaptation 25
2.6.2 Convergent Genetic Evolution
The study of pathoadaptation in CF has increased our knowledge
of chronic infections by identifying common genetic and functional
changes in the infecting bacteria, between clone types and between
patients, also called CONVERGENT EVOLUTION. In CF the hall-
marks of phenotypic adaptation of P. aeruginosa entails a decrease in
growth rate, biofilm mode of growth, increased resistance towards
antibiotics, and a loss of virulence factors[5, 21, 23, 24, 93, 94]. These
phenotypic changes are all rooted in genotypic alterations and to
some extent this phenotypic convergence is also reflected by a con-
vergence of genotypic adaptations.
Looking at four large scale studies from Smith (2006)[64], Marvig
(2013)[33], and Feliziani (2014)[36], together with Study 2 (Marvig et
al., Nat Genet), 19 candidate pathoadaptive genes were found in more
than one study, Figure 9.
Figure 9: Overlap of Pathoadaptive Genes from four Different Studies.
From Marvig (2015)[95].
The lack of overlap between the studies is to some extent a reflection
of differences in patient populations, with regards to infection status
(early/late stage colonisation/infection). It is also possibe that differ-
ences in treatment regimes, between countries and CF centres, play
a role, as was hypothesised by Feliziani (2014)[36] to cause divergent
genetic evolution of resistance, between a Danish and an Argentinian
CF patient.
The impact of differences in the patient population, with regards to
age and infection status is apparent, when looking closer at Study 2
and the study by Marvig (2013)[33], representing early colonisation
and infection and progressed chronic infection by the DK2 clone, re-
spectively. Three genes, found to be highly mutated in Study 2 (mucA,
algU, and mexZ), were not included in the pathoadaptive gene list of
DK2. Even though almost all isolates in the DK2 lineage have muta-
tions in these genes. By looking back at the evolutionary history of
DK2 we find that the genes were mutated early in the infection stage,
and are therefore only represented by few unique mutations, thereby
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excluding the genes from the pathoadaptive gene list, Figure 10.
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Figure 10: Early and Late Stage Adaptation of DK2. Bayesian phylogenetic
reconstruction and divergence date estimates of the P. aeruginosa
DK2 clones. X’es denote when mutations in each of three genes
occured: red: mexZ, blue: mucA, and green: algU. Adapted from
Marvig (2013)[33]
A third reason for the lack of overlap could be the approach with
which the pathoadaptive genes are considered, where the genes are
viewed as single entities instead of as a piece of a whole. This can
be exemplified by the retS-gacS-gacA-rsmZ-rsmA system where, as
explained further below, many genes can be hit and result in the
same phenotypic adaptive change. However, in the approach used
currently either one of the genes needs to be individually mutated
enough times to be recognised as pathoadaptive.
One way of pursuing a more ideal approach, for the identification of
pathoadaptive genes, could be to use a more holistic approach. Where
as an example, the retS-gacS-gacA-rsmZ-rsmA system is recognised as
a whole.
This could be achieved by methods such as those used in metabolic
profiling, where genes are put into context of the pathways they are
present in[96, 97].
2.7 historic contingencies and regulatory pathways
Study 2, continued:
Convergent evolution and adaptation of Pseudomonas
aeruginosa within patients with cystic fibrosis
Chapter 4 Section 4.2
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Figure 11: Regulatory Pathways and Historic Contingencies. The
order of mutations in mutants with two nonsynonym-
ous mutations in the same regulatory pathway. (a - d)
We identified 25 and 11 unique double mutants with
mutations in 2 of the genes in the mucA-algU (a) and
retS-gacS-gacA-rsmZ-rsmA (c) regulatory pathways, re-
spectively. On the basis of the phylogeny of the mutants,
we were able to infer the order of the mutations in the
mucA-algU (b) and retS-gacS-gacA-rsmZ-rsmA (d) reg-
ulatory pathways, that is, which of the possible muta-
tional routes (A, B, or C) led to the double mutant. WT,
wild type.
We were able to document historic contingencies of the two
above mentioned systems of mucA-algU and retS-gacS-gacA-
rsmZ-rsmA, Figure 11.
That is, we found a strong indication that the mutations in
algU were dependent on a previous mutation in mucA, and
the same pattern was found for retS and subsequent muta-
tions in either of the genes gacA/S or rsmA.
These results are based on the investigation of pathways as a means to
better understand the evolutionary processes. In particular the contin-
gency of retS-gacS-gacA-rsmZ-rsmA illustrates the importance of this
approach. Here we have an example where mutations in multiple
genes are contingent on a previous mutation in another gene. How-
ever, either of the genes downstream of retS can result in the same
phenotypic adaptation[98], making it difficult to identify the single
genes as pathoadaptive, when looking at genetic markers of parallel
evolution.
The above results also underline the importance of linking laboratory
studies with findings in natural systems. The contingency of mucA-
algU is in line with the phenotypic findings for P. aeruginosa isolates
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collected from CF patients.
In general initial isolates, of CF airway infections, are non-mucoid.
The transition to a chronic infection is often marked by a transition
of the isolates to a mucoid phenotype, frequently caused by a mucA
mutation[99, 100]. This is then abated by a subsequent mutation in
for example algU[29, 94].
However, considering the model for retS-gacS-gacA-rsmZ-rsmA devised
by Goodman (2004)[98] the results found in Study 2 indicate that by
the first mutation in retS the population moves towards a chronic in-
fection mode, but the subsequent mutations then re-direct the popu-
lation towards an acute infection mode. This is in opposition to what
we observe for the clone types found in the patients, which in reality
move toward a chronic infection. This suggests that to consider the
retS-gacS-gacA-rsmZ-rsmA signalling pathway as bimodal switch for
acute or chronic infection, might be too simple.
By looking at the direct effects off the pathway, the chronic state
equates transcription of the genes psl, pel, and hsl, where two of the
genes (psl and pel) are responsible for the production of exopolysac-
charides. Considering the decrease in attachment/biofilm formation,
as seen in the laboratory, of CF isolates over time[24], this redirection
away from transcription of pel and psl might actually not be contra-
dictory.
This is not to say that P. aeruginosa does not form biofilm. On the con-
trary, it has been shown and is generally accepted, that they live in
biofilm formations in the CF airways[101, 102].
However, considering the viscous mucus of CF patients, P. aeruginosa
might not need to produce extracellular polysaccharides themselves,
as they may be able to "cheat" off the human host, or cheat off other
sub-populations.
It is highly unlikely that all isolates of the population mutate simul-
taneously, or that the mutations rapidly sweep the population, in line
with the diversity found in most P. aeruginosa populations in CF pa-
tients. This population diversity could result in a cheater-cooperator
dynamic reflecting a diversity of the population with regards to exo-
polysaccharide production, as have been shown previously for sidero-
phore production.
We were able to find support for the initial hypothesis of the posib-
ility that isolates cheat off the human host mucus, by investigating
P. aeruginosa isolates from primary ciliary dyskinesia (PCD) patients.
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PCD patients have normal (non-viscous) mucus compared to CF pa-
tients, but have similar infection patterns[103] also caused by mucus
stasis in the airways. This is briefly explained below and in detail in
Study 4.
Study 4:
Evolutionary and adaptational differences of Pseudomo-
nas aeruginosa in primary ciliary dyskinesia and cystic
fibrosis patients
Chapter 4 Section 4.4
By sequencing 35 longitudinal P. aeruginosa isolates and
phenotypically characterising 41 from 12 chronically in-
fected patients with primary ciliary dyskenesia (PCD) we
identified 14 clone types. Five of which had previously been
identified in CF patients in Study 2.
We were able to find overlaps of clone types and genetic ad-
aptations previously identified in CF. Nonetheless, we were
not able to find the same overlap of adaptive phenotypes. For
the PCD isolates we identified biofilm formation to increase
or remain status quo, over time. We did not find the rapid
increase of generation time as found in CF isolates, and we
found a retention of swimming motility and protease pro-
duction. All opposing previous findings for CF isolates of
chronic infections, and possibly a result of the low-viscocity
mucus found in PCD as compared to CF.
2.8 comparative clonal lineages and transmission
In Study 2, 3, and 4 we identified clonal lineages found in multiple
patients, between and within studies (Figure 12). This clonal overlap
between different patients has been found before, with examples from
the United Kingdom and the Liverpool Epidemic Strain (LES)[83],
Australia and the Australian Epidemic Strain-2 (AES-2)[84], Denmark
and the DK1 and DK2 clone types[85], amongst others[86]. And again
between CF patients found in Denmark and Italy as well as Danish
PCD patients (Study 2, 3, and 4, respectively).
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Figure 12: Clone Type Overlap between Study 2, 3, and 4. The numbers
indicate unique clone types that have been identified in the indi-
vidual or in multiple studies.
Similar events as described previously for the persistence of infection
in CF, can also result in the presence of common clonal lineages: (1)
The existence of common environmental clonal lineages, (2) indirect
transmission via instruments in the clinic or exposure to the same en-
vironmental reservoirs, or (3) direct patient-to-patient transmission in
the outpatient clinic or in the ward[79, 80].
The first notion is supported by the existence of common clonal lin-
eages expanding to more than a single country as shown by the
overlap of clone types between the patients from Denmark and Italy
(Study 2 and 3, respectively) as well as the study by Wiehlmann
(2007)[79], who identified a widespread geographic distribution of
a few major clone types throughout Europe. The presence of DK06 in
all three studies, without evidence of patient-to-patient transmission,
further highlights that some clones are highly abundant in the envir-
onment. This is also shown in other studies, where the same clone
type has been found in multiple patients[83, 85, 84, 86].
The second notion of common environmental reservoirs is supported
by the overlap of clone types between patients within both Study 2
and Study 4, as well as the overlap between these studies. This is po-
tentially caused by common environmental reservoirs since the PCD
clinic and the CF clinic resides at the same hospital.
The third and last notion, of patient-to-patient transmission is suppor-
ted by studies of transmission of Burkholderia cepacia[104] and P. aeru-
ginosa[5, 33, 86] including Study 2. As well as findings of viable Gram
negative bacteria that can travel up to 4 m and persist for 45 min in
cough aerosols[81, 82]. This risk of transmission of already adapted
clonal lineages to uninfected patients has lead to patient segregation
in the Copenhagen CF clinic, since the early eighties[105]. Greatly
minimising the risk of a chronic patient transferring an already ad-
apted clonal lineage to an uninfected patient, or to a patient infected
with a naive environmental clonal lineage[15, 89].
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3.1 conclusions
Genomic investigations of longitudinally collected isolates and meta-
genomes have provided evidence for the heterogeneity of infecting
bacterial populations in CF airways. This diversity of the infecting
populations questions the use of single longitudinal isolates as a
means to elucidate the evolution and adaptation of an entire bactarial
population.
We sought to investigate this by analysing five sputum metagenomes
together with longitudinally collected single isolates from four CF pa-
tients in Study 1. With this approach we were able to link the clone
type and the SNP profiles of the single isolates to that of the metagen-
ome(s) for each individual patient. This indicates that comprehensive
sampling of single isolates is sufficient for the study of evolution and
adaptation of P. aeruginosa in CF airways. Another important find-
ing was that even though the metagenomic approach increases the
amount of information gained per sample, it is still important to have
a comprehensive collection when investigating evolution and popula-
tion dynamics, – as is the case for the single isolate approach.
By the genome sequencing of longitudinal single isolates from young
Danish CF patients, we found that 75% of the patients harboured the
same clone type from the first culturing of P. aeruginosa an onward.
This calls for a re-evaluation of the current definitions of intermittent
colonisation and chronic infection, as well as the treatment regimes
applied to a "first-time" infection.
Nevertheless this persistent infection with the same clonal lineage en-
abled us to investigate the initial phases of adaptation found in CF
airways.
By genome sequencing a total of 535 isolates collected from 34 young
Danish CF patients (474 isolates, Study 2), four Italian CF patients
(26 isolates, Study 3) and 12 PCD patients (35 isolates, Study 4) we
were able to identify initial genetic adaptation markers (pathoadapt-
ive genes).
The genome comparisons of the 474 single isolates, constituting 53
unique clone types, revealed a high degree of convergence, where we
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identified 52 candidate pathoadaptive genes. These were later iden-
tified to be significant for adaptation of P. aeruginosa in Italian CF
paients as well, and overlapping with mutated genes found to be sig-
nificant for the adaptation to PCD airways.
This list of genes suggests a role in host adaptation for remodelling of
regulatory networks and central metabolism, acquisition of antibiotic
resistance and loss of extracellular virulence factors. This is consistent
with both genomic and phenotypic findings of other studies investig-
ating P. aeruginosa infections in CF patients[15, 21, 36, 64, 96, 97, 106].
Furthermore, by investigating mutation patterns in key regulatory
networks, we were able to identify a dependence of sequential muta-
tions. Downstream transcriptional regulators were found to be con-
tingent on mutations in upstream regulators, further supporting the
importance of remodelling regulatory networks for adaptation to CF
airways.
By comparison to three other large scale studies, Smith (2006)[64],
Marvig (2013)[33], and Feliziani (2014)[36] we found merely 19 genes
overlapping at least two studies, and none overlapping all four stud-
ies. This poses an important question: If these candidate pathoad-
aptive genes are important for the adaptation to the CF airways in
general, then why do they not overlap?
One reason to look for these genes in the first place, was to find spe-
cific markers for the transition from colonisation to infection, but if
there is no overlap between studies then this is not possible.
There is ample evidence that the candidate pathoadaptive genes are
a result of convergent evolution within the studies, however not so
much between the studies.
By looking closer at the patient groups represented in the studies it
was shown that the infection stage of the isolates investigated was im-
portant to which genes were identified as highly mutated. As it turns
out, some genes are primarily mutated in the early stage adaptation,
and therefore possibly not included in the list of candidate pathoad-
aptive genes in studies of late stage adaptation.
By drawing a parallel to the historic contingencies found in Study 2
of the regulatory pathway of retS-gacS-gacA-rsmZ-rsmA, it is possible
that by changing the approach from looking at single genes to look-
ing at pathways, and thereby groups of genes we might find a higher
degree of overlap.
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In Study 2 we also found evidence of patient-to-patient transmission,
as have been found in many studies previously[83, 85, 84, 86]. We
were able to link possible transmission events to temporary overlaps
of hospital visits, providing epidemiological evidence to the genomic
results in three cases.
By comparing the sequencing results from the young CF patients’ P.
aeruginosa isolates, to results found for Italian CF patients we were
able to correlate and identify convergence of genetic adaptation across
two countries. We also found that clone types shared between pa-
tients can show a greater similarity between countries than within,
underlining the presence of common clonal lineages across borders.
Clone types found in either or both studies were also found in PCD
patients, indicating that there are no specific clone types responsible
for infection of either of these patient groups.
By an investigation of both genetic and phenotypic adaptational mark-
ers for the PCD isolates we identified a discontinuity in comparison
to CF isolates: In other words, we identified candidate pathoadaptive
genes for the PCD isolates, which correspond with previous findings
of CF isolates. However, despite this overlap of genetic adaptation
we did not identify a similar overlap in phenotypic adaptation. We
identified retention of swimming motility, protease production and
attachment, as a contrast to what has been found in CF.
These results indicate that the viscosity of the mucus provides a sig-
nificant selective pressure on the infecting P. aeruginosa populations,
which is in agreement with the structural differences of CF mucus as
compared with normal mucus[14].
Independently and together the studies presented in this thesis provide
new knowledge of adaptation and evolution in both CF and PCD air-
ways. With further characterisation of pathoadaptive mutations and
phenotypic adaptations it should be possible to translate these results
into clinically relevant information, leading to better epidemiological
predictions, valuable information with regards to treatment strategies,
and perhaps extrapolation of this knowledge to other infection scen-
arios.
OVER ALL: Through the convergence of genetic and phenotypic ad-
aptations observed in CF studies and by linking processes of evolu-
tion to these observations, it is shown that collections of P. aeruginosa
isolates from CF patients provide a valuable basis for the study of
adaptation and evolution in natural environments.
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3.2 future perspectives
In Study 2 we found that adaptation was associated with mutations
in regulatory networks, which probably changes the functionality of
these networks and guides adaptation towards specific evolutionary
routes. However, despite the high number of sequenced isolates and
clone types presented here, we have still not been able to pinpoint any
specific evolutionary route, even though the phenotypic results point
toward a specific end point. A possible explanation for the lack of a
more clear genetic adaptational route might be patient specific factors
that are as yet not fully incorporated in the analyses of adaptation
and evolution. These factors include co-infection or co-colonisation of
multiple species or multiple clones, or differentiated antibiotic treat-
ment.
Since co-colonisation has already been established to have an effect
on the evolution of both P. aeruginosa and S. aureus[28, 107]. A logical
next step could be to integrate the knowledge of co-infections and
inter-species dynamics to get a better understanding of the microbial
evolution. By concurrently addressing the limitations of resolution
when using single isolates, this could be carried out by metagnomic
sampling in combination with single isolates of the species of partic-
ular interest.
The antibiotic treatments could be incorporated to a larger extent than
is the case at the moment. In general antibiotic treatments are only in-
corporated by taking the drugs used against the specific bacteria of
interest into account. However, because of the possibility of interspe-
cies interactions, drugs that do not have a direct effect on the bacterial
organism of interest may still have an unrecognised potential as an
indirect selective factor for adaptation and evolution.
Another approach could be the application of methods previously
used for metabolic modelling, where genes are not considered as sep-
arate entities but rather as a part of different pathways. This, may give
us an opportunity to connect genes in an until now unknown pattern
of interrelated highways of adaptation and evolution, giving us the
possibility to more thoroughly understand evolution, as well as in-
crease our chances of identifying key markers of transition from an
initial environmental isolate to persistent colonisation and further to
chronic infection. In turn, this may enable the development of better
diagnostic and treatment approaches and postpone or even elimin-
ate the final progression to a chronic and incurable bacterial infection
with P. aeruginosa.
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ABSTRACT	  	  	  20	   The	  primary	  cause	  of	  morbidity	  and	  mortality	  in	  cystic	  fibrosis	  (CF)	  patients	  is	  lung	  21	   infection	  by	  Pseudomonas	  aeruginosa,	  a	  versatile	  opportunistic	  pathogen.	  Therefore	  22	   much	  work	  has	  been	  done	  to	  understand	  the	  adaptation	  and	  evolution	  of	  P.	  23	  
aeruginosa	  to	  the	  CF	  lung.	  However,	  many	  of	  these	  studies	  have	  focused	  on	  24	   longitudinally	  collected	  single	  isolates,	  and	  only	  few	  have	  included	  cross-­‐sectional	  25	   analyses	  of	  the	  whole	  P.	  aeruginosa	  populations	  in	  sputum	  samples.	  To	  date	  only	  26	   few	  studies	  have	  used	  the	  approach	  of	  metagenomic	  analysis	  for	  the	  purpose	  of	  27	   investigating	  P.	  aeruginosa	  populations	  in	  CF	  airways.	  	  28	   Here	  we	  combine	  the	  approach	  of	  analysing	  single	  longitudinally	  collected	  samples	  29	   with	  a	  metagenomic	  analysis	  of	  single	  sputum	  samples,	  with	  the	  aim	  of	  investigating	  30	   whether	  the	  genomic	  information	  from	  single	  isolates	  is	  sufficient	  to	  document	  31	   evolutionary	  and	  adaptational	  patterns	  of	  the	  P.	  aeruginosa	  populations	  within	  CF	  32	   patients’	  airways.	  33	   We	  analysed	  five	  metagenomes	  together	  with	  longitudinally	  collected	  single	  isolates	  34	   from	  four	  CF	  patients.	  With	  this	  approach	  we	  were	  able	  to	  link	  the	  clone	  type	  and	  35	   the	  SNP	  profile	  (or	  part	  of)	  of	  the	  single	  isolates	  to	  that	  of	  the	  metagenome(s)	  for	  36	   each	  individual	  patient.	  	  37	   Based	  on	  our	  analysis	  we	  conclude	  that	  using	  comprehensive	  collections	  of	  38	   longitudinal	  single	  isolates	  it	  is	  possible	  to	  rediscover	  the	  genotypes	  of	  the	  single	  39	   isolates	  in	  the	  metagenomic	  samples.	  This	  indicates	  that	  the	  information	  gained	  by	  40	   the	  genome	  sequencing	  of	  single	  isolates	  is	  sufficient	  for	  the	  research	  of	  adaptation	  41	   and	  evolution	  of	  P.	  aeruginosa	  to	  the	  CF	  airways.	  	  42	  
	  43	  
	  44	  
INTRODUCTION	  45	   Cystic	  fibrosis	  (CF)	  is	  a	  hereditary	  disease	  that	  causes	  malfunction	  of	  a	  chloride	  46	   channel	  affecting	  the	  viscosity	  of	  the	  mucus	  on	  all	  muco-­‐epithelial	  surfaces.	  Among	  47	   other	  things,	  this	  results	  in	  impaired	  clearance	  of	  bacteria	  and	  other	  48	   microorganisms	  from	  the	  airways	  with	  an	  associated	  increased	  risk	  of	  lung	  49	   infections1.	  CF	  is	  the	  most	  common	  life-­‐limiting	  genetic	  disorder	  in	  Caucasians,	  and	  50	   lung	  infection	  with	  Pseudomonas	  aeruginosa	  is	  the	  primary	  cause	  of	  morbidity	  and	  51	   mortality	  in	  CF	  patients2,3.	  In	  the	  clinic,	  antibiotic	  treatment	  of	  these	  infections	  is	  52	   usually	  based	  on	  the	  assumption	  that	  the	  bacterial	  populations	  in	  CF	  airways	  are	  53	   homogeneous.	  In	  accordance	  with	  this	  assumption,	  several	  studies	  of	  the	  adaptation	  54	   of	  P.	  aeruginosa	  to	  the	  CF	  airway	  environment	  with	  regard	  to	  e.g.	  resistance	  55	   development4,5,	  metabolism6,	  avoidance	  of	  the	  immune	  system7,	  and	  transmission	  56	   between	  niches	  in	  the	  airways	  of	  a	  patient8	  and	  between	  patients9,10,	  have	  primarily	  57	   been	  carried	  out	  based	  on	  investigations	  of	  single	  longitudinally	  stored	  bacterial	  58	   isolates11–13.	  59	  
	   3	  
	  60	   However,	  it	  was	  recently	  shown	  that	  long-­‐term	  bacterial	  infections	  of	  CF	  airways	  61	   cannot	  solely	  be	  described	  as	  a	  “dominant	  lineage”	  model,	  where	  the	  infecting	  clone	  62	   type	  adapts	  in	  a	  linear	  fashion,	  and	  new	  variants	  with	  increased	  fitness	  quickly	  63	   outcompete	  their	  less	  fit	  ancestors14.	  Because	  of	  the	  heterogeneous	  environment	  of	  64	   the	  CF	  airways,	  it	  is	  more	  likely	  a	  “diverse-­‐community”	  model	  that	  best	  describes	  65	   the	  bacterial	  populations	  of	  the	  CF	  airways.	  This	  is	  an	  effect	  of	  adaptive	  radiation	  66	   and	  the	  development	  of	  different	  subpopulations	  with	  a	  high	  degree	  of	  polymorphic	  67	   mutations11,14–16.	  	  	  68	   Thus,	  the	  question	  remains	  whether	  genomic	  information	  from	  single	  isolates	  69	   collected	  longitudinally	  from	  the	  same	  patient	  is	  sufficient	  for	  the	  characterization	  70	   of	  adaptive	  and	  evolutionary	  processes	  in	  P.	  aeruginosa	  populations	  in	  CF	  airways,	  71	   and	  consequently	  also	  for	  the	  development	  of	  new	  diagnostic	  and	  therapeutic	  72	   strategies.	  To	  answer	  this	  question,	  our	  approach	  has	  been	  to	  compare	  sequences	  73	   from	  longitudinally	  collected	  single	  isolates	  with	  single	  metagenomes	  from	  four	  CF	  74	   patients.	  	  75	   In	  this	  analysis,	  rediscovery	  in	  the	  metagenomes	  of	  the	  genome	  sequences	  derived	  76	   from	  the	  single	  isolates	  has	  been	  considered	  evidence	  that	  the	  single	  isolates	  have	  77	   proliferated	  in	  the	  population	  and	  thus	  are	  representative	  for	  the	  infecting	  78	   population	  of	  the	  patient.	  If	  the	  single	  isolates	  are	  propagating	  lineages	  representing	  79	   the	  adapting	  population,	  we	  would	  expect	  to	  find	  a	  clear	  correlation	  between	  their	  80	   genomes	  and	  the	  metagenome(s).	  Moreover,	  we	  would	  only	  expect	  to	  find	  this	  81	   correlation	  between	  isolates	  and	  metagenomes	  from	  the	  same	  patient,	  in	  contrast	  to	  82	   cases	  of	  closely	  related	  bacterial	  populations	  established	  by	  patient-­‐to-­‐patient	  83	   transmissions.	  84	   	  85	  
MATERIALS	  &	  METHODS	  86	  
	  87	   We	  included	  four	  CF	  patients	  followed	  at	  the	  CF-­‐center	  at	  Rigshospitalet,	  88	   Copenhagen,	  Denmark.	  The	  age	  of	  the	  patients	  ranged	  from	  15	  to	  31	  years	  and	  they	  89	   were	  all	  recently	  diagnosed	  as	  chronically	  infected	  with	  P.	  aeruginosa	  (Copenhagen	  90	   criteria17).	  91	   	  92	  
Longitudinally	  collected	  single	  isolates	  93	   Genome	  sequenced	  longitudinally	  collected	  single	  isolates	  from	  the	  patients	  are	  94	   described	  in	  details	  in	  Marvig	  et	  al.	  (2014)	  18.	  The	  single	  isolates	  included	  in	  this	  95	   study	  cover	  P.	  aeruginosa	  sampled	  from:	  endolaryngeal	  suction,	  sputum	  samples,	  96	   sinus	  samples	  taken	  at	  endoscopic	  sinus	  surgery,	  swabs	  from	  the	  sinuses,	  and	  97	   broncho	  alveolar	  lavage	  (BAL)	  samples.	  98	  
	  99	  
	   4	  
Metagenomic	  samples	  100	   Sputum	  samples	  were	  collected	  at	  the	  CF	  clinic	  at	  Rigshospitalet	  and	  samples	  were	  101	   processed	  a	  median	  of	  two	  days	  after	  expectoration	  (range:	  one	  to	  three	  days).	  102	   During	  the	  lag-­‐time	  between	  expectoration	  and	  processing	  the	  samples	  were	  stored	  103	   at	  4°C.	  	  104	  
	  105	  
Processing	  of	  metagenomic	  samples	  106	   The	  samples	  were	  treated	  with	  ca.	  1:1	  (v/v)	  10x	  diluted	  Sputasol	  (Oxoid,	  c/o	  107	   Thermo	  Fisher	  Scientific,	  UK)	  with	  continuous	  vigorous	  shaking	  for	  30	  min.	  for	  108	   homogenisation.	  109	   The	  samples	  were	  divided	  into	  two	  fractions,	  one	  was	  plated	  on	  PIA	  plates	  and	  110	   incubated	  in	  24-­‐72h	  at	  37°C	  depending	  on	  when	  colonies	  appeared	  and	  before	  111	   single	  colonies	  could	  no	  longer	  be	  picked.	  The	  single	  colonies	  were	  then	  grown	  in	  96	  112	   well	  microtitter	  plates	  with	  150µl	  Luria	  Broth	  (LB)	  for	  24-­‐48h.	  100µl	  50%	  glycerol	  113	   was	  added	  and	  the	  isolates	  were	  stored	  at	  -­‐80°.	  The	  other	  fraction	  was	  directly	  114	   subjected	  to	  DNA	  extraction	  (200-­‐600µl	  Sputasol	  treated	  sample),	  or	  stored	  at	  -­‐20°C	  115	   until	  batch	  DNA	  purification	  could	  take	  place.	  116	   DNA	  extraction	  was	  carried	  out	  as	  in	  Lim	  et	  al.	  (2013)19,	  with	  slight	  modifications:	  117	   β-­‐mercapoethanol	  was	  replaced	  by	  Sputasol	  treatment,	  centrifugation	  times	  were	  118	   extended	  to	  20	  min	  at	  3800x	  g,	  the	  volumes	  were	  adjusted	  to:	  1.5ml	  autoclaved	  119	   milliQ,	  100-­‐200µl	  DNase	  buffer	  and	  3-­‐6µl	  DNase	  (depending	  on	  pellet	  size),	  and	  1.5	  120	   SE	  buffer,	  with	  the	  Powersoil®	  DNA	  isolation	  kit	  (MO	  BIO	  Laboratories,	  USA)	  used	  121	   according	  to	  the	  manufacturer,	  for	  DNA	  purification.	  	  122	   	  123	  
Sequencing	  and	  analysis	  of	  metagenomic	  reads	  124	   Libraries	  were	  prepared	  in	  triplicates	  with	  Nexter	  XT	  Sample	  Preparation	  kit	  125	   (Illumina	  Inc.,	  USA)	  and	  pooled	  prior	  to	  sequencing	  on	  an	  Illumina	  MiSeq®	  bench-­‐126	   top	  sequencer	  with	  MiSeq	  reagent	  kit	  V2,	  300	  cycles	  (Illumina	  Inc.,	  USA),	  resulting	  in	  127	   150bp	  paired	  end	  reads.	  128	   Initial	  analysis	  of	  the	  reads	  (also	  used	  for	  species	  identification)	  was	  carried	  out	  129	   using	  Novoalign	  V2.07.18	  (Novocraft	  Technologies20)	  for	  alignment	  to	  a	  library	  of	  130	   human	  (GRCh37,	  131	   ftp://ftp.ncbi.nlm.nih.gov/genomes/H_sapiens/Assembled_chromosomes/seq/hs_r132	   ef_GRCh37.p13_chr*mfa.gz),	  bacterial,	  archaeal,	  viral,	  and	  fungal	  (The	  NCBI	  133	   database,	  downloaded:	  November	  11th	  2013)	  sequences.	  All	  sequences	  aligning	  to	  134	   the	  human	  genome	  were	  discarded.	  135	   The	  analysis	  of	  the	  P.	  aeruginosa	  population	  was	  performed	  according	  to	  Marvig	  et	  136	  
al.	  (2014)18:	  Alignment	  of	  reads	  to	  PAO1	  simultaneously	  removing	  all	  non-­‐P.	  137	  
aeruginosa	  reads	  with	  SAM	  tools	  V0.1.7	  (r50),21	  The	  Genome	  Analysis	  Toolkit	  138	   (GATK)	  V1.0.5085	  (compiled	  2011/01/26	  10:13:39),22	  and	  Bowtie2	  V2.0.223.	  139	  
	   5	  
SNP	  calling	  was	  carried	  out	  manually	  from	  via	  the	  .totalpileup	  files	  from	  Bowtie2	  140	   with	  the	  aid	  of	  information	  from	  the	  single	  isolates18.	  	  141	   The	  rediscovery	  of	  SNPs	  from	  the	  single	  isolates	  in	  the	  metagenomes	  have	  been	  142	   done	  on	  the	  assumption	  that	  if	  a	  SNP	  is	  present	  in	  more	  than	  10%	  of	  the	  reads	  at	  the	  143	   specific	  position	  of	  the	  SNP,	  this	  is	  regarded	  as	  a	  rediscovered	  SNP.	  	  144	   When	  looking	  at	  polymorphisms,	  only	  positions	  with	  a	  phred	  score	  >30	  and	  with	  145	   >=4	  read	  coverage	  were	  considered.	  This	  was	  then	  compared	  to	  the	  coverage,	  where	  146	   positions	  were	  only	  considered	  if	  the	  phred	  score	  was	  >30,	  to	  make	  the	  ratio	  147	   presented	  in	  Figure	  6.	  148	   	  149	  
Diversity	  measurement	  of	  metagenomic	  samples	  150	   Polymorphic	  positions	  were	  identified	  as	  described	  above.	  Because	  of	  the	  varying	  151	   coverage	  of	  the	  different	  samples,	  the	  polymorphisms	  found	  were	  compared	  to	  the	  152	   overall	  coverage	  of	  the	  PAO1	  genome,	  and	  diversity	  was	  calculated	  as	  a	  ratio	  of	  153	   polymorphisms	  and	  coverage.	  The	  reason,	  for	  using	  polymorphisms	  as	  a	  diversity	  154	   measurement,	  is	  based	  on	  the	  assumption	  that	  the	  more	  positions	  a	  population	  155	   diverge	  in,	  the	  more	  diverse	  is	  it	  likely	  to	  be.	  156	   To	  explain:	  if	  we	  have	  e.g.	  two	  or	  three	  subpopulations	  they	  will	  differ	  from	  each	  157	   other	  in	  a	  number	  of	  positions	  creating	  more	  ambiguous	  base	  calls	  and	  thus	  a	  higher	  158	   ratio	  of	  polymorphisms,	  than	  a	  single	  homogeneous	  population.	  It	  is	  important	  to	  159	   keep	  in	  mind,	  that	  it	  is	  not	  possible	  to	  differentiate	  between	  two,	  three,	  or	  more	  160	   different	  subpopulations	  based	  on	  this	  method.	  This	  is	  because	  of	  the	  possibility	  of	  a	  161	   deep	  phylogenetic	  branching	  of	  two	  subpopulations	  and	  a	  shallow	  branching	  of	  162	   three	  or	  more	  subpopulations.	  	  163	   However,	  the	  importance	  of	  this	  differentiation	  can	  be	  discussed,	  as	  it	  has	  always	  164	   been	  difficult	  to	  determine	  diversity	  depending	  on,	  more	  or	  less	  subpopulations	  and	  165	   higher	  or	  lower	  degrees	  of	  phylogenetic	  branching.	  166	   	  167	  
Diversity	  measurement	  by	  phylogenetic	  analysis	  of	  single	  isolates	  168	   Diversity	  is	  shown	  as	  the	  mean	  distance	  to	  the	  Line	  of	  Decent	  (LOD)12.	  LOD	  is	  the	  169	   immediate	  line	  from	  the	  root	  (here	  based	  on	  PAO1	  as	  out-­‐group)	  to	  the	  latest	  170	   sampled	  isolate	  (the	  red	  line	  in	  the	  phylogenetic	  trees	  in	  Figure	  5),	  and	  the	  mean	  171	   distance	  to	  LOD	  is	  the	  mean	  number	  of	  SNPs	  from	  this	  line	  to	  the	  remaining	  isolates.	  172	   	  173	  
Statistics	  174	   All	  statistics	  were	  done	  in	  R24.	  175	   	  176	  
Ethics	  177	   The	  local	  ethics	  committee	  at	  the	  Capital	  Region	  of	  Denmark	  Region	  Hovedstaden	  178	   approved	  the	  use	  of	  the	  samples:	  registration	  number	  H-­‐4-­‐2015-­‐FSP.	  All	  patients	  179	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have	  given	  informed	  consent.	  In	  patients	  bellow	  18	  years	  of	  age,	  informed	  consent	  180	   was	  obtained	  from	  their	  parents.	  181	   	  182	  
RESULTS	  183	  
Patient	  information	  and	  P.	  aeruginosa	  infection	  patterns	  184	   Four	  CF	  patients	  were	  enrolled	  in	  this	  study	  (median	  age	  24	  years;	  range	  15-­‐31,	  at	  185	   the	  time	  of	  metagenome	  sampling),	  from	  each	  of	  whom	  we	  have	  previously	  genome	  186	   sequenced	  9	  to	  27	  longitudinally	  collected	  single	  P.	  aeruginosa	  isolates18.	  From	  the	  187	   four	  patients	  we	  collected	  either	  one	  (n=3)	  or	  two	  (n=1)	  sputum	  samples	  for	  188	   metagenomic	  analysis	  (Figure	  1A).	  	  189	   Accordingly,	  sputum	  samples	  S1,	  S2,	  and	  S3	  were	  sampled	  from	  patients	  P41M3,	  190	   P99F4	  and	  P92F3,	  and	  sputum	  samples	  S4a	  and	  S4b,	  separated	  by	  two	  weeks,	  were	  191	   sampled	  from	  patient	  P82M3.	  The	  sputum	  samples	  used	  for	  the	  meta-­‐genome	  192	   sequencing	  were	  collected	  approximately	  one	  year	  after	  the	  most	  recently	  genome	  193	   sequenced	  single	  isolate.	  	  194	   The	  time	  period	  between	  the	  most	  recently	  genome	  sequenced	  isolate	  and	  the	  195	   metagenome	  is	  not	  critical,	  since	  the	  main	  question	  addressed	  here	  is	  whether	  or	  196	   not	  the	  genotypes	  of	  the	  single	  isolates	  can	  be	  rediscovered	  in	  the	  metagenomic	  197	   samples.	  If	  so,	  this	  would	  indicate	  that	  the	  respective	  single	  isolates	  are	  198	   representative	  of	  a	  dominant	  propagating	  genotype(s)	  of	  the	  P.	  aeruginosa	  199	   population	  of	  the	  patients.	  	  200	   Three	  of	  the	  four	  patients	  (P41M3,	  P92F3,	  and	  P82M3)	  have	  infection	  patterns	  that	  201	   are	  characteristic	  for	  the	  majority	  of	  the	  P.	  aeruginosa	  infected	  CF	  patients	  at	  the	  202	   Copenhagen	  CF	  Center	  at	  Rigshospitalet25,	  with	  a	  single	  primary	  clone	  type	  in	  the	  203	   entire	  collection	  period.	  One	  patient	  (P99F4)	  has	  a	  change	  in	  clone	  type,	  where	  one	  204	   clone	  type	  is	  outcompeted	  by	  another	  (Figure	  1A).	  Together	  the	  four	  patients	  205	   display	  infection	  patterns	  representing	  approximately	  90%	  of	  the	  Copenhagen	  CF	  206	   children	  and	  young	  adults,	  as	  previously	  described18,25.	  	  207	   All	  four	  patients	  in	  this	  study	  have	  been	  recently	  diagnosed	  as	  chronically	  infected	  208	   with	  P.	  aeruginosa	  according	  to	  the	  Copenhagen	  definitions	  at	  the	  time	  of	  209	   metagenome	  sampling17.	  	  210	   	  211	  
Processing	  of	  sputum	  sample	  reads	  212	   The	  metagenome	  sequences	  were	  aligned	  to	  a	  database	  containing	  all	  bacterial,	  213	   fungal,	  and	  viral	  genome	  sequences	  deposited	  at	  NCBI	  (see	  Materials	  and	  Methods).	  214	   With	  a	  median	  of	  96.11%	  of	  all	  bacterial	  reads	  P.	  aeruginosa	  was	  the	  dominating	  215	   microbial	  species	  in	  the	  patients,	  corresponding	  to	  their	  clinical	  diagnosis	  as	  216	   chronically	  infected	  with	  P.	  aeruginosa.	  	  217	   	  218	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We	  further	  aligned	  reads	  from	  the	  sputum	  metagenomes	  to	  the	  P.	  aeruginosa	  PAO1	  219	   reference	  genome,	  as	  we	  have	  previously	  done	  for	  the	  single	  isolates18.	  In	  all	  cases,	  220	   the	  metagenomic	  reads	  aligned	  to	  nearly	  all	  positions	  in	  the	  6.3	  Mbp	  reference	  221	   genome,	  and	  on	  average	  5.9	  Mbp	  were	  covered	  by	  >3	  reads.	  This	  high	  genomic	  222	   coverage	  ensured	  that	  the	  presence	  or	  absence	  of	  polymorphisms	  in	  the	  223	   metagenomes	  could	  be	  determined	  at	  the	  majority	  of	  genomic	  positions.	  On	  average,	  224	   sequenced	  positions	  were	  covered	  by	  10	  to	  31	  reads	  (Supplementary	  Table	  S1)	  225	   giving	  us	  the	  opportunity	  to	  identify	  subpopulations	  that	  are	  present	  in	  more	  than	  226	   10%	  of	  the	  population	  at	  the	  positions	  with	  the	  lowest	  coverage.	  	  227	   In	  order	  to	  compare	  the	  P.	  aeruginosa	  population	  structure	  and	  diversity	  as	  228	   displayed	  by	  the	  single	  isolates	  and	  the	  compliance	  with	  the	  metagenomic	  read	  229	   assemblies,	  we	  conducted	  a	  three	  step	  analysis:	  1)	  Identification	  of	  the	  dominant	  230	   clone	  type(s)	  in	  the	  sputum	  samples,	  2)	  investigation	  of	  mutations	  in	  the	  genomes	  of	  231	   the	  single	  isolates	  also	  identified	  in	  the	  metagenomes,	  i.e.	  rediscovery	  of	  SNPs	  in	  the	  232	   metagenomes,	  and	  (3)	  comparison	  of	  diversity	  measurements	  of	  the	  populations	  233	   represented	  by	  the	  single	  isolates	  and	  the	  metagenomes.	  234	   	  235	  
Identification	  of	  the	  dominant	  clone	  type(s)	  	  236	   To	  identify	  the	  P.	  aeruginosa	  clone	  types	  represented	  in	  the	  metagenomes,	  de	  novo	  237	   assemblies	  of	  single	  isolates	  and	  metagenomes	  were	  compared,	  using	  dnadiff	  from	  238	   MUMmer,	  with	  default	  parameters.	  That	  is,	  for	  each	  patient	  the	  clone	  types	  239	   represented	  by	  the	  single	  isolates	  within	  a	  patient	  were	  compared	  with	  the	  240	   metagenome(s)	  from	  the	  same	  patient.	  241	   For	  all	  four	  patients,	  the	  clone	  type	  of	  the	  most	  recently	  sampled	  single	  isolate	  242	   corresponded	  to	  the	  clone	  type	  identified	  from	  the	  metagenome	  with	  less	  than	  528	  243	   bp	  of	  difference	  (median	  131	  bp,	  range	  91-­‐527	  bp).	  In	  contrast,	  when	  comparing	  the	  244	   metagenomes	  with	  single	  isolates	  of	  other	  clone	  types	  they	  differed	  by	  more	  than	  245	   17,843	  bp	  (median	  17,844	  bp,	  range	  16,269-­‐30,918	  bp)	  (Supplementary	  Table	  S2).	  	  246	   This	  shows	  that	  the	  most	  recent	  clone	  type	  identified	  by	  the	  genomes	  of	  the	  single	  247	   isolates	  of	  each	  patient	  match	  the	  dominating	  clone	  type	  in	  the	  P.	  aeruginosa	  248	   populations	  as	  identified	  in	  the	  sputum	  sample	  metagenomes.	  249	   	  250	  
Rediscovery	  of	  SNPs	  in	  the	  metagenomes	  251	   Previous	  investigations	  of	  genome	  evolution	  in	  the	  clonal	  lineages	  of	  P.	  aeruginosa	  252	   strains	  from	  each	  of	  the	  four	  patients18	  led	  to	  identification	  of	  SNPs	  accumulating	  in	  253	   the	  clonal	  populations	  present	  in	  the	  individual	  patients.	  If	  these	  SNPs	  are	  indeed	  254	   present	  in	  actual	  propagating	  lineages	  of	  the	  P.	  aeruginosa	  population	  of	  these	  255	   patients,	  they	  should	  also	  be	  present	  in	  the	  metagenome(s).	  When	  looking	  at	  all	  the	  256	   SNPs	  identified	  in	  all	  the	  single	  isolates,	  it	  is	  expected	  that	  the	  ratio	  of	  rediscovery	  of	  257	   SNPs	  between	  single	  isolates	  and	  metagenomes	  from	  the	  same	  patients	  should	  258	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exceed	  the	  ratio	  determined	  between	  single	  isolates	  and	  metagenomes	  of	  different	  259	   patients.	  Further,	  this	  ratio	  should	  reach	  a	  value	  of	  one	  if	  all	  mutations	  found	  in	  the	  260	   single	  isolates	  are	  also	  present	  in	  the	  metagenome.	  261	   With	  the	  exception	  of	  patient	  P99F4	  and	  P92F3,	  who	  share	  the	  same	  clone	  type	  262	   (DK26),	  the	  rediscovery	  of	  SNPs	  from	  isolates	  in	  metagenomes	  of	  the	  same	  patient	  263	   was	  found	  to	  be	  significantly	  higher	  than	  between	  patients	  (Figure	  2,	  p<0.05,	  264	   Fisher’s	  exact	  test	  with	  Holm	  correction).	  This	  supports	  the	  specific	  linkage	  between	  265	   single	  isolates	  and	  the	  P.	  aeruginosa	  population	  as	  a	  whole,	  as	  hypothesised	  above.	  266	   In	  one	  case	  (S2	  from	  P99F4),	  the	  ratio	  of	  the	  rediscovery	  of	  SNPs	  reached	  one,	  267	   suggesting	  that	  all	  SNPs	  identified	  in	  the	  single	  isolates	  are	  present	  in	  more	  than	  268	   10%	  of	  the	  population	  as	  a	  whole.	  In	  all	  other	  cases	  the	  ratio	  was	  below	  one,	  which	  269	   could	  be	  due	  to:	  1)	  not	  all	  mutations	  being	  fixed	  in	  the	  population,	  i.e.	  they	  were	  lost	  270	   during	  the	  time	  of	  sampling	  of	  the	  single	  isolates	  (harbouring	  the	  mutations)	  until	  271	   sampling	  of	  the	  metagenome,	  or	  2)	  some	  of	  the	  mutations	  being	  present	  in	  only	  a	  272	   small	  fraction	  (<10%)	  of	  the	  population	  and	  therefore	  not	  sampled	  by	  the	  273	   metagenomic	  reads.	  In	  the	  case	  of	  P92F3	  the	  SNPs	  that	  are	  not	  rediscovered	  are	  274	   only	  present	  in	  11-­‐22%	  of	  the	  single	  isolates,	  and	  thus	  could	  be	  explained	  by	  the	  275	   first	  point	  stated	  above.	  276	   The	  metagenomes	  S4a	  and	  S4b	  from	  patient	  P82M3	  illustrate	  both	  explanations:	  277	   The	  first	  may	  explain	  the	  much	  lower	  ratio	  of	  rediscovery	  of	  SNPs	  in	  patient	  P82M3	  278	   compared	  to	  the	  other	  patients,	  because	  P82M3	  has	  been	  shown	  to	  harbour	  hyper-­‐279	   mutators.	  Hyper-­‐mutators	  are	  known	  to	  accumulate	  many	  unfavourable	  280	   mutations26,	  which	  are	  not	  expected	  to	  remain	  in	  the	  population,	  thus	  leading	  to	  a	  281	   low	  ratio	  of	  rediscovery	  (assuming	  that	  the	  mutations	  are	  not	  hitch-­‐hiking	  with	  282	   more	  favourable	  mutations).	  	  283	   Concerning	  the	  second	  explanation	  regarding	  low	  coverage	  of	  the	  metagenomic	  284	   samples,	  we	  found	  that	  in	  S4b	  26%	  (54	  of	  461)	  of	  the	  SNPs	  from	  the	  single	  isolates	  285	   of	  patient	  P82M3	  were	  rediscovered	  (the	  latest	  metagenome),	  whereas	  only	  12%	  286	   (122	  of	  461)	  were	  identified	  in	  S4a	  (the	  first	  metagenome).	  This	  is	  contradictory	  287	   since	  the	  mutations	  were	  previously	  identified	  in	  the	  single	  isolates	  and	  therefore	  288	   must	  be	  present	  to	  some	  degree	  in	  S4a	  in	  order	  to	  be	  identified	  in	  S4b.	  This	  suggests	  289	   that	  the	  subpopulation	  represented	  by	  the	  S4b	  metagenome	  is	  present	  below	  the	  290	   limit	  of	  detection	  in	  the	  S4a	  metagenome	  sequences	  and	  is	  therefore	  not	  identified.	  	  291	   For	  the	  two	  patients:	  P99F4	  and	  P92F3,	  the	  similar	  rediscovery	  ratios	  of	  SNPs	  292	   between	  the	  metagenomes	  and	  the	  single	  isolates	  from	  the	  two	  patients	  can	  be	  293	   explained	  by	  a	  co-­‐infection	  of	  the	  same	  clone	  type,	  DK26.	  294	   This	  relationship	  was	  noted	  previously	  and	  seems	  to	  be	  the	  consequence	  of	  a	  295	   patient-­‐to-­‐patient	  transmission	  event	  of	  the	  DK26	  clone	  from	  P92F3	  to	  P99F418,	  296	   explaining	  the	  lack	  of	  differentiation	  between	  the	  P.	  aeruginosa	  populations.	  297	   However,	  despite	  this	  close	  relationship	  between	  the	  populations,	  Figure	  3	  shows	  298	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that	  it	  is	  possible	  to	  distinguish	  between	  the	  SNPs	  of	  the	  single	  isolates	  and	  the	  299	   respective	  metagenomes.	  300	   We	  have	  identified	  SNPs	  in	  genome	  sequences	  of	  longitudinal	  single	  isolates,	  which	  301	   seem	  to	  be	  specific	  and	  representative	  for	  the	  patient	  specific	  community,	  including	  302	   cases	  of	  infections	  caused	  by	  patient-­‐to-­‐patient	  transmitted	  clones.	  A	  phylogenetic	  303	   analysis	  of	  the	  single	  isolates	  and	  metagenomes	  of	  the	  hyper-­‐mutator	  population	  of	  304	   patient	  P82M3	  underlines	  the	  patient	  specific	  relationship	  between	  metagenomes	  305	   and	  single	  isolates.	  	  306	   Figure	  4	  shows	  that	  the	  metagenomes	  are	  placed	  within	  the	  phylogeny	  of	  the	  single	  307	   isolates,	  confirming	  that	  the	  mutations	  identified	  in	  the	  single	  isolates	  are	  also	  308	   identified	  in	  the	  respective	  metagenomes,	  and	  that	  the	  these	  single	  isolates	  309	   therefore	  document	  the	  evolution	  and	  adaptation	  of	  the	  P.	  aeruginosa	  population.	  310	   	  311	  
	  312	  
Diversity	  of	  the	  P.	  aeruginosa	  populations	  	  313	   In	  the	  single	  isolates,	  the	  diversity	  of	  the	  P.	  aeruginosa	  populations	  was	  determined	  314	   from	  the	  phylogenies	  as	  the	  mean	  distance	  to	  the	  Line	  of	  Decent	  (LOD),	  as	  315	   previously	  described	  by	  Marvig	  (2013)12	  (Figure	  5).	  For	  the	  metagenome-­‐estimated	  316	   diversity	  (Figure	  6)	  we	  used	  the	  number	  of	  polymorphisms	  normalised	  to	  the	  317	   number	  of	  positions	  covered	  in	  the	  PAO1	  genome	  in	  order	  to	  correct	  for	  differences	  318	   in	  coverage	  between	  the	  different	  metagenomes	  (see	  Materials	  and	  Methods	  for	  319	   details).	  Because	  S4a	  and	  S4b	  (both	  from	  patient	  P82M3)	  are	  representative	  of	  the	  320	   same	  population	  we	  chose	  to	  merge	  the	  samples	  to	  carry	  out	  the	  inter-­‐patient	  321	   comparison	  of	  diversity	  (Figure	  6:	  S4,	  avg.).	  	  322	   In	  both	  the	  LOD	  calculations	  and	  the	  number	  of	  polymorphisms	  we	  find,	  not	  323	   surprisingly,	  that	  the	  hyper-­‐mutator	  population	  of	  patient	  P82M3	  had	  the	  highest	  324	   diversity	  and	  that	  patients	  with	  the	  shortest	  period	  of	  infection/colonisation	  325	   (P92F3)	  as	  expected	  harboured	  the	  least	  diverse	  population.	  We	  calculated	  LODs	  of	  326	   34.89	  and	  1.33	  mean	  distances	  to	  LOD	  for	  the	  two	  single	  isolate	  populations,	  and	  327	   diversity	  ratios	  of	  7.08E-­‐5,	  and	  4.20E-­‐05	  for	  the	  metagenome	  populations	  from	  the	  328	   two	  patients	  P82M3	  and	  P92F3,	  respectively.	  Thus,	  in	  both	  cases	  of	  diversity	  329	   measurements	  (single	  isolates	  and	  metagenomes)	  we	  see	  a	  significant	  difference	  330	   between	  the	  diversity	  of	  the	  P.	  aeruginosa	  populations	  of	  patient	  P82M3	  and	  P92F3	  331	   (p<0.05,	  Fisher’s	  Exact	  test	  with	  Holm	  correction)	  (Figure	  5	  and	  Figure	  6).	  332	   When	  analysing	  further	  the	  single	  population	  of	  patient	  P82M3,	  the	  diversity	  333	   calculations	  for	  the	  samples	  S4a	  and	  S4b	  illustrate	  that	  exhaustive	  sampling	  is	  334	   essential,	  not	  only	  when	  using	  single	  isolates	  but	  also	  for	  metagenomic	  samples,	  in	  335	   order	  to	  get	  the	  true	  picture	  of	  the	  population	  diversity.	  Because	  these	  two	  336	   metagenomes	  represent	  a	  non-­‐mutator	  and	  a	  hyper-­‐mutator	  subpopulation,	  337	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respectively,	  they	  have	  significantly	  different	  diversity	  ratios	  (4.90E-­‐05	  and	  9.25E-­‐338	   05,	  respectively,	  p<0.05	  Fisher’s	  Exact	  test	  with	  Holm	  correction).	  	  339	   In	  general,	  single	  isolates	  and	  metagenome	  analyses	  are	  dependent	  on	  exhaustive	  340	   sampling	  and	  because	  of	  the	  possibility	  of	  temporal	  dominance	  by	  different	  341	   subpopulations,	  as	  seen	  by	  the	  hyper-­‐mutator	  population	  of	  P82M3,	  the	  342	   metagenomic	  approach	  will	  also	  require	  multiple	  samples	  to	  reveal	  the	  complete	  343	   profile	  of	  the	  P.	  aerugonosa	  population,	  especially	  in	  cases	  of	  high	  diversity,	  e.g.	  344	   mutator	  populations.	  345	   	  346	  
	  347	  
DISCUSSION	  348	   Several	  investigations	  of	  long-­‐term	  bacterial	  infections	  based	  on	  the	  analysis	  of	  349	   longitudinally	  collected	  single	  isolates	  have	  been	  published	  in	  recent	  350	   years5,6,12,13,27,28,	  and	  some	  have	  included	  cross-­‐sectional	  analyses	  of	  the	  population	  351	   diversity	  at	  the	  genomic	  level11,16,29,30.	  	  352	   One	  reason	  to	  question	  the	  validity	  of	  using	  single	  isolates	  to	  infer	  evolutionary	  353	   dynamics	  of	  the	  entire	  population	  is	  the	  apparent	  heterogeneity	  of	  the	  P.	  aeruginosa	  354	   population	  in	  the	  CF	  patients11,15,16,29–32.	  This	  heterogeneity	  may	  be	  the	  result	  of	  355	   spatial	  heterogeneity	  of	  the	  CF	  airways	  and	  the	  confinement	  of	  different	  356	   subpopulations	  to	  different	  niches11,31.	  Or,	  a	  skewed	  community	  composition,	  where	  357	   one	  lineage	  is	  dominant	  where	  others	  are	  rare,	  in	  a	  form	  of	  frequency	  dependence32.	  	  358	   Our	  results	  and	  previous	  findings	  by	  Marvig	  (2015)13	  do	  not	  confirm	  spatial	  359	   isolation	  of	  different	  subpopulations	  in	  upper	  and	  lower	  airways	  (Figure	  4)	  as	  has	  360	   been	  suggested	  by	  Markussen	  (2014)11	  and	  Hansen	  (2012)31.	  In	  accordance	  with	  361	   Ciofu	  (2013)33	  and	  Johansen	  (2012)34	  we	  find	  that	  the	  same	  genetic	  populations	  362	   occupy	  both	  the	  upper	  and	  lower	  airways.	  Mixing	  of	  bacterial	  populations	  colonizing	  363	   different	  airway	  compartments	  is	  also	  supported	  by	  other	  studies	  showing	  both	  364	   genotypic	  and	  phenotypic	  overlap	  between	  samples	  from	  the	  upper	  and	  lower	  CF	  365	   airways33,35.	  Population	  mixing	  is	  expected	  to	  result	  in	  more	  homogenous	  366	   populations	  and	  might	  explain	  the	  low	  diversity	  in	  P99F4.	  However,	  we	  suspect	  that	  367	   the	  low	  diversity	  found	  in	  this	  particular	  patient	  is	  better	  explained	  by	  a	  recent	  368	   infection	  event.	  	  369	   Despite	  the	  evidence	  for	  population	  mixing,	  we	  and	  others11,32	  have	  observed	  370	   relatively	  diverse	  populations	  of	  P.	  aeruginosa	  in	  the	  CF	  airways,	  more	  in	  line	  with	  a	  371	   “Diverse	  Community”	  model	  as	  described	  by	  Lieberman	  et	  al.	  (2014)14.	  This	  model	  372	   was	  used	  to	  describe	  the	  evolutionary	  and	  adaptational	  dynamics	  of	  Burkholderia	  373	  
dolsa	  in	  CF	  airways.	  It	  is	  further	  supported	  for	  P.	  aeruginosa	  by	  others	  e.g.	  Mowat	  374	   (2011)15,	  Feliziani	  (2014)16,	  and	  Workentine	  (2013)29,	  and	  has	  been	  confirmed	  for	  375	  
Escherichia	  coli	  in	  vitro	  in	  homogenous	  laboratory	  cultures36,37.	  376	   	  377	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In	  this	  study	  we	  have	  compared	  five	  meta-­‐genomes	  obtained	  from	  four	  CF	  patient	  378	   sputum	  samples	  with	  corresponding	  single,	  longitudinally	  collected,	  P.	  aeruginosa	  379	   isolates,	  and	  a	  high	  degree	  of	  correlation	  was	  found.	  In	  addition,	  a	  highly	  diverse	  380	   population	  was	  investigated	  by	  including	  two	  meta-­‐genomes	  from	  a	  patient	  with	  381	   previously	  identified	  hyper-­‐mutator	  isolates.	  The	  meta-­‐genomes	  were	  sampled	  from	  382	   patients	  with	  the	  most	  common	  P.	  aeruginosa	  infection	  pattern	  at	  the	  Copenhagen	  383	   CF	  Centre	  (Johansen	  H.K.,	  unpublished),	  and	  they	  are	  therefore	  assumed	  to	  be	  384	   representative	  for	  most	  of	  the	  CF	  patients.	  	  385	   One	  of	  the	  limitations	  of	  our	  study	  compared	  to	  that	  of	  Lieberman	  et	  al.	  (2014)14	  is	  386	   the	  sequencing	  depth.	  This	  is	  especially	  true	  for	  the	  highly	  diverse	  population	  of	  387	   P82M3,	  in	  which	  we	  were	  unable	  to	  identify	  subpopulations	  if	  present	  in	  less	  than	  388	   10.03%	  of	  the	  population	  (the	  lowest	  coverage	  is	  9.97).	  Despite	  this,	  we	  were	  able	  to	  389	   document	  the	  same	  diversification	  of	  populations	  as	  Lieberman	  (2014)14	  and	  390	   others16,38,39.	  In	  addition,	  we	  were	  also	  able	  to	  determine	  that	  the	  different	  391	   subpopulations	  comprising	  this	  diversity	  differ	  in	  frequency	  over	  time.	  Especially	  in	  392	   the	  hyper-­‐mutator	  population,	  we	  noticed	  that	  the	  bacterial	  population	  is	  393	   dominated	  by	  different	  subpopulations	  at	  different	  time	  points	  (Table	  1	  and	  Figure	  394	   4).	  	  395	   	  396	   If	  diversity	  is	  stably	  maintained	  you	  would	  expect	  that	  the	  main	  diversity	  of	  the	  397	   metagenome	  is	  reflected	  by	  the	  bulk	  of	  the	  total	  SNPs	  identified	  in	  the	  single	  isolates	  398	   from	  the	  specific	  patient.	  The	  P.	  aeruginosa	  population	  of	  patient	  P82M3	  clearly	  399	   shows	  fluctuation	  of	  the	  frequency	  of	  mutations	  comprising	  the	  main	  diversity	  at	  400	   different	  time	  points.	  For	  the	  other	  three	  patients,	  especially	  P99F4	  and	  P92F3,	  the	  401	   diversity	  of	  the	  populations	  are	  maintained	  and	  most	  or	  all	  of	  the	  mutations	  found	  402	   in	  all	  the	  single	  isolates	  are	  present	  in	  the	  metagenomes	  in	  a	  high	  degree.	  403	   Specifically	  the	  finding	  for	  the	  P.	  aeruginosa	  population	  of	  P82M3	  is	  in	  agreement	  404	   with	  results	  from	  Mowat	  (2011)39,	  where	  they	  find	  that	  specific	  phenotypic	  405	   subpopulations	  (haplotypes)	  have	  a	  higher	  chance	  of	  being	  resampled,	  and	  thus	  are	  406	   more	  prevalent,	  than	  others	  at	  certain	  time	  points.	  Overall,	  they	  conclude	  that	  their	  407	   results	  are	  consistent	  with	  either	  1)	  continual	  emergence	  of	  new	  haplotypes,	  and/or	  408	   2)	  persistence	  of	  a	  diverse	  pool	  of	  haplotypes	  from	  which	  different	  haplotypes	  409	   exhibit	  fluctuating	  relative	  abundance.	  Especially	  the	  second	  hypothesis	  is	  410	   compatible	  with	  our	  results,	  from	  which	  we	  see	  the	  frequency	  of	  different	  mutations	  411	   changing	  over	  a	  time	  period	  as	  short	  as	  two	  weeks	  (S4a	  and	  S4b).	  This	  is	  further	  412	   consistent	  with	  the	  stable	  maintenance	  of	  most	  of	  the	  mutations	  from	  the	  early	  413	   single	  isolates	  to	  the	  late	  sampled	  metagenomes.	  	  414	   It	  is	  important	  to	  stress	  that	  in	  our	  previous	  analysis	  in	  Marvig	  (2015)13	  we	  see	  a	  415	   consistent	  pattern	  of	  mutations	  occurring	  over	  time	  during	  the	  infection.	  Genes	  such	  416	   as	  gyrA/B,	  rpoB,	  mucA,	  algU,	  lasR,	  mexZ	  are	  continuously	  observed	  to	  accumulate	  417	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mutations	  independent	  of	  the	  study	  approach11–13,16,27,31,40,	  indicating	  that	  418	   evolutionary	  and	  adaptational	  patterns	  can	  be	  documented	  by	  investigations	  such	  419	   as	  those	  applied	  here,	  including	  investigations	  of	  longitudinally	  collected	  single	  420	   isolates.	  421	   	  422	   In	  summary,	  our	  results	  show	  that	  it	  is	  possible	  to	  align	  population	  dynamic	  results	  423	   obtained	  from	  genomic	  investigations	  of	  longitudinally	  collected	  single	  isolates	  of	  P.	  424	  
aeruginosa	  populations	  (metagenomes),	  as	  exemplified	  by	  the	  culture	  independent	  425	   analysis	  of	  sputum	  samples.	  426	   The	  results	  of	  this	  study,	  taken	  together	  with	  similar	  results	  from	  other	  studies,	  427	   suggest	  that	  using	  comprehensive	  collections	  of	  longitudinally	  collected	  single	  428	   isolates	  in	  the	  research	  of	  adaptation	  and	  evolution	  of	  P.	  aeruginosa	  to	  the	  CF	  429	   airways	  will	  yield	  useful	  results.	  However,	  considering	  the	  cost	  and	  ease	  of	  430	   sequencing	  the	  use	  of	  metagenomic	  analyses	  for	  a	  deeper	  understanding	  of	  the	  431	   population	  dynamics	  of	  P.	  aeruginosa	  evolution	  and	  adaptation	  is	  indeed	  432	   encouraged.	  433	   	  434	  
Supplementary	  material:	  435	   Supplementary	  Table	  S1:	  Average	  coverage	  of	  bases	  that	  have	  been	  sequenced	  and	  436	   aligned	  to	  the	  reference	  genome	  of	  PAO1.	  437	   	  438	   Supplementary	  Table	  S2:	  Clone	  type	  comparisons	  between	  single	  isolates	  439	   (Corresponding	  to	  the	  isolate	  numbers	  previously	  published	  in	  Study	  2)	  and	  440	   metagenomes	  from	  same	  patient.	  Next	  to	  the	  isolates	  of	  DK26	  there	  is	  also	  written	  441	   the	  patient	  from	  where	  it	  was	  sampled,	  since	  two	  patients	  in	  this	  study	  were	  442	   colonised	  and	  infected	  with	  this	  clone	  type.	  443	   	  444	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FIGURES	  AND	  TABLES	  
	  
Table	  1:	  Examples	  of	  rediscovered	  SNPs	  in	  S4a	  and	  S4b.	  Examples	  of	  mutations	  571	   not	  found	  in	  S4a	  but	  in	  S4b.	  572	  
	  573	   	  	  
	  
Figure	  1,	  Overview.	  A)	  Overview	  of	  single	  isolate	  sampling	  from	  four	  CF	  patients,	  574	   clone	  types	  that	  are	  considered	  to	  be	  transient	  (found	  in	  1-­‐2	  time	  points)	  are	  575	   marked	  with	  #,	  +,	  x,	  or	  *,	  whereas	  clones	  considered	  to	  be	  persistent	  in	  the	  patient	  is	  576	   marked	  by	  coloured	  circles.	  Metagenomes	  are	  marked	  with	  stars,	  black	  if	  sampled	  577	   before	  i.v.	  antibiotic	  treatment,	  and	  white	  if	  sampled	  after	  i.v.	  antibiotic	  treatment.	  578	  
B)	  Overview	  of	  metagenome	  sampling	  from	  patients,	  in	  correlation	  with	  two-­‐week	  579	   i.v.	  antibiotic	  treatment.	  	  580	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Figure	  2,	  SNP	  rediscovery	  in	  metagenomes.	  Above	  each	  subfigure	  it	  is	  indicated	  581	   which	  single	  isolates’	  SNPs	  that	  have	  been	  sought	  rediscovered	  in	  the	  metagenomes	  582	   (clone	  type	  and	  patient).	  The	  grey	  bars	  indicate	  the	  ratio	  of	  SNP	  positions	  that	  were	  583	   sequenced	  in	  the	  metagenomes	  and	  the	  black	  bars	  indicate	  the	  ratio	  of	  the	  584	   rediscovered	  reads	  to	  the	  sequenced	  positions.	  The	  metagenomes	  belonging	  to	  the	  585	   same	  patient	  as	  the	  single	  isolates	  they	  are	  compared	  to	  is	  indicated	  with	  a	  larger	  586	   font.	  NOTE,	  S2	  and	  S3	  are	  from	  different	  patients	  but	  the	  same	  clone	  type.	  P<0.05,	  587	   Fisher’s	  exact	  test	  with	  Holm	  correction,	  significant	  differences	  are	  indicated	  by	  “a”	  588	   and/or	  “b”.	  589	   	  
	  
Figure	  3,	  Patient	  specific	  correlation	  of	  rediscovered	  SNPs	  within	  a	  single	  590	  
clone	  type.	  A	  comparison	  of	  the	  SNPs	  found	  in	  the	  single	  isolates	  of	  the	  patients	  591	   P99F4	  and	  P92F3	  as	  well	  as	  their	  respective	  metagenomes,	  S2	  and	  S3.	  For	  the	  single	  592	   isolates	  a	  dark	  green	  colour	  indicates	  the	  presence	  of	  SNPs	  and	  white	  the	  absence.	  593	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For	  the	  metagenomes	  the	  green	  colours	  (dark,	  medium,	  light)	  indicates	  that	  >90%,	  594	   51-­‐90%,	  and	  11-­‐50%	  of	  the	  reads	  covering	  the	  position	  of	  the	  SNP	  confirms	  the	  595	   mutation,	  and	  if	  the	  SNP	  is	  confirmed	  with	  <=10%	  the	  SNP	  is	  not	  considered	  to	  be	  596	   found	  in	  the	  metagenomes,	  indicated	  by	  white.	  597	  
	  598	  
Figure	  4:	  DK32	  P82M3	  maximum	  likelihood	  phylogeny	  including	  599	  
metagenomes.	  Blue	  shapes	  indicate	  single	  isolates	  sampled	  with	  different	  methods	  600	   and	  from	  different	  locations	  (see	  legend)	  and	  stars	  indicate	  metagenomes.	  The	  scale	  601	   bar	  indicates	  0.1	  likelihood	  of	  mutation.	  602	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  603	  
Figure	  5,	  Mean	  distance	  to	  Line	  of	  Decent	  (LOD).	  Maximum	  parsimonious	  604	   phylogenetic	  trees	  for	  all	  clone	  types	  identified	  in	  the	  metagenomes	  as	  being	  the	  605	   latest.	  The	  red	  line	  in	  the	  trees	  indicates	  the	  LOD	  wherefrom	  SNPs	  (numbers	  on	  606	   branches)	  have	  been	  counted.	  The	  LOD	  is	  set	  from	  the	  root	  (created	  for	  P41M3	  and	  607	   P82M3	  using	  PAO1	  as	  out-­‐group)	  to	  the	  divergence	  of	  latest	  sampled	  isolates.	  White	  608	   circles	  indicate	  the	  earliest	  sampled	  isolates	  and	  black	  circles	  indicates	  the	  latest	  609	   sampled	  isolates	  from	  each	  patient,	  the	  coloured	  circles	  are	  comparable	  to	  the	  610	   colours	  of	  Figure	  1.	  For	  each	  patient	  a	  mean	  distance	  to	  LOD	  is	  indicated	  below	  the	  611	   patient	  name	  to	  the	  right	  of	  the	  corresponding	  tree.	  The	  LOD	  of	  P82M3	  is	  612	   significantly	  different	  from	  the	  other	  patients,	  p<0.01,	  Fisher’s	  Exact	  test	  with	  Holm	  613	   correction.	  614	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Figure	  6,	  Polymorphic	  positions	  in	  the	  metagenomes.	  Because	  of	  the	  differing	  615	   coverage	  of	  the	  PAO1	  reference	  genome,	  the	  number	  of	  polymorphisms	  is	  shown	  as	  616	   a	  ratio	  of	  polymorphisms	  and	  the	  coverage	  of	  each	  metagenome	  to	  PAO1.	  S4,	  avg.	  is	  617	   the	  average	  of	  S4a	  and	  S4b.	  p<0.05	  Fisher’s	  exact	  test	  with	  Holm	  correction.	  	  618	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Supplementary	  Table	  S1.
Average coverage of bases that have been sequenced and alligned to the refference genome of PAO1.
Sample Total	  reads Total	  bases	  of	  PAO1 Total	  bases	  sequenced	  of	  PAO1 Coverage	  of	  positions	  sequenced Resolution	  (%)*
S1 159590945 6264404 6060807 26.33 3.80
S2 186456550 6264404 6084424 30.64 3.26
S3 123114192 6264404 6075272 20.26 4.93
S4a 59893402 6264404 6009803 9.97 10.03
S4b 68510406 6264404 6013647 11.39 8.78
*That	  is,	  if	  a	  subpopulation	  isto	  be	  detected	  by	  the	  sequencing	  it	  needs	  to	  be	  present	  with	  more	  than	  X%	  of	  the	  population.
Supplementary	  Table	  S2.
REF QRY
Patient Isolate Clone Metagenome Clone	  (presumed) total	  bases	  (ref) total	  bases	  (qry) unaligned	  bases	  (ref) % unaligned	  bases	  (qry) % total	  GSNPs
156 DK19 LM_4833 DK19 6559603 5992396 570509 8.70% 3686 0.06% 91
382 DK26	  (P99F4) LM_4833 DK19 7002729 5992396 1108299 15.83% 93554 1.56% 30918
390 DK06 LM_5085 DK26	  (P99F4) 6676808 6002328 783036 11.73% 102156 1.70% 17339
382 DK26	  (P99F4) LM_5085 DK26	  (P99F4) 7002729 6002328 1010190 14.43% 2290 0.04% 131
388 DK51 LM_5085 DK26	  (P99F4) 6311260 6002328 361076 5.72% 44807 0.75% 17844
386 DK50 LM_5085 DK26	  (P99F4) 6261092 6002328 345715 5.52% 78021 1.30% 27331
272 DK26	  (P92F3) LM_4711 DK26	  (P92F3) 6666214 5993232 681864 10.23% 7738 0.13% 111
156 DK19 LM_4711 DK26	  (P92F3) 6559603 5993232 672137 10.25% 105926 1.77% 30862
224 DK32 LM_4866 DK32 6371360 5606193 797887 12.50% 6501 0.12% 407
224 DK32 LM_5137 DK32 6381360 5829566 571810 8.96% 5368 0.09% 527
272 DK26	  (P92F3) LM_4866 DK32 6666214 5606193 1132616 16.99% 56614 1.01% 16269
272 DK26	  (P92F3) LM_5137 DK32 6666214 5829566 909380 13.64% 58946 1.01% 17043
P41M3
P99F4
P92F3
P82M3
Clone	  type	  comparisons	  between	  single	  isolates	  (Corresponding	  to	  the	  isolate	  numbers	  previously	  published	  in	  Study	  2)	  and	  metagenomes	  from	  same	  patient.	  Next	  to	  the	  isolates	  of	  DK26	  there	  is	  also	  written	  the	  patient	  from	  
where	  it	  was	  sampled,	  since	  two	  patients	  in	  this	  study	  were	  colonised	  and	  infected	  with	  this	  clone	  type.
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4.2 study 2 :
Convergent evolution and adaptation of Pseudomonas
aeruginosa within patients with cystic fibrosis.
Marvig R. L., Sommer L. M., Molin S., and Johansen H. K.
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A molecular understanding of how bacterial pathogens evolve during 
infection in their human hosts is important for the ability to treat infec-
tions. Advances in genome sequencing have made it possible to follow 
the evolution of bacteria by sequencing the genomes of the same strain 
over shorter or longer time periods1–12. Genome sequencing of bacte-
rial pathogens has shown how the pathogenicity of bacterial clones can 
evolve via mutational changes in preexisting genes, a mechanism also 
known as pathogenicity or pathoadaptive mutation13. Although many 
such studies have provided insight into the genomic evolution of single 
clonal lineages (or clonal complexes) of human pathogens, little is 
known about how evolutionary paths compare between large numbers 
of genotypically different strains of the same species. For example, it 
remains unclear (i) to what extent natural selection restricts lineages 
with different genetic backgrounds to common pathways leading to 
adaptive phenotypes and (ii) in which way evolutionary outcomes 
become intertwined over time such that future alternatives may be 
contingent on the previous history of an evolving population.
To address these questions about evolutionary convergence and the 
role of historical contingency, we investigated the molecular evolution 
of distinct clonal lineages of P. aeruginosa from initial invasion of 
cystic fibrosis airways onward, as the lineages genetically adapted to 
a human host after transition from their environmental habitat. Our 
study was based on a large and diverse collection of 474 longitudinally 
collected isolates of P. aeruginosa sampled from the airways of patients 
with cystic fibrosis, in which P. aeruginosa was the predominant 
pathogen associated with increased morbidity and mortality14.
RESULTS
Clinical collection of genome-sequenced bacterial isolates
Patients with cystic fibrosis attending the Copenhagen Cystic Fibrosis 
Center are closely followed, and sputum samples are cultured monthly 
to identify cystic fibrosis–associated bacterial pathogens at an early 
stage15. As a consequence, sputum samples are tested every month for 
the presence of P. aeruginosa, and antibiotic chemotherapy is initiated 
whenever P. aeruginosa is cultured (Online Methods). Furthermore, 
P. aeruginosa isolates are freeze stored for further characterization 
(Fig. 1). In this study, we have sequenced the whole genomes of 
a total of 474 isolates of P. aeruginosa sampled from the airways of 
34 children and young individuals with cystic fibrosis (median age 
at first sequenced P. aeruginosa isolate = 8.8 years, range = 1.4–26.3 
years). To obtain a bacterial collection that would give insight into 
the longitudinal progression of the early phase of infection, we 
chose to sequence the genomes of initial and subsequent isolates of 
P. aeruginosa from each of the subjects. On average, we sequenced 
the genomes of 12.9 isolates (range = 3–28 isolates) from each subject 
(Fig. 2 and Supplementary Fig. 1), and the average time span for the 
sequenced isolates of P. aeruginosa from each subject was 4.8 years 
(range = 1–10 years) (Fig. 2 and Supplementary Fig. 2).
Phylogenetically distinct clone types of P. aeruginosa
We compared the genomes of the 474 sequenced isolates and found 
that they grouped into 53 genetically distinct clone types (clonal 
complexes16) (Fig. 1b). Genomes for isolates of the same clone type 
differed on average by 122 SNPs (median = 9 SNPs, range = 0–1,333 
SNPs), whereas genomes from different clone types differed by 
>10,000 SNPs (Fig. 1c).
Common clone types and transmission
Children with cystic fibrosis are anticipated to acquire their first 
P. aeruginosa colonization from unique environmental clone types 
of P. aeruginosa that are naive to the airways of the human host17. In 
agreement with this, we found 43 of the 53 clone types in only a single 
Convergent evolution and adaptation of Pseudomonas 
aeruginosa within patients with cystic fibrosis 
Rasmus Lykke Marvig1,2, Lea Mette Sommer2,3, Søren Molin2,3 & Helle Krogh Johansen1,3
Little is known about how within-host evolution compares between genotypically different strains of the same pathogenic species. 
We sequenced the whole genomes of 474 longitudinally collected clinical isolates of Pseudomonas aeruginosa sampled from 
34 children and young individuals with cystic fibrosis. Our analysis of 36 P. aeruginosa lineages identified convergent molecular 
evolution in 52 genes. This list of genes suggests a role in host adaptation for remodeling of regulatory networks and central 
metabolism, acquisition of antibiotic resistance and loss of extracellular virulence factors. Furthermore, we find an ordered 
succession of mutations in key regulatory networks. Accordingly, mutations in downstream transcriptional regulators were 
contingent upon mutations in upstream regulators, suggesting that remodeling of regulatory networks might be important in 
adaptation. The characterization of genes involved in host adaptation may help in predicting bacterial evolution in patients with 
cystic fibrosis and in the design of future intervention strategies.
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subject. However, we also identified ten clone types that were found 
in multiple subjects (Fig. 2).
The occurrence of the same clone type in several patients could 
be due to (i) direct patient-to-patient transmission in the outpa-
tient clinic or in the ward, (ii) indirect transmission via instruments 
in the clinic or exposure to the same environmental reservoirs, or 
(iii) the existence of common environmental clone types16,18. When 
we measured the genetic distances between isolates of the same clone 
type sampled from different patients, we found that, in most cases 
(n = 19), at least 50 SNPs separated isolates from different patients 
(Fig. 3a). Taking into account that the within-patient mutation rate 
of P. aeruginosa is around 2.6 SNPs/year1, we consider it unlikely 
that the presence of the same clone type in such cases is due to recent 
and/or direct patient-to-patient transmission. Instead, the presence 
of genetically distant isolates of the same clone type in these patients 
might be the result of transmission via patients not included in this 
study or the result of independent acquisitions of the clone type from 
the environment.
In a few cases (n = 5), only a few SNPs (range = 0–29 SNPs) dif-
ferentiated clonal isolates from different patients (Fig. 3a), suggest-
ing the occurrence of recent transmission events between patients, 
including P36F2 and P19F5 infected by clone type DK15; P21F4, 
P77F4 and P99F4 infected by clone type DK06; and P99F4 and P92F3 
infected by clone type DK26. To investigate whether there were any 
epidemiological data to support recent transmission between these 
individuals, we retrieved information on the patients’ visits to the hos-
pital. In all cases of suggested patient-to-patient transmission, there 
were temporal overlaps in the respective patients’ visits to the hospital 
during the period before the detection of transmission (Fig. 3b). We 
presume that the clone types were transmitted from the older patients, 
in whom they were first identified, to the younger patients, in whom 
they were identified later. However, one should note that within-host 
population heterogeneity might confound such conclusions about the 
direction and source of transmission19.
Identification of recent mutational events in clone types
It has previously been shown that P. aeruginosa genetically adapts 
to the human host environment1–4. Accordingly, each of the 
53 clone types might have genetically adapted to human airways upon 
transition from the environment. To detect such recent mutational 
events in each clonal type, we compared the genomes of isolates 
from the same clone type to reconstruct the evolutionary history of 
each of the clonal lineages (that is, to identify mutations that 
have accumulated since the most recent common ancestor (MRCA)) 
(Fig. 1c). Note that such genetic comparisons were only possible for 
36 of the 53 clone types, as 17 of the clone types were only represented 
by a single isolate.
The mutations in each of the lineages accumulated in a highly 
parsimonious fashion (average parsimonious consistency of 0.94; 
Supplementary Table 1), reflecting unidirectional and clonal evo-
lution of the lineages since the MRCA. Thus, using a maximum-
parsimony phylogenetic model, we were able to make inferences 
about the succession of mutations and the relationship among 
P. aeruginosa clones.
As a measure of the within-patient diversity of clonal popula-
tions, we counted the number of SNPs each isolate had accumu-
lated since the MRCA of clonal isolates from the same patient. The 
median genetic distance to the MRCA of clonal isolates from the 
same patient was 8 SNPs, but 55 isolates belonging to 7 different clone 
types diverged from the MRCA by >50 SNPs (Supplementary Fig. 3). 
X Y Z
Different clone types
Variants of
the same
clone type
a Genome sequencing
Patient with cystic brosis
Pseudomonas aeruginosa
Comparative genomics
Pseudomonas aeruginosa
XClone type ZY
Most recent common ancestor
Genome-sequenced clonesDistant evolutionary history
>10,000 SNPs
Recent evolutionary history
~100 SNPs
Clinical sampling
c
bFigure 1 Overview of the present investigations. (a) To study within-
patient evolution, we collected 474 isolates of P. aeruginosa from  
the airways of 34 patients with cystic fibrosis. (b) Genome sequencing 
identified 53 different clone types among the 474 isolates of P. aeruginosa.  
(c) Considerable genetic diversity existed between isolates of different 
clone types (>10,000 SNPs), whereas isolates from the same clone 
type differed by relatively few SNPs. On the basis of intraclonal genome 
comparisons, we reconstructed the phylogenetic history of each of the 
clonal complexes to gain insight into its recent evolutionary history, which 
most likely contains recent adaptive events that have occurred in the 
human host environment.
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Figure 2 Overview of the 474 genome-sequenced P. aeruginosa isolates. 
Each symbol represents a genome-sequenced isolate of P. aeruginosa. 
Axes indicate the patient from whom the isolate was derived and the time 
of sampling for each of the isolates. Specific symbols are indicated for 
isolates belonging to clone types (n = 10) that have been sampled from 
multiple patients. Colors are used where the same clone type was found in 
more than two patients (see Fig. 3 for further details).
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The large within-patient clone diversity in six of the seven line-
ages (DK01, DK12, DK15, DK32, DK36 and DK53) was due to an 
increased frequency of transition substitutions (note, in DK12, only 
part of the high degree of variation was due to an excess of transition 
substitutions; see the explanation below and Supplementary Fig. 4). 
This finding suggests hypermutation caused by defects in the DNA 
mismatch repair (MMR) genes1,20, and, in agreement with this, we 
found that the six lineages were the only ones to have accumulated 
nonsynonymous mutations in one of the DNA MMR genes mutS  
(n = 2) and mutL (n = 3) or in both genes (n = 1). Nonetheless, no 
mutational signatures of hypermutation or of horizontal gene transfer 
were evident to explain the large within-patient variation of DK40 
isolates from patient P73M4 (Supplementary Fig. 5). Similarly, part 
of the genetic variation among DK12 isolates from patient P44F5 
could not be explained by hypermutation, as the particular isolates did 
not carry mutations in MMR genes nor exhibited mutational skews 
in transition-to-transversion ratios (Supplementary Fig. 4). Instead, 
we speculate that, in these two patients, the clonal variation was gen-
erated before infection and that the presence of genetically distant 
isolates of the same clone type is the result of multiple independent 
acquisitions of the same clone type from the environment or of a 
single acquisition of a diverse population.
Parallel evolution of genes involved in host adaptation
In total, we identified 12,324 mutations (9,517 SNPs and 2,807 small 
insertions and deletions (microindels)) that accumulated in the recent 
evolutionary history of the 36 clone types for which we had sam-
pled multiple isolates (Supplementary Tables 2 and 3). We expect 
all clonal lineages to accumulate adaptive mutations in response to 
the environment of the human hosts in which they propagate. We 
therefore anticipate that parallelism might exist in the adaptive genetic 
routes of the different lineages. To identify such convergent evolution, 
we sought to identify genes that were mutated in parallel in multiple 
clone types. On the basis of the number of nonsynonymous mutations 
that accumulated in each lineage, we estimated the expected number 
of genes having nonsynonymous mutations in ≥x clone types, con-
sidering a scenario in which mutations were randomly introduced 
by genetic drift (Online Methods and Supplementary Table 4). As 
larger genes are more likely to be randomly mutated, the criterion 
for which genes we would identify as subject to convergent evolution 
took into account the lengths of genes. Accordingly, we identified a 
total of 52 genes that were more frequently mutated than what would 
be expected under genetic drift (Fig. 4 and Supplementary Table 5). 
Our findings suggest that parallel nonsynonymous mutations in these 
52 genes are the result of positive selection for mutations in genes 
undergoing adaptive evolution. Therefore, we refer to these as can-
didate pathoadaptive genes in which mutations optimize pathogen 
fitness1, although the presence of neutral mutational hotspots might 
contribute to the high mutation number in some genes.
We also note that, despite clinical tests for the presence of 
P. aeruginosa in the patients on a monthly basis, we cannot formally 
exclude the possibility that lineages might have acquired adaptive 
mutations that were already in the ancestor of the sampled isolates. 
Nonetheless, this possibility did not seem to confound our analyses, 
and, for example, no insertions or deletions were found to be fixed 
a priori in any of the lineages in the mucA, lasR and rpoN genes 
in which loss-of-function mutations are typical markers of cystic 
fibrosis–associated lung infections2,14.
Function of pathoadaptive genes
We grouped the 52 candidate pathoadaptive genes according to 
their PseudoCap functions21 (Fig. 5a and Supplementary Table 5), 
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Figure 3 Clone types found in more than one patient.  
(a) Shortest genetic distances between P. aeruginosa  
isolates of the same clone type but from different patients.  
Numbers indicate the minimum number of SNPs that differentiate  
two isolates of the same clone type sampled from different  
patients. SNPs separated by ≤50 bp on the chromosome were  
not counted, as they might represent horizontal gene transfer  
(our conclusions were unaffected by this correction;  
see supplementary table 9 for the total number of SNPs).  
Colors are used where isolates of the same clone type were found in more than two patients. Lines with arrows show the direction of patient-to-
patient transmission as suggested by epidemiological data. (b) Overview of the patients’ visits to the hospital (Copenhagen Cystic Fibrosis Center, 
Rigshospitalet). The phylogenetic data presented in a suggest that clone type DK15 was transmitted between patients P36F2 and P19F5, that 
clone type DK06 was transmitted between patients P21F4, P77F4 and P99F4, and that clone type DK26 was transmitted between patients P99F4 
and P92F3. Vertical black lines show information about the patients’ visits to the hospital in the period before detection of transmission. In all 
cases of suggested patient-to-patient transmission, the respective patients’ visits to the hospital overlap temporally.
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finding an over-representation of the classes 
‘antibiotic resistance and susceptibility’, 
‘motility and attachment’, ‘DNA replication, 
modification and repair’, ‘cell wall/LPS/
capsule’, ‘secreted factors (toxins, enzymes, 
alginate)’ and ‘transcriptional regulators’ 
(Supplementary Table 6). These results 
are in line with previous studies that have 
reported that P. aeruginosa host adaptation 
is mediated by loss of motility, acquisition of 
antibiotic resistance, remodeling of regula-
tory networks, loss of extracellular virulence 
factors and modification of the cell enve-
lope1,22–29. Furthermore, we anticipate that 
mutations, in general, are associated with 
loss of gene function, as 45 of the 52 genes 
were targeted by frameshift mutations (with 
the exceptions of gyrA, gyrB, PA1471, pcoA, 
mexS, vgrG and yecS).
A large proportion of the 52 candidate pathoadaptive genes have 
previously been associated with cystic fibrosis–associated infections. 
For example, ten of the genes (gyrA, gyrB, mexA, mexB, mexR, mexS, 
mexZ, nalD, nfxB and oprD) have been shown to be involved in resist-
ance against a range of antibiotics27,30–33, such as β-lactams, quinolo-
nes, chloramphenicol, macrolides, aminoglycosides and penicillins, 
and eight of the genes (bifA, lasR, morA, phaF, rbdA, retS, wspA and 
wspE) are involved in regulation of biofilm formation34–40.
Yet, the implications for pathogenesis of other candidate pathoa-
daptive genes are less apparent. For example, 11 clone types 
accumulated nonsynonymous mutations (3 frameshifting indels, 
1 in-frame indel, 10 missense mutations and 1 nonsense mutation) 
in either aceE or aceF encoding the E1 and E2 components, respec-
tively, of the pyruvate dehydrogenase complex, which controls the 
flux of glycolytic carbon entering the tricarboxylic acid (TCA) cycle. 
Analyses of P. aeruginosa growth on a medium designed to represent 
the nutritional content of sputum from patients with cystic fibro-
sis have shown that aceE and aceF knockout strains produce large 
amounts of pyruvate41, and, under anaerobic growth conditions 
(and in the absence of alternative electron acceptors), P. aeruginosa 
uses the conversion of pyruvate to acetate and lactate for long-term 
survival42. This observation suggests that the remodeling of central 
metabolism signaling has a role in the pathogenesis of P. aeruginosa 
within the host.
Finally, we also identified genes of unknown function and without 
previous implication in pathogenesis, for example, the PA3290 gene, 
which were among the 13 genes with the highest frequency of non-
synonymous mutations (Fig. 5b).
Convergence and constraints in genetic adaptation
Repeated nonsynonymous mutation of the same genes suggests that 
evolution toward some common beneficial phenotype is constrained 
to mutations in a single or a few genes. The wsp signal transduc-
tion pathway encoded by wspABCDEFR regulates biofilm formation 
through the modulation of cyclic diguanylate levels40. Although none 
of the 7 pathway genes were mutated in more than 7 clone types, 
we found that 14 of the clone types had acquired nonsynonymous 
mutations in at least one of the wsp genes. This finding indicates that 
there is strong selection for mutation of this regulatory network and 
that the adaptive phenotype is obtainable through multiple different 
evolutionary pathways.
In contrast, the mutational routes to some beneficial phenotypes 
might be more constrained. Accordingly, we found that the most 
frequently mutated gene, mexZ, had nonsynonymous mutations 
(24 frameshifting indels, 6 in-frame indels and 10 missense SNPs) 
in more than half (n = 20) of the 36 lineages (Fig. 5b), indicating 
that mutation of mexZ is part of a strongly selected but constrained 
evolutionary pathway. The MexZ protein is a negative regulator of the 
MexXY-OprM multidrug efflux pump43,44, whose overexpression is 
associated with resistance to the aminoglycoside tobramycin45, one 
of the first-line antibiotics used in the cystic fibrosis clinic, and mexZ 
has previously been reported to be frequently mutated during cystic 
fibrosis airway infections2,46.
Contingency between mutations in signaling pathways
Constitutive or conditional overproduction of alginate lead-
ing to mucoid colony morphologies is another hallmark of cystic 
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fibrosis–associated infections14. Alginate 
production is positively regulated by the 
alternative sigma factor AlgU (also known as 
σ22 or σE)47,48, which is normally sequestered 
by binding to the anti-sigma factor MucA 
(Fig. 6a), and we found both of the cor-
responding genes to be among the most 
mutated candidate pathoadaptive genes, 
with 28 and 31 nonsynonymous mutations, 
respectively (Fig. 5b). There was a strong co-
occurrence of mutations in algU and mucA, 
and 25 of the 28 algU mutations were found in 
isolates that also carried mutations in mucA. 
Intriguingly, the order in which the algU and 
mucA mutations occurred was not random, 
as the mutations in algU were consecutive to 
the mutations in mucA in 20 of the 25 mucA and algU double mutants 
(in the remaining 5 cases, phylogenetic inference could not be used to 
resolve the order of the mutations) (Fig. 6b). This finding constitutes 
an example of historical contingency, where a constitutive mucoid 
phenotype caused by loss-of-function mutation in mucA is fully or 
partly abolished by secondary mutation in algU. We suggest that 
this evolutionary trajectory is selected for in cystic fibrosis airways 
because constitutive mucoidity may have immediate benefits; however, 
regulation of this energy-draining phenotype may subsequently be 
remodeled by mutation of algU23,48–50. Because AlgU is also a positive 
regulator of the stress response47,48, another possibility might be that a 
constitutive stress response, not mucoidity, is selected for by mutation 
of mucA. In this way, mucoidity might just be a pleiotropic effect that 
is compensated for by subsequent mutation of algU.
We searched our data set for other mutational dependencies, find-
ing 11 cases in which the infecting lineages had acquired more than 
one nonsynonymous mutation in the retS-gacS-gacA-rsmZ-rsmA 
signaling pathway since the MRCA (Supplementary Fig. 6). The 
retS-gacS-gacA-rsmZ-rsmA signaling pathway reciprocally controls 
the expression of genes important for acute and chronic infection39 
(Fig. 6c), so we anticipated that mutations in this pathway might 
constitute another example of historical contingency.
RetS inhibits GacA/GacS-activated expression of the small reg-
ulatory RNA rsmZ, which binds to and sequesters RsmA. RsmA 
is responsible for the reciprocal regulation of genes important 
for acute and chronic infection (Fig. 6c). In all 11 infecting line-
ages, the upstream regulator retS was mutated before mutation 
of the downstream regulators gacA, gacS or rsmA (Fig. 6d and 
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Figure 5 The most frequently mutated 
functional classes and genes. (a) Distribution 
on the PseudoCap functional classes of the 
genes (n = 52) subject to convergent evolution. 
Asterisks denote functional classes that are 
significantly over-represented among the 52 
mutated genes (P(X ≥ x) ~binom(X; p) < 0.05, 
where P(X ≥ x) is the probability of observing 
≥x of the 52 genes belonging to a functional 
class present in the genome with a frequency 
p; supplementary table 6). The asterisk in 
parentheses indicates the P value for secreted 
factors (toxins, enzymes, alginate), 0.058.  
(b) Genes (n = 13) mutated in at least 9 
different clone types. Horizontal bars show 
the number of mutated clonal types and the 
total number of nonsynonymous mutations 
(supplementary table 5).
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Figure 6 The order of mutations in mutants with two nonsynonymous 
mutations in the same regulatory pathway. (a–d) We identified 25 and 11 
unique double mutants with mutations in 2 of the genes in the mucA-algU 
(a) and retS-gacS-gacA-rsmZ-rsmA (c) regulatory pathways, respectively. 
On the basis of the phylogeny of the mutants, we were able to infer the 
order of the mutations in the mucA-algU (b) and retS-gacS-gacA-rsmZ-
rmsA (d) regulatory pathways, that is, which of the possible mutational 
routes (A, B or C) led to the double mutant. WT, wild type.
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Supplementary Fig. 6). The mutational signatures of retS, gacA  
and gacS suggest that these genes are targeted by loss-of-function 
mutations (all three genes had frameshift mutations), whereas 
the two missense substitutions in RsmA were located in the RNA-
binding site51, thus preventing binding by rsmZ. Using the regulatory 
model devised by Goodman and colleagues39 (Fig. 6c), we predicted 
that the retS mutations directed the bacteria toward a chronic infec-
tion state, whereas the secondary mutations in either gacA, gacS or 
rsmA reverted this effect. Furthermore, our findings suggest that, 
although the retS-gacS-gacA-rsmZ-rsmA signaling pathway seems to 
be important for infection, it might be overly simplifying to regard 
the regulatory pathway as a bimodal switch between either an acute 
or chronic infection state.
DISCUSSION
By sequencing and analyzing the genomes of 474 isolates of 
P. aeruginosa, we have gained insight into the evolution of an 
opportunistic pathogen after its environmental transition into the 
airways of patients with cystic fibrosis. To our knowledge, this is the 
largest and most diverse collection of genome-sequenced bacterial 
isolates from patients with cystic fibrosis. Although there are already 
a few other studies encompassing several hundreds of whole genome–
sequenced isolates of bacterial pathogens5–12, our study is unique in 
its focus on an opportunistic pathogen causing long-term infections. 
Initial bacterial isolates were sampled at the onset of infection in 
34 young patients with cystic fibrosis, and sampling was continued, 
on average, for 4.8 years (~20,000 bacterial generations52), allowing 
us to obtain a comprehensive picture of the genetic adaptation of 
microorganisms to a new environment4,53.
In addition, whereas many other studies are focusing on single 
clonal lineages or complexes of a pathogenic species, our collection 
compares the within-host evolution of 36 genotypically different 
strains of the same species. This is an important issue, as mutations 
or genes associated with pathogenicity in one strain of P. aeruginosa 
might not be predictive of pathogenicity in other strains54. We found 
evidence for convergent molecular evolution in 52 genes across the 
36 lineages, with the majority having annotated functions related to 
phenotypes considered important for infection. Mutation of five of 
these genes (lasR, mexA, mexS, nexZ and yecS) was suggested to be 
involved in host adaptation in a study by Smith et al. that carried 
out the first genome comparison of longitudinally collected clinical 
isolates of P. aeruginosa2. Furthermore, another 7 of the 52 genes 
(algU, gyrA, gyrB, mexB, oprD, pelA and rbdA) are homologous to 
65 genes previously reported to be important for cystic fibrosis– 
associated infections in our earlier study that followed the genomic 
evolution of the P. aeruginosa DK02 lineage as it disseminated through 
a cohort of adult patients with cystic fibrosis between the years 1972 
and 2010 (ref. 1).
However, in this previous study, we were limited in our ability to 
identify mutations that are of immediate importance for P. aeruginosa 
upon transition from the environmental reservoir to cystic fibrosis 
airways, as such events might only have occurred once in the his-
tory of the DK02 lineage. Because the current study is conducted 
on young patients with cystic fibrosis who had been infected with 
P. aeruginosa for the first time, we anticipate that our investigation will 
facilitate a better understanding of the genetic adaptation that occurs 
right at the initial colonization of cystic fibrosis airways. In support 
of this hypothesis, we find that the 52 candidate pathoadaptive genes 
identified by us are more frequently mutated in the earlier stages of 
DK02 evolution (mutations accumulated before 1979) relative to the 
later stages (15 of 173 versus 109 of 4,962 nonsynonymous mutations, 
respectively; Fisher’s exact test, P = 1.4 × 10−5).
The congruence between our suggested list of candidate pathoad-
aptive genes and genes found by others to be involved in host adapta-
tion demonstrates the validity of our conclusion that different genetic 
backgrounds of an opportunistic pathogen show convergent adaptive 
evolution upon transition from the environment to human airways.
Nonetheless, it is also notable that we identified convergent molecu-
lar evolution in genes of unknown function or without previous impli-
cation in pathogenesis. Further investigations of the function of these 
genes are required to determine their potential as future therapeutic 
targets against infection. Furthermore, continued characterization 
of pathoadaptive mutations will help to link genotype to phenotype, 
and such knowledge will be valuable for clinicians with regard to the 
treatment and segregation of patients.
Cystic fibrosis airways constitute a complex environment with both 
spatial and temporal heterogeneity, allowing for the presence of mul-
tiple niches. This means that infecting populations may genetically 
diversify to establish sublineages, each genetically adapting under the 
selection pressure of its niche. Further studies are necessary to address 
whether some of the pathoadaptive mutations are linked to certain 
niches in the airways. Also, our results may in general be comple-
mented by studies that take population heterogeneity into considera-
tion when analyzing the genomic evolution of pathogens55.
The role of historical contingency in evolution is challenging 
to assess in natural systems in which one cannot rewind the tape 
of evolution and replay it. Nonetheless, we demonstrated how the 
order of mutations in two different regulatory networks is highly con-
strained, and, as a result, mutations in downstream transcriptional 
regulators were contingent upon mutations in upstream regulators. 
Intriguingly, initial mutation of these networks directs the bacteria 
toward a chronic infection state (for example, with increased produc-
tion of biofilm-promoting polysaccharides), but a secondary muta-
tion followed to interfere with the effect of the first mutation. The 
secondary mutations might rebalance the regulatory network to the 
wild-type status quo, or, alternatively, the historical contingency pat-
terns exemplify evolutionary adaptation facilitated by remodeling of 
regulatory networks. In the latter case, the secondary mutation modu-
lates the detrimental pleiotropic effects of the primary mutation of a 
global regulator23. We speculate that these evolutionary trajectories 
are the result of a complex fitness landscape in which multiple strictly 
ordered mutations are necessary to reach fitness peaks. Furthermore, 
we anticipate that knowledge of constraints on the order of mutations 
might help in the prediction of bacterial evolution in patients with 
cystic fibrosis and the design of future treatment strategies. For exam-
ple, certain bacterial evolutionary trajectories may entail a fitness cost 
that can be targeted by treatment, or treatment may even be used to 
direct bacteria toward evolutionary trajectories that are associated 
with lower patient morbidity.
Finally, we found hypermutator strains in 5 of the 34 patients in 
our study (15%). This fraction is lower than the range of 36–54% that 
has been reported from four other systematic studies of hypermutator 
prevalence1,20,56,57. We ascribe this difference to the relatively young 
age of the patients in this study, as Ciufo et al. found no mutators until 
5 years after the onset of chronic lung infection among the 79 patients 
with cystic fibrosis tested56.
In conclusion, we have shown how a clinical collection of bacte-
ria sampled from chronically infected patients constitutes a valuable 
basis for understanding the evolutionary convergence and contin-
gency of pathogens in vivo. Our results facilitate comparative studies 
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as sequencing data sets become increasingly available and may help in 
the design of future intervention strategies for the clinical setting.
METhODS
Methods and any associated references are available in the online 
version of the paper.
Accession codes. Sequence reads from all P. aeruginosa isolates have 
been deposited in the Sequence Read Archive (SRA) under accession 
ERP004853. See Supplementary Table 7 for the accession codes for 
individual isolates.
Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
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Bacterial isolates. This study included 474 clinical isolates of P. aeruginosa that 
were sampled from 34 patients with cystic fibrosis attending the Copenhagen 
Cystic Fibrosis Center at the University Hospital, Rigshospitalet, Denmark. 
Isolation and identification of P. aeruginosa from sputum was carried out as 
previously described58. Use of the samples was approved by the local eth-
ics committee of the Capital Region of Denmark (Region Hovedstaden; 
registration numbers H-A-141 and H-1-2013-032), and all patients gave 
informed consent.
Genome sequencing. Genomic DNA was prepared from P. aeruginosa iso-
lates on a QIAcube system using a DNeasy Blood and Tissue kit (Qiagen) and 
sequenced on an Illumina HiSeq 2000 platform, generating 100-bp paired-end 
reads and using a multiplexed protocol to obtain an average of 7,139,922 reads 
(range of 3,111,062–13,085,190) for each of the genomic libraries. On average, 
we sequenced the isolates with an estimated genomic coverage of 107-fold 
(range of 55- to 195-fold). See Supplementary Table 7 for information about 
genomic coverage depths for individual isolates.
Definition of clone types. Sequence reads from each isolate were de novo 
assembled using Velvet59 (version 1.2.03) with a k-mer length of 33 and the 
options set as follows: ‘-scaffolding no -ins_length 500 -cov_cutoff 3 -min_
contig_lgth 300’. De novo–assembled genomes were aligned against each other 
using MUMmer3 (ref. 60) (version 3.23), and SNPs bounded by 20 exact base-
pair matches on both sides were extracted from the alignment. Isolates with 
genomes that differed by >10,000 SNPs were considered to belong to differ-
ent clone types. When considering only SNPs bounded by 50 exact base-pair 
matches on both sides, genomes belonging to different clone types differed 
by >6,000 SNPs.
Mutation detection and analysis. Mutations were identified as described 
in Marvig et al.1 with the following modifications. We aligned reads to the 
P. aeruginosa PAO1 reference genome (GenBank accession NC_002516.2; 
genome size of 6.4 Mb) with Bowtie 2 (ref. 61), used the Genome Analysis 
Toolkit (GATK) for realignment around indels62 and produced pileups of the 
read alignments with SAMtools release 0.1.7 (ref. 63).
SNPs were extracted from the read pileup if they met the following 
criteria: (i) a quality score (Phred-scaled probability of the sample reads being 
homozygous reference) of at least 50 (i.e., P ≤ 1 × 10−5), (ii) a root-mean-square 
(RMS) mapping quality of at least 25, (iii) a minimum of three reads covering 
the position and (iv) only unambiguous SNP calls. Microindels were extracted 
from the read pileup if they met the following criteria: (i) a quality score of at 
least 500, (iii) an RMS mapping quality of at least 25 and (iii) support from at 
least one-fifth of the covering reads.
To avoid false positives caused by strain-specific (native) differences relative 
to the published genome sequence of P. aeruginosa strain PAO1, we excluded 
polymorphisms specific to the genetic background. This means that polymor-
phisms shared by all members of a clone type were excluded from the analysis; 
that is, only mutations that had accumulated since the MRCA of the clonal 
isolates were included. Only genomic positions covered by at least three reads 
in all members of a clone type were included in the analysis.
Maximum-parsimonious phylogenetic analyses were carried out with 
PAUP* version 4.0b10 (ref. 64) using alleles of reference strain PAO1 as a root. 
Consistency indexes (CI = m/s) were calculated as the number of mutations 
(m) divided by the minimum number of mutational events required to explain 
the phylogenies (s). The CI equals 1 when there is no homoplasy.
Identification of candidate pathoadaptive genes. To identify significant pat-
terns of convergent evolution of nonsynonymous mutations across multiple 
clone types, we evaluated the observed distribution of mutations considering 
a scenario in which mutations were randomly introduced by genetic drift. 
For each clone type, we randomly selected m positions in the coding part 
of the P. aeruginosa reference genome, where m was the number of nonsyn-
onymous mutations in the respective clone type. We then recorded the genes 
that were randomly targeted by mutation and repeated the procedure 1,000 
times. For each of the 1,000 rounds of mutation, we counted the number of 
genes that were mutated in ≥x clone types. As larger genes are more likely to 
be randomly mutated, we grouped the results on the basis of the lengths of the 
genes. Finally, we compared the observed counts of nonsynonymous mutations 
with the distribution of nonsynonymous mutations expected by genetic drift, 
and, whenever the observed number of mutations for a gene was significantly 
higher (P ≤ 0.0011) and at least tenfold higher relative to expectance, the 
gene was added to the list of candidate pathoadaptive genes (Supplementary 
Table 4). Accordingly, genes in the size range of 1–1,000 nt were listed when 
mutated in ≥5 clone types, genes in the size range of 1,001–3,000 nt were listed 
when mutated in ≥7 clone types and genes in the size range of 3,001–5,000 nt 
were listed when mutated in ≥9 clone types.
The counts of the clone types mutated in the candidate pathoadaptive genes 
were not affected by removing densely clustered mutations (mutations within 
50 bp of each other) that were linked in the phylogenetic reconstruction, for 
example, because of recombination events.
Antibiotic treatment of patients. Early and systematic antibiotic chemo-
therapy is used to treat patients for P. aeruginosa, and 33 of the 34 patients in 
the study were treated with fluoroquinolone (ciprofloxacin), aminoglycoside 
(tobramycin), macrolide (azithromycin), β-lactam (piperacillin, meropenem, 
ceftazidime and/or aztreonam) and antimicrobial peptide (colistin) antibiotics. 
The only exception was patient P51M5 who was not treated with a macrolide 
antibiotic. Patients were treated according to the following guidelines.
Treatment was initiated at first detection of P. aeruginosa through the 
administration of oral ciprofloxacin in combination with nebulized colis-
tin for 3 months (or for 3 weeks, beginning in 2008). If P. aeruginosa still 
appeared in sputum samples after 3 months (weeks), intravenous treatment 
with piperacillin or tazobactam in combination with tobramycin was given 
(tobramycin might be inhaled in some cases). If more than 3 months (weeks) 
elapsed before P. aeruginosa reappeared, treatment with ciprofloxacin and col-
istin was restarted. When piperacillin or tazobactam resistance was observed, 
meropenem, ceftazidime or aztreonam might be used in combination with 
tobramycin or colistin. Supplementary Table 8 lists the antibiotics used to 
treat each of the patients for P. aeruginosa.
58. Hoiby, N. & Frederiksen, B. in Cystic Fibrosis (eds. Hodson, M. & Geddes, D.) 
83–107 (Arnold, London, 2000).
59. Zerbino, D.R. & Birney, E. Velvet: algorithms for de novo short read assembly using 
de Bruijn graphs. Genome Res. 18, 821–829 (2008).
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Abstract
Background: Chronic infection with Pseudomonas aeruginosa is a major cause of morbidity and mortality
in cystic fibrosis (CF) patients, and a more complete understanding of P. aeruginosa within-host genomic
evolution, transmission, and population genomics may provide a basis for improving intervention strategies.
Here, we report the first genomic analysis of P. aeruginosa isolates sampled from Italian CF patients.
Results: By genome sequencing of 26 isolates sampled over 19 years from four patients, we elucidated the
within-host evolution of clonal lineages in each individual patient. Many of the identified mutations were
located in pathoadaptive genes previously associated with host adaptation, and we correlated mutations with
changes in CF-relevant phenotypes such as antibiotic resistance. In addition, the genomic analysis revealed
that three patients shared the same clone. Furthermore, we compared the genomes of the Italian CF isolates
to a panel of genome sequenced strains of P. aeruginosa from other countries. Isolates from two of the Italian lineages
belonged to clonal complexes of P. aeruginosa that have previously been identified in Danish CF patients,
and our genomic comparison showed that clonal isolates from the same country may be more distantly
related than clonal isolates from different countries.
Conclusions: This is the first whole-genome analysis of P. aeruginosa isolated from Italian CF patients, and
together with both phenotypic and clinical information this dataset facilitates a more detailed understanding
of P. aeruginosa within-host genomic evolution, transmission, and population genomics. We conclude that the
evolution of the Italian lineages resembles what has been found in other countries.
Keywords: Bacterial pathogens, Genetic adaptation, Evolution, Cystic fibrosis
Background
Advances in high-throughput DNA sequencing tech-
niques have made it possible to follow the within-host
genomic evolution of bacterial pathogens by comparing
genomes of longitudinally collected bacterial isolates sam-
pled from human hosts [1]. The genomic information
may be used to understand pathogen population diversity,
host adaptation, and routes and sources of transmission.
Pseudomonas aeruginosa infections in cystic fibrosis
(CF) patients represents an infectious disease scenario in
which within-host genomic evolution of clonal lineages
of infecting bacteria can be followed by making genomic
comparisons of clonal isolates sampled over time [2]. A
number of clinical collections of freeze-stored P. aerugi-
nosa isolates from CF patients have been genome se-
quenced to investigate pathogen microevolution. This
includes investigation of within-host evolution of P. aeru-
ginosa lineages isolated from CF patients from Argentina,
Canada, Denmark, Germany, United Kingdom, and
United States, respectively [3–10]. Nonetheless, to obtain
a more complete basis for understanding P. aeruginosa in-
fections in CF patients and to facilitate comparative stud-
ies to assess the generality of findings, it is necessary to
investigate more clinical collections of P. aeruginosa. In
order to serve as references, such investigations should be
as comprehensive as possible, for example by including
both genomic, phenotypic, and clinical information.
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Here, we report the first genomic analysis of P. aerugi-
nosa isolates sampled from Italian CF patients, aiming to
compare whether within-host evolution of P. aeruginosa
in Italian CF patients resembles what has been found in
other countries.
In total, we sequenced 26 isolates sampled over a
period of 19 years from four different patients. Genomic
comparisons showed that the 26 isolates belonged to six
different clone types (clonal complexes), which we
named IT01-IT06. Each clone type was found to infect a
single patient, except for clone type IT05 that was
shared among three patients.
We conducted both an inter-clonal genomic analysis
to determine the genetic relationship between different
strains, and an intra-clonal genomic analysis to reveal
within-host microevolution of the individual clonal lin-
eages. We correlated the genetic changes with changes
in relevant phenotypes and patient treatment. Finally,
we compared the findings from this study of evolution
of P. aeruginosa in Italian CF patients to the findings
from similar studies encompassing lineages and patient
cohorts from other countries. Altogether, continued
genome sequencing of bacterial pathogens will improve
our understanding of within-host genomic evolution,
transmission, and population genomics.
Results
Collection of P. aeruginosa isolates from Italian CF
patients
In order to investigate the within-host genomic evolu-
tion of P. aeruginosa lineages infecting CF patients, we
performed a retrospective study of a collection of P. aer-
uginosa isolates from four patients attending the Cystic
Fibrosis Center at Anna Meyer’s Children University
Hospital (Florence, Italy). The four patients named E, F,
H and L were all born in the beginning of the 1990s
(1991–1993), and they had their first colonization by
P. aeruginosa within the first three years of life. The
first and subsequent lung isolates of P. aeruginosa
from the four patients were all stored to yield a col-
lection of 35 isolates sampled over a time period of
19 years (1993 to 2012) (Fig. 1).
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The ability of P. aeruginosa to cause infection in CF
patients is not pertained to a single or a few strains (i.e.
clonal complexes or clone types) of P. aeruginosa, and
CF children are anticipated to acquire their first P. aeru-
ginosa infection from environmental strains that are
naïve to the human airways. Accordingly, many different
and unique strains are observed to infect CF patients [9,
11–13]. While the early P. aeruginosa infections may
possibly be eradicated, it is commonly observed that the
same clone type persist in the airways of CF patients,
and a single clone type is typically observed to be dom-
inant [9]. In order to identify such persistent lineages,
we typed the 35 strains using the ArrayTube multimar-
ker microarray targeting 13 single nucleotide polymor-
phisms (SNPs) in the core genome and additional
genetic markers in the accessory genome [13]. Array-
Tube genotyping revealed that all four patients harbored
reoccurring genotypes (Fig. 1). The reoccurrence of
identical bacterial genotypes in the same patient likely
reflect that strains persist in the airways of the patients
[14]. Alternatively, the reoccurrence of identical geno-
types may be due to independent re-colonization from
the same environmental source.
Genome sequencing of isolates to determine genetic
relationships
To further elucidate the possibility that P. aeruginosa
lineages persisted within the airways of the patients, we
genome sequenced 26 of the isolates to investigate their
genomic relationships (Fig. 1). Genome sequencing con-
firmed that isolates of the same genotype were closely
related (i.e. isolates are of the same clonal lineage), and
we name these clonal lineages IT01, IT02, IT03, IT05,
and IT06. Only one isolate of ArrayTube genotype
2C1A was sequenced, and we name this strain IT04.
Isolates of the same lineage differed at most by 84
SNPs (isolates E1 and E36 sampled 17 years apart), and
on average 41 SNPs separated clonal isolates. Most di-
versity was present among isolates of the IT01 lineage
(average genetic distance between IT01 isolates: 57
SNPs), whereas almost no SNP differences were ob-
served between isolates belonging to lineage IT05 (iso-
lates were separated by at most 2 SNPs).
Transmission of the IT05 lineage between patients
Lineages IT01, IT02, IT03, and IT06 were found to in-
fect only a single patient (patients E, H, L, and F, re-
spectively), suggesting that the patients had picked up
the respective lineages from the environment. Contrary,
lineage IT05 was found in both patients F, H, and L, sug-
gesting that the IT05 lineage had spread among the pa-
tients by either direct patient-to-patient transmission or
indirect transmission via a common environmental res-
ervoir. Interestingly, the IT05 lineage is the first clone
type of P. aeruginosa to be isolated from all three pa-
tients in years 1993, 1993, and 1994, respectively. How-
ever, in all cases other clone types of P. aeruginosa
replace the IT05 clone type. We speculate that the IT05
lineage reside in a common environmental source to
which the patients are frequently exposed, enabling the
IT05 lineage to successfully colonize multiple patients,
but that the IT05 lineage in the long run is replaced by
other clone types that are inherently better to thrive in
the patients’ airways.
Phylogeny and mutational signatures
Next, we compared clonally related genomes to recon-
struct the evolutionary history of each of the clonal
lineages (Fig. 2). The mutations in each of the lineages
accumulated in a highly parsimonious fashion (average
parsimonious consistency of 0.99; Table 1), reflecting a
unidirectional and clonal evolution since the most recent
common ancestor. Thus, using a maximum-parsimonious
phylogenetic model, we were able to make accurate infer-
ences about the succession of mutations and the relation-
ship among P. aeruginosa clones.
General conclusions about to what extent natural se-
lection has been the driving force in the fixation of gen-
etic variants, can be inferred from measuring the relative
rates of nonsynonymous (dN) and synonymous (dS)
genetic changes [15]. A dN/dS ratio greater than one im-
plies that there has been an overall positive selection for
mutations; whereas a ratio less than one implies that
there has been a selection for removal of mutations, i.e.
negative selection. However, note that the dN/dS ratio
should be interpreted as an average signal of selection
not giving any information on if both positive and nega-
tive selection has acted at different sites and/or times
during the evolution. We found a significant signature of
negative selection in lineages IT01 (dN/dS = 0.7) and
IT03 (dN/dS = 0.3), whereas the dN/dS ratios in the
other three lineages were neither significantly positive
nor negative (Table 1). Our observed range of dN/dS
from 0.3 to 1.2 is in accordance with previous findings
of within-host microevolution to be affected by both
negative [5, 8] and positive selection [10].
Furthermore, we performed Bayesian analyses of
mutation rates, and we estimated the yearly rate of
SNP mutations in IT01 lineage to be 2.7 SNPs/year
(95 % highest posterior density (HPD; see Methods)
1.0–4.4 SNPs/year), which is equivalent to 4.5 × 10−7
SNPs/year per site. This means that the mutation rate
of the IT01 lineage is almost identical to the within-
host mutation rate (2.6 SNPs/year) estimated for the
DK02 lineage evolving in chronically infected Danish
CF patients [8]. Also, the rate is within the range of
mutation rates estimated in a number of other stud-
ies: Snyder et al. reported a mutation rate of 2.4-3.0
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SNPs/year during a hospital outbreak [16]; Markussen
et al. found the DK01 lineage to accumulate 1.3
SNPs/year in a chronically infected Danish CF patient;
and Cramer et al. estimated the mutation rate of
lineage PA14 to be ~1 SNP/year over the course of
infection of a German CF patient [3]. Mutation rates
of the other lineages (IT02, IT03, IT05, IT06) could
not be estimated since the number and temporal dis-
tribution of isolates were insufficient to obtain proper
estimates of the mutation rates (effective sample sizes
(ESS) of modeled parameters were below 10).
Positive selection for mutations in pathoadaptive genes
Genetic adaptation is hypothesized to play a major role
in the successful establishment of chronic P. aeruginosa
infections of CF patients [3, 8–10, 17–22], and Marvig
et al. recently performed a genome-wide mutational
analysis of 36 different P. aeruginosa lineages to identify
52 candidate ‘pathoadaptive genes’ targeted by muta-
tions to optimize pathogen fitness [9]. We found that
34 of 365 identified intragenic mutations were located
within the 52 candidate pathoadaptive genes, corre-
sponding to an 11-fold enrichment of mutations in
Table 1 Mutations accumulated in Pseudomonas aeruginosa lineages during infection
Lineage IT01 IT02 IT03 IT05 IT06
SNPs 193 38 21 3 48
Missense 104 17 7 1 25
Nonsense 7 1 0 1 2
Silent 53 5 7 1 11
Intergenic 29 15 7 0 10
Intragenic indels 46 23 7 4 43
Intergenic indels 18 6 3 2 13
dN/dS 0.70 1.20 0.33 0.67 0.82
Probability of dN/dS = 1 3.61E-05 8.19E-01 3.95E-04 4.23E-01 1.70E-01
Maximum-parsimonious SNP events 193 39 21 3 48
Parsimony consistency 1.00 0.97 1.00 1.00 1.00
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these particular 52 genes relative to all other genes
(P(X ≥ 34) ~ pois(λ = 3.34) = 7.8 × 10−22, where λ is the
expected number of mutations in 52 genes). This sug-
gests that the mutations in the pathoadaptive genes
have been positively selected in the host airways. In
agreement with this, we found a significant mutational
signature of positive selection of SNPs in pathoadaptive
genes (P = 0.007; dN/dS > 5; 15 nonsynonymous SNPs
and none syonymous SNPs) whereas SNPs in the re-
mainder of genes showed a signature of negative selec-
tion (dN/dS = 0.7). Mutations in pathoadaptive genes
includes nonsynonymous mutations in aceF, algU, bifA,
gyrA, gyrB, lasR, mexA, mexB, mexZ, morA, mucA,
nfxB, pvdS, and retS.
Furthermore, several other of the mutations accumulated
in lineages IT01, IT02, IT03, IT05, and IT06 may as well
confer a selective advantage. For example, the exact C to T
phuR promoter mutation (PAO1 genome position
5289158) found in isolates F23, F40, and F41 has previ-
ously been shown to increase the expression of the Pseudo-
monas heme uptake (phu) system; an adaptive trait shown
to improve the uptake of iron from host hemoglobin [19].
Also, loss-of-function mutations in rpoN have frequently
been found to be typical markers of CF lung infection [10],
and in this study we found an rpoN(11-12insCT) frame-
shift mutation in IT02 strains H24 and H25.
Finally, we identified an A2058G mutation and a
C2611T (Escherichia coli numbering) mutation in the
23S rRNA gene in the IT02 lineage (isolates H24 and
H25) and the IT06 lineage (isolates F23, F40, and F41),
respectively. The exact mutations have previously been
shown to confer macrolide resistance in P. aeruginosa
[20]. Thus, we hypothesize that the mutations have been
selected due the use of azithromycin in clinic (see
Methods section for description of antibiotic therapy),
and in accordance with this the mutations were not ob-
served until after the start of oral azithromycin treat-
ment of the respective patients.
Genetic relationship between IT01-IT06 lineages and
other P. aeruginosa strains
Next, we sought to determine the genetic relationship
between lineages IT01-IT06 and other genome se-
quenced strains of P. aeruginosa. We de novo assembled
the genome of the earliest isolate(s) of each of the six
clonal lineages and aligned the genomes to a panel of 60
genome sequences of other strains of P. aeruginosa. The
panel consisted of eight completed genomes of P. aerugi-
nosa reference strains (PAO1 [23], PA14 [24], LESB58
[25], PA7 [26], DK02 [21], 2192 and C3719 [27],
PACS2), and 53 incomplete draft genomes of strains
DK01-DK53, which we recently genome sequenced in a
study of Danish CF patients [9].
Using the Harvest suite [28], we aligned the panel
of genomes and constructed a phylogenetic tree based
on 188,727 SNPs identified in the core genome of the
aligned strains (Fig. 3). Clustering of genomes based
on core genome SNPs confirmed previous findings
that, except for a few outlier strains (e.g. PA7), strains
group into two major phylogenetic clusters containing
strains PAO1 and PA14, respectively (Fig. 3a) [29, 30].
We observed no evidence that the geographical linked
strains IT01-IT06 grouped more closely in the phylo-
genetic tree. However, we noted that strains IT01-
IT06 all belong to the phylogenetic cluster containing
strain PAO1 (Fig. 3a).
Genetic distances between closely related isolates from
different countries
We found that the IT02 and IT03 lineages were closely
related to isolates of the DK26 and DK06 clone types,
respectively (Fig. 3b), which have been isolated from
Danish CF patients [9]. The close genetic relationship
was also supported by multilocus sequence typing
(MLST) analysis, showing the IT02/DK26 strains to be
of sequence type ST-27 and the IT03/DK06 strains to be
of sequence type ST-17.
To further investigate these two cases, we repeated the
phylogenetic analysis, now only including the relevant iso-
lates (Fig. 4). Note, since both clone types DK06 and
DK26 were found in multiple patients in the study of the
Danish patients, we included the earliest isolate from all
the respective patients in our analysis (DK06 and DK26
isolates were from years 2006–2010 and 2011–2012,
respectively). Interestingly, we found that more diversity
was present between isolates from Denmark relative to
the diversity present between isolates from Italy and
Denmark (Fig. 4). For example, only 47 SNPs separated
the Italian isolate H4 from isolate 294 sampled from a
Danish CF patient (P21F4), whereas Danish isolates of the
same clone type were different by up to 265 SNPs (isolates
294 and 34) (Table 2).
Host adaptation is associated with reduction in metabolic
capacity
Finally, we sought to investigate the phenotypic changes
that occurred during the course of infection. Reductions
in metabolic capacity, for example caused by rpoN muta-
tions, have previously been associated with host adapta-
tion [5, 22], so we used phenotype microarrays (Biolog)
to characterize the metabolic capacity of three strains
from each of the lineages IT01, IT02, and IT06. The
metabolic capacities of isolates of both lineages IT01
and IT02 decreased over time (19 and 10 years, respect-
ively), whereas no change was observed for lineage IT06
over 4 years of infection (Fig. 5).
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Fig. 3 Phylogenetic tree based on core-genome alignment of different Pseudomonas aeruginosa strains. Genomes of the earliest isolate(s) of each
of the lineages IT01-IT06 were aligned against a panel of 60 genome sequences of other strains of P. aeruginosa. a Tree showing the phylogeny
of all isolates. b Subset of tree showing phylogeny of all isolates, except the outlier isolate PA7. Strains are either named after their lineage
(IT01-IT06 or DK01-DK53) followed by the name of the specific isolate in parenthesis, or by the name of the reference strains (strains with
completed genome sequences) followed by ‘ref’ in parenthesis. Phylogenetic tree was constructed using Harvest [28]
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Mutants with loss-of-function mutations in the CbrAB
two-component system is known to be unable or poor
at utilizing a large range of carbon and nitrogen sources
[31]. Therefore, we speculate that two nonsynonymous
mutations accumulated in cbrAB may explain the loss of
metabolic capacity in isolates H18 and H24 of the IT02
lineage.
In the IT01 lineage, several mutations may explain the
reduced metabolic capacities of isolates E19 and E43
from years 2006 and 2012, respectively, relative to the
ancestral isolate E1 from 1993. Both isolates E19 and
E43 accumulated nonsynonymous mutations in genes
aceF, dgcB, gcdH, glcD, glnD, and vanA belonging to
PseudoCap function classes ‘Amino acid biosynthesis
and metabolism’ and/or ‘Carbon compound catabolism’.
In addition, isolate E43 harbor mutations in genes cysB,
pdxJ, PA4910, sdhA that are involved in biosynthesis of
amino acids, biosynthesis of cofactors, amino acid trans-
port, and central metabolism, respectively. We suggest
that the mentioned mutations may explain the reduction
of metabolic capacity in the IT01 lineage.
Changes in mucoidity, motility, ciprofloxacin
susceptibility, and protease production
Besides reduction in metabolic capacity, the CF lung
infection is associated with the appearance of a num-
ber of other phenotypes of which many are not usually
observed among environmental, wild type isolates of
this species. For example, mucoid colony formation,
reduction in secretion of extracellular proteases, loss
of flagella dependent motility, and antibiotic resistance
0.001
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DK06 (294/P21F4/2006)
DK06 (398/P77F4/2009)
DK06 (34/P44F5/2010)
DK06 (35/P44F5/2010)
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IT03 (L6/L/2006)
IT02 (H4/H/2001)
DK26 (272/P92F3/2012)
DK26 (188/P26F5/2011)
DK26 (382/P99F4/2012)
Fig. 4 Phylogenetic trees based on core-genome alignment of Pseudomonas aeruginosa strains of the IT02/DK26 and IT03/DK06 clonal complexes.
Phylogenetic trees were constructed using Harvest [28]. Name, patient origin, and year of isolation are shown for each isolate in parenthesis
Table 2 Genetic distances (SNPs) between Pseudomonas aeruginosa strains
IT02/DK26 188/P26F5 272/P92F3 382/P99F4 H4
188/P26F5 0 197 108 204
272/P92F3 197 0 41 108
382/P99F4 193 41 0 96
H4 204 108 96 0
IT03/DK06 294/P21F4 295/P21F4 34/P44F5 35/P44F5 398/P77F4 390/P99F4 L6
294/P21F4 0 18 265 259 21 26 47
295/P21F4 18 0 256 258 28 25 58
34/P44F5 265 256 0 23 259 262 277
35/P44F5 259 258 23 0 263 260 277
398/P77F4 21 28 259 263 0 26 53
390/P99F4 26 25 262 260 26 0 64
L6 47 58 277 277 53 64 0
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are characteristics of isolates from chronic CF infec-
tions [32–34].
We phenotypically characterized the 25 isolates of
clone types IT01-IT03 and IT05-06, and in accordance
with previous studies, we found that nearly all isolates
exhibited reduced swimming and swarming motility and
protease secretion relative to the wild type-like reference
strain PAO1 [35] (Fig. 2). The only isolates showing
swimming and/or swarming capabilities better than
PAO1 were L11, F4, and H1. Furthermore, three of the
patients (E, F, and H) harbored mucoid isolates, and the
two latest isolates of the IT02 lineage (H24 and H25)
were resistant to ciprofloxacin.
The relative large numbers of mutations that appear
in each of the clonal lineages make it difficult to associ-
ate specific mutations with phenotypic changes. Nonethe-
less, only mutations GacS(L309Q) and GacA(Y186stop),
respectively, discriminated isolates F4 and H1 from the
other isolates of the IT05 lineage. In agreement with lit-
erature [36, 37], this suggest that the mutations in the
GacAS two-component regulatory system is the cause of
increased motility and decreased extracellular protease ac-
tivity of isolates F4 and H1. Furthermore, we suggest that
a GyrA(T83I) mutation, which has previously been associ-
ated with ciprofloxacin resistance [38], explains ciproflox-
acin resistance observed in isolates H24 and H25. Also,
we suggest that mucoidity of isolates E37 and E42 may be
caused by a nonsense mutation in mucA present in these
two, but no other, isolates of the IT01 lineage.
In the IT02 lineage, a reduction of extracellular protease
activity in isolates H18, H24, and H25 coincides with the
fixation of a missense mutation in lasR encoding a regula-
tor required for the expression of virulence-associated
extracellular proteases LasA and LasB [39, 40]. In the
same isolates, we suggest a loss of swimming motility to
be caused by a missense mutation in fleQ encoding a posi-
tive regulator of flagella biosynthesis genes [41].
Discussion
We have gained insight into P. aeruginosa infections
using a collection of isolates sampled over 19 years from
four Italian CF patients. We sequenced the genomes of
26 of the isolates and correlated identified mutations to
changes in relevant phenotypes and antibiotic treatment
used in the clinic. While there are several other clinical
collections of P. aeruginosa that have been genome se-
quenced [2], this is the first genome analysis of isolates
from Italian CF patients. We therefore anticipate that
our study may serve as a reference for future research
and helps to obtain a more complete basis for under-
standing P. aeruginosa infections in CF patients.
We found the genomic evolution of lineages from
Italian patients to resemble the evolution of P. aerugi-
nosa lineages from other countries. This included
similar observed rates of mutation and evidence for
host-associated selection for mutations in pathoadap-
tive genes. Accordingly, our results support previous
findings of significant mutational signature of positive
selection in relatively few pathoadaptive genes in con-
trast to neutral change in the large remainder of
genes. Inter-study parallelism of mutations in the
same pathoadaptive genes may by part be driven by
similarities in antibiotic treatment regimes. However,
we also found parallelism of mutations in genes that
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are not directly associated to antibiotic resistance (e.g.
aceF, bifA, morA, and retS), and this may reflect simi-
larities in host-dependent selective forces.
Unlike other studies [5, 8, 9, 42–44], we did not iden-
tify hypermutable lineages. Since our study only encom-
passes four patients, the lack of hypermutators may be
accidental, and hypermutators may eventually appear as
these are observed more frequently in late stage infec-
tions [42].
Patients were predominantly infected with strains
unique to the particular patient. One exception was
clone type IT05 which was shared by three patients.
Despite of IT05’s occurrence in multiple patients, the
IT05 clone type resembled a wild type phenotype, and
this may explain why other clone types with typical
host-associated phenotypes replace IT05 in all patients.
As such, the pattern of strain replacement may be due
to initial infections from a strain that reside in a com-
mon environmental source to which the patients are fre-
quently exposed, and that this strain is subsequently
replaced by other more rare, but also more fit, strains.
While other studies have given insight into P. aerugi-
nosa within-host population diversity [5, 7, 45, 46], fur-
ther investigations are needed to make conclusions
about the diversity of P. aeruginosa in our four patients.
However, we conducted an inter-clonal genomic analysis
to determine the genetic relationship between lineages
IT01-IT06 and a panel of 60 genome sequenced strains
of P. aeruginosa from other countries. Hereby, we
showed that lineages IT02 and IT03 were closely related
to lineages DK26 and DK06, respectively, which have
been isolated from Danish CF patients [9]. Since more
diversity was present between isolates from Denmark
relative to the diversity present between isolates from
Italy and Denmark, our findings show that one must be
cautious of using genome analysis to infer the country
origin of lineages.
Conclusions
This is the first whole-genome analysis of P. aeruginosa
isolated from Italian CF patients, and together with both
phenotypic and clinical information this dataset facili-
tates a better understanding of P. aeruginosa within-host
genomic evolution, transmission, and population gen-
omics. This may help the design of future intervention
strategies for the clinical setting.
Methods
Bacterial isolates
The 35 P. aeruginosa isolates used in this study origi-
nates from the bacterial collection available at the Tus-
can Regional Referral Center for Cystic Fibrosis in
Florence, Italy. At this center, P. aeruginosa isolates sam-
pled from CF patients have been stored twice a year
since 1993. All patients enrolled in the study were in
follow-up according to published guidelines [47, 48]. CF
diagnosis was based on clinical features of the disease
and concentration of chloride in sweat >60 mmol/liter
[49]. Patients were regularly examined every 3 months.
Data regarding their weight, height, body mass index
(BMI), forced expiratory volume in one second (FEV1),
microbiological status (including antibodies against P.
aeruginosa) and antibiotic treatments were stored in the
database. Cough swabs or sputum samples were proc-
essed following the national and international guidelines
[50] (https://www.cysticfibrosis.org.uk/media/82034/CD_
Laboratory_Standards_Sep_10.pdf ).
The patients gave written consent to participate and
for publication of their details. The study and use of bac-
terial isolates has been approved by the local ethics com-
mittee at the Department of Paediatric Medicine, Anna
Meyer Children's University Hospital, Florence, Italy
(approval no. 210).
Antibiotic therapy principles in the clinic
Early eradication treatment was started at first detec-
tion of P. aeruginosa by administration of oral cipro-
floxacin in combination with either nebulized colistin
for three weeks or three months or inhaled tobramycin
[48, 51, 52]. When P. aeruginosa reappeared after eradi-
cation therapy, treatment with oral ciprofloxacin and
inhaled antibiotics was restarted.
At development of chronic P. aeruginosa infection
[53], intravenous antibiotic treatment was administered
together with inhaled colistin or inhaled tobramycin. Pa-
tients also received treatments with oral azitromycin
[54]. During follow-up, in the case of mild pulmonary
exacerbation, all patients were treated with oral cipro-
floxacin in combination with inhaled antibiotics. Severe
pulmonary exacerbations were treated with parenteral
antibiotic treatments (ceftazidime or meropenem in
combination with tobramycin once a day) according to
suggested dosage [47].
Patient information
Patient E (cystic fibrosis transmembrane conductance
regulator gene (CFTR) genotype F508del/F508del) had his
first P. aeruginosa colonization at the age of 19 months
and developed chronic infection at the age of three years.
He remained stable without pulmonary exacerbation until
2012. Due to excellent lung function (FEV1 = 115 % of
predicted) he was treated only intermittently with oral cip-
rofloxacin in combination with inhaled antibiotics. Oral
azithromycin was started in 2006.
Patient F (CFTR genotype 711 + 19 A/T /3272-9 A/t)
had her first P. aeruginosa colonization at the age of
33 months and developed chronic infection at the age
of four years. She had a stable FEV1 (60 %) until 2008,
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when she began a progressive clinical deterioration with
FEV1 (20 %) in 2012. She was frequently treated with
high doses of ciprofloxacin with inhaled antibiotics
from 2001 until 2010, with repeated parenteral anti-
biotic cycles with ceftazidime or meropenem in associ-
ation with tobramycin once a day. Oral azithromycin
was started in 2004.
Patient H (CFTR genotype F508del/F508del) had his
first P. aeruginosa colonization at the age of 8 months
and was chronically infected at the age of 1 year. After
chronic P. aeruginosa infection was developed, he was
treated with fluoroquinolones and tobramycin by inhal-
ation. Oral quinolones were used to treat mild pulmon-
ary exacerbations. He underwent parenteral antibiotic
treatment (ceftazidime and tobramycin) twice from 2011
to 2013 for severe pulmonary exacerbations. His lung
function declined from 2006 (FEV1 = 80 %) to 2011
(FEV1 ≤ 40 %). Oral azithromycin was started in 2005. In
addition, tetracyclines, trimethoprim-sulfamethoxazole,
and linezolid were used to treat methicillin-resistant
Staphylococcus aureus.
Patient L (CFTR genotype F508del/N1303K) had her
first P. aeruginosa colonization at the age of 27 months.
She developed chronic infection at the age of 20 years.
However, her clinical conditions were stable and she had
good lung function (FEV1 = 80 %). After chronic P. aeru-
ginosa lung infection developed, she was treated with
antibiotics by inhalation. She used oral quinolones for
mild pulmonary exacerbations together with parenteral
antibiotic treatment (ceftazidime and tobramycin), which
was necessary twice in the period 2011 to 2013. She did
not tolerate treatment with oral macrolides.
ArrayTube genotyping
P. aeruginosa genotypes were determined using an
ArrayTube multimarker microarray targeting 13 SNPs
in the core genome and additional genetic markers in
the accessory genome (Clondiag Chip Technologies,
Germany) [13]. The ArrayTube genotyping assay was
performed according to the protocol provided by the
manufacturer.
Genome sequencing
Genomic DNA was prepared from P. aeruginosa isolates
on a QIAcube system using a DNeasy Blood and Tissue
Kit (Qiagen). Genomes were sequenced by BGI (Shenzhen,
China) to an average coverage depth of at least 75-fold
(range 75- to 139-fold) on an Illumina HiSeq2000 platform
generating 100-nt paired-end reads.
Mutation detection and construction of phylogenetic
trees
Mutations that had accumulated in P. aeruginosa line-
ages IT01-IT03 and IT05-IT06, were identified as
previously described (without any modifications) [9].
Based on the identified SNPs, we computed maximum-
parsimonious phylogenetic trees using PAUP* version
4.0b10 [55]. Consistency indexes were calculated as the
number of mutations divided by the minimum number
of mutational events required to explain phylogenies.
The consistency index will equal one when there is no
homoplasy.
Estimation of mutation rates
Bayesian analysis of evolutionary rate was performed using
BEAST, version 1.7.0 [56], with a lognormal relaxed mo-
lecular clock model and a general time-reversible substitu-
tion model. Mutation rate of the IT01 lineage was
calculated from a chain length of 50 million steps, sam-
pled every 5,000 steps. The first 5 million steps were dis-
carded as a burn-in. The ESS of all parameters were
>1,000 as calculated by Tracer, version 1.5 (available from
http://beast.bio.ed.ac.uk/Tracer), which was also used to
calculate the 95 % HPD confidence intervals of the muta-
tion rate (i.e. an interval within which the modeled param-
eter resides with 95 % probability). Mutation rates of the
other lineages (IT02, IT03, IT05, IT06) could not be esti-
mated since the number and temporal distribution of iso-
lates were insufficient to obtain proper estimates of the
mutation rates (ESS of modeled parameters < 10).
De novo assembly and inter-clonal whole-genome
alignments
We de novo assembled the genome of the earliest iso-
late(s) of each of the six clonal lineages (E1, F23, F24,
H4, L1, L6, L16) and genomes of representatives of
strains DK01-DK53, which we recently genome se-
quenced in a study of Danish CF patients [9].
Sequence reads from each isolate were error corrected
using ALLPATHS-LG’s stand-alone error correction tool
[57] and de novo assembled using the de Bruijn graph-
based assembler Velvet (version 1.2.08) [58]. For each
sample several assemblies were run. This implies that
for each dataset ‘velveth’ command was executed using
k-mer sizes in the range of 35 to 95. Next, the ‘velvetg’
command was run using the parameters: min_con-
tig_lgth = 400, exp_cov = auto, and scaffolding = no.
Based on the number of contigs, the best cumulative
rank for N50, and the length of the largest contig, the
best k-mer size was selected and the exp_cov was noted.
A final assembly was performed using the best k-mer
size for velveth and with velvetg using the parameters:
min_contig_lgth = 400, scaffolding = no, and the exp_cov
that was calculated in the first ensemble of assemblies.
The size range of the de novo assembled genomes of
strains of lineages IT01-06 was 6.3-6.9 Mbp, and each
genome shared 95.8–97.0 % of the content P. aeruginosa
reference strain PAO1.
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De novo assembled genomes and completed genomes
from the public domain [59] were aligned against each
other using the Harvest suite [28] with default parame-
ters using all genomes (option ‘–c’ set to ‘YES’) and with
genome sequence of strain PAO1 as reference.
MLST sequence types were determined using a public
available online tool developed for use on de novo as-
sembled genomes [60]. Sequence types of lineages IT01-
06 were ST-111, ST-27, ST-17, ST-389, ST-1748, and
ST-348, respectively.
Biolog phenotype profiling
Phenotype MicroArray (Biolog, Hayward, CA) experi-
ments were performed in duplicate according to the
manufacturer’s instructions [61, 62]. P. aeruginosa
strains were streaked on LB agar plates and incubated at
37 °C until colonies appeared on the plates (16–30 hours
(h)). Cells were swabbed from the plates and suspended
in IF-0 GN Base (inoculation fluid) at a density corre-
sponding to 42 % transmittance in the Biolog turbidim-
eter. The cell suspensions were diluted 1:6 in IF-0
minimal medium containing Biolog redox dye mixture D
(tetrazolium), and 100-μL aliquots were added to
carbon-source plates (PM1 and PM2A). For the
nitrogen-source plate (PM3B), inoculations were supple-
mented with 30 mM glucose and 2 μM ferric citrate.
The plates were incubated at 37 °C in an OmniLog plate
reader (Biolog) for 72 h, and growth/respiration was
measured kinetically by determining the colorimetric re-
duction of tetrazolium dye. Export of OmniLog data was
performed using OmniLog OL_FM/Kin 1.20.02 software
(Biolog). The average area beneath each kinetic curve
was used for analysis. OD600 was measured after 60 h
of growth at 37 °C, and relative catabolic capacities of
individual substrates were determined as previously de-
scribed [63].
Motility assays
The motility of all isolates was tested on ABT minimal
medium supplemented with 0.5 % Casamino acids and
0.5 % glucose as previously described [64]. Briefly, agar
plates were inoculated with single colonies on the top or
in the middle of the plates to measure swarming or
swimming motility, respectively. Swimming and swarm-
ing were measured on 0.3 % (wt/vol) and 0.6 % (wt/vol)
agar, respectively, with incubation for 24 h at 30 °C. The
motility zones in triplicates were measured relative to
the motility of the reference strain PAO1.
Skim milk protease assay
The production of protease was determined by applying
one colony of the isolate grown on Luria-Bertani (LB)
medium agar plates to skim milk agar plates (LB agar
with 10 % skim milk). The plates were incubated for
24 h at 37 °C, and the clearing zones were measured.
Ciprofloxacin susceptibility testing
Ciprofloxacin susceptibility was tested by the Bauer-Kirby
agar disk diffusion method. Discs (Neo-Sensitabs) were
purchased from Rosco Diagnostica (Taastrup, Denmark).
The diameters of clearing zones were measured in milli-
meters (mm) after 20 h at 37 °C.
Availability of data and materials
Sequence reads from all P. aeruginosa isolates are depos-
ited in the Short Read Archive under accession number
PRJEB8020 [EMBL:PRJEB8020].
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ABSTRACT	  20	   Opportunistic	  infections	  by	  Pseudomonas	  aeruginosa	  is	  a	  major	  cause	  of	  morbidity	  and	  21	   mortality	  in	  immune-­‐compromised	  patients.	  Genome	  sequencing	  of	  P.	  aeruginosa	  isolates	  22	   from	  cystic	  fibrosis	  patients	  has	  shown	  that	  persistence	  of	  clonal	  lineages	  of	  P.	  aeruginosa	  in	  23	   the	  airways	  is	  facilitated	  by	  genetic	  adaptation.	  While	  these	  findings	  are	  of	  clinical	  24	   importance,	  it	  is	  unknown	  whether	  they	  also	  apply	  to	  P.	  aeruginosa	  airway	  infections	  in	  25	   patients	  with	  primary	  ciliary	  dyskinesia	  (PCD).	  Both	  diseases	  are	  caused	  by	  disruption	  of	  the	  26	   mucociliary	  clearance;	  however,	  while	  disruption	  of	  mucociliary	  clearance	  in	  PCD	  is	  caused	  by	  27	   unfunctional	  ciliary,	  the	  failure	  is	  caused	  by	  thickening	  of	  the	  mucus	  in	  CF.	  Consequently,	  we	  28	   hypothesize	  that	  investigating	  parallelism	  in	  within	  host	  evolution	  across	  opportunistic	  29	   infections	  across	  diseases	  can	  infer similarities in the selective pressures governing infection in 30	  
PCD and CF, respectively, and help to separate the role of unfunctional	  ciliary	  versus	  thick	  31	   mucus	  in	  relation	  to	  selective	  pressures.	  32	   Here,	  we	  genome	  sequenced	  35	  longitudinally	  collected	  P.	  aeruginosa	  isolates	  and	  33	   characterised	  41	  isolates	  phenotypically,	  from	  12	  patients	  with	  PCD.	  This	  comprised	  on	  34	   average	  2.9	  (2-­‐5)	  sequenced	  isolates	  per	  patient	  with	  an	  average	  timespan	  of	  2	  years	  (0.4-­‐35	   3.6),	  and	  phenotypical	  analysis	  of	  3.4	  isolates	  per	  patient	  (2-­‐6)	  with	  an	  average	  timespan	  of	  36	   2.4	  years	  (0.4-­‐4.8).	  37	   We	  identified	  14	  clone	  types,	  and	  9	  out	  of	  12	  patients	  were	  infected	  with	  a	  unique	  clone	  type.	  38	   Among	  these	  clone	  types	  we	  found	  eight	  genes	  to	  be	  mutated	  in	  parallel,	  suggesting	  that	  39	   mutations	  were	  positively	  selected.	  Further,	  six	  of	  these	  genes	  have	  been	  found	  to	  be	  40	   important	  for	  infections	  in	  CF	  airways.	  There	  was	  not	  much	  overlap	  of	  the	  bacterial	  41	   phenotypic	  adaptations	  between	  the	  two	  diseases.	  In	  opposition	  to	  what	  is	  described	  in	  CF,	  42	   PCD	  isolates	  show	  either	  no	  change	  or	  increased	  ability	  to	  produce	  biofilm	  over	  time,	  and	  a	  43	   general	  preservation	  of	  swimming	  motility.	  44	   PCD	  and	  CF	  patients	  have	  comparable	  airway	  disease	  but	  PCD	  patients	  have	  in	  general	  a	  much	  45	   milder	  degree	  of	  airway	  infections	  with	  better	  prognosis	  than	  CF	  patients.	  This	  study	  sheds	  46	   light	  on	  the	  differences	  between	  genotype	  and	  phenotype	  adaptation	  of	  P.	  aeruginosa	  to	  the	  47	   airways	  of	  PCD	  patients,	  as	  compared	  to	  CF	  patients.	  Our	  findings	  may	  resolve	  the	  basic	  48	   questions	  of	  evolutionary	  adaptation	  of	  P.	  aeruginosa	  in	  airway	  infections	  in	  PCD	  and	  CF,	  and	  49	   through	  this	  knowledge	  we	  provide	  important	  information	  that	  may	  consider	  new	  treatment	  50	   strategies	  for	  P.	  aeruginosa	  infections.	  	  51	  
	  52	  
INTRODUCTION	  53	  
Pseudomonas	  aeruginosa	  is	  an	  opportunistic	  pathogen	  that	  frequently	  causes	  chronic	  54	   infections	  in	  the	  upper	  and	  lower	  airways	  of	  both	  PCD	  and	  CF	  patients	  and	  it	  is	  the	  primary	  55	   cause	  of	  morbidity	  and	  mortality	  in	  CF	  patients	  [1-­‐3].	  Patients	  are	  usually	  intermittently	  56	   colonised	  in	  childhood,	  but	  despite	  intensive	  antibiotic	  therapy	  a	  chronic	  infection	  is	  rarely	  57	   prevented.	  Thus,	  approximately	  30%	  of	  all	  Danish	  CF	  patients	  are	  chronically	  infected	  in	  early	  58	   adulthood	  [4],	  and	  approximately	  the	  same	  percentage	  of	  PCD	  patients	  eventually	  become	  59	   chronically	  infected	  [5].	  60	  
Investigations	  of	  P.	  aeruginosa	  have	  shown	  how	  the	  clone	  types	  can	  adapt	  and	  evolve	  to	  the	  61	   CF	  lung	  environment,	  via	  phenotypic	  and	  mutational	  changes	  [6-­‐13].	  The	  most	  important	  62	   characteristics	  include	  overproduction	  of	  alginate	  (mucoidity),	  slow	  growth,	  altered	  biofilm	  63	   mode	  of	  growth,	  loss	  of	  motility,	  quorum	  sensing,	  and	  protease	  production	  [6,9,14-­‐17].	  These	  64	   adaptational	  changes	  have	  to	  a	  large	  degree	  been	  linked	  with	  antibiotic	  treatments,	  the	  65	   activity	  of	  the	  immune	  defence,	  and	  specific	  physical	  characteristics	  of	  the	  CF	  mucus.	  However	  66	   it	  is	  not	  clear	  to	  what	  degree	  these	  factors	  independently	  and	  together	  impact	  the	  adaptation	  67	   and	  evolution	  of	  P.	  aeruginosa.	  	  68	   These	  adaptive	  and	  evolutionary	  investigations	  have	  to	  our	  knowledge	  not	  been	  described	  in	  69	   PCD	  patients	  and	  for	  the	  first	  time	  we	  describe	  the	  genetic	  and	  phenotypic	  evolution	  of	  70	   distinct	  clonal	  lineages	  of	  P.	  aeruginosa	  from	  the	  PCD	  airways,	  and	  compare	  these	  with	  the	  71	   evolutionary	  processes	  previously	  identified	  in	  the	  airways	  of	  CF	  patients	  [6,8,14-­‐16,18,19].	  	  	  72	   Stasis	  of	  respiratory	  secretions	  is	  inevitable	  in	  patients	  with	  primary	  ciliary	  dyskinesia	  (PCD)	  73	   and	  cystic	  fibrosis	  (CF)	  predisposing	  both	  patient	  groups	  to	  airway	  infections,	  inflammations	  74	   and	  declining	  lung	  function.	  Inhaled	  pathogens	  are	  trapped	  in	  mucus	  in	  the	  airways	  as	  a	  first	  75	   line	  of	  defence.	  In	  non-­‐diseased	  airways,	  these	  entrapped	  pathogens	  are	  then	  removed	  by	  76	   mucociliary	  clearance:	  Constant	  beating	  of	  motile	  cilia	  drives	  the	  mucus	  and	  pathogens	  up	  77	   and	  out	  of	  the	  airways,	  where	  it	  is	  cleared	  by	  expectoration	  or	  ingestion.	  However,	  in	  PCD	  and	  78	   CF	  this	  function	  of	  airway	  clearance	  is	  impaired:	  either	  directly	  by	  mutations	  resulting	  in	  79	   structural	  or	  functional	  abnormalities	  of	  the	  cilia	  [20],	  or	  indirectly	  by	  mutations	  in	  a	  chloride	  80	   ion	  channel	  resulting	  in	  thickened	  mucus	  in	  the	  airways	  and	  thereby	  impairing	  the	  ciliary	  81	   movements	  [21].	  82	   We	  hypothesise,	  that	  if	  the	  main	  selective	  pressures	  found	  in	  the	  CF	  airways	  are	  the	  host	  83	   immune	  defence	  system	  and	  the	  constant	  presence	  of	  antibiotics,	  then	  the	  adaptation	  and	  84	   evolution	  of	  P.	  aeruginosa	  should	  not	  differ	  significantly	  between	  the	  two	  groups	  of	  patients.	  85	   However,	  if	  the	  main	  selective	  pressure	  is	  the	  immediate	  environment	  comprising	  the	  86	   structure	  and	  composition	  of	  the	  mucus	  found	  in	  the	  airways,	  then	  the	  adaptation	  and	  87	   evolutionary	  pathways	  should	  differ	  significantly.	  The	  information	  provided	  by	  this	  study	  is	  of	  88	   paramount	  importance	  to	  resolve	  the	  basic	  questions	  of	  evolutionary	  drive	  in	  P.	  aeruginosa	  in	  89	   airway	  infections	  in	  both	  PCD	  and	  CF,	  and	  this	  knowledge	  may	  provide	  new	  insight	  and	  90	   considerations	  that	  may	  help	  form	  new	  effective	  treatment	  strategies	  for	  infections	  with	  P.	  91	  
aeruginosa.	  92	   	  93	   	  	  94	  
MATERIALS	  AND	  METHODS	  95	  
Patients	  96	   We	  included	  12	  patients	  with	  definitive	  PCD	  diagnosis based on presentation of the characteristic 97	  
clinical phenotype, ciliary ultrastructural defects visualized by electron microscopy, high speed 98	  
video recordings showing abnormal ciliary function and/or a genetic mutation recognized to cause 99	  
PCD [22].	  All	  patients	  were	  diagnosed	  and	  treated	  at	  the	  Danish	  PCD	  Centre,	  at	  Rigshospitalet	  100	   in	  Copenhagen.	  Patients	  are	  followed	  on	  a	  routine	  basis	  every	  three	  months,	  where	  a	  sputum	  101	  
sample	  is	  collected,	  and	  clinical	  data	  such	  as	  medication,	  height,	  weight,	  and	  lung	  function	  are	  102	   recorded.	  	  103	   	  104	  
Antibiotic	  treatment	  of	  patients	  105	   Chronic	  lung	  infection	  with	  P.	  aeruginosa	  is	  treated	  the	  same	  way	  in	  PCD	  and	  CF	  patients	  106	   [5,23].	  Treatment	  is	  initiated	  when	  a	  sample	  from	  the	  lower	  airways	  is	  positive	  for	  a	  relevant	  107	   pathogen,	  including	  instances	  where	  clinical	  symptoms	  are	  absent.	  Chronically	  infected	  108	   patients	  are	  treated	  with	  a	  combination	  of	  intravenous	  antibiotic	  therapy	  according	  to	  109	   susceptibility	  testing	  either	  with	  a	  broad-­‐spectrum	  beta-­‐lactam	  or	  a	  carbapenem	  together	  110	   with	  an	  aminoglycoside	  or	  a	  quinolone,	  every	  third	  month.	  	  111	   	  112	  
Clinical	  P.	  aeruginosa	  isolates	  113	   Isolation	  and	  identification	  of	  P.	  aeruginosa	  from	  sputum	  samples	  was	  carried	  out	  as	  114	   previously	  described,	  independent	  of	  underlying	  condition.	  In	  brief,	  sputum	  samples	  were	  115	   cultured	  at	  37°C	  on	  standard	  agar	  media	  for	  2	  to	  5	  days.	  The	  media	  included	  a	  Sabouraud	  116	   plate,	  a	  7%	  NaCl	  plate,	  a	  “blue	  plate”	  (modified	  Conradi	  Drigalski's	  medium)	  selective	  for	  117	   Gram-­‐negative	  rods	  and	  non-­‐selective	  media	  including	  5%	  Danish	  blood	  agar	  and	  chocolate	  118	   agar	  [24].	  Selected	  isolates	  were	  stored	  from	  PCD	  patients	  with	  chronic	  P.	  aeruginosa	  119	   infection.	  Chronic	  infection	  status	  was	  based	  on	  P.	  aeruginosa	  positive	  airway	  samples	  in	  120	   combination	  with	  elevated	  serum	  precipitating	  antibodies	  [5].	  	  	  	  121	   	  122	  
Genome	  sequencing	  and	  analysis	  of	  PCD	  isolates	  123	   Preparation	  of	  Genomic	  DNA	  from	  35	  longitudinally	  collected	  P.	  aeruginosa	  isolates	  from	  12	  124	   PCD	  patients	  and	  the	  sequence	  analysis,	  including	  clone	  type	  identification,	  was	  performed	  as	  125	   previously	  described	  [13].	  	  126	   The	  identification	  of	  significantly	  mutated	  genes	  was	  carried	  out	  using	  the	  same	  principles	  as	  127	   in	  Marvig	  et	  al.	  [13].	  All	  genes	  were	  considered	  separately	  dependent	  on	  their	  specific	  size	  128	   incorporating	  the	  random	  roulette	  theory	  of	  random	  mutation	  generation.	  We	  further	  limited	  129	   the	  number	  of	  significantly	  mutated	  genes	  by	  only	  including	  genes	  with	  a	  tenfold	  enrichment	  130	   as	  compared	  to	  the	  generated	  number	  of	  mutated	  clones.	  Also,	  genes	  had	  to	  be	  mutated	  in	  131	   more	  than	  two	  clone	  types,	  or	  mutated	  in	  exactly	  two	  clone	  types	  if	  we	  did	  not	  observe	  132	   mutation	  in	  more	  than	  one	  clone	  type	  as	  generated	  by	  the	  1000	  iterations.	  133	   	  134	  
Growth	  rate	  analysis	  135	   All	  isolates	  were	  picked	  from	  freezing	  stock	  and	  incubated	  directly	  in	  a	  96	  well	  plate	  with	  136	   100µl	  Luria	  Bertani	  (LB)	  broth,	  leaving	  the	  outer	  wells	  as	  blank.	  The	  plates	  were	  incubated	  at	  137	   37°C	  in	  a	  microtitter	  plate	  reader	  (Holm	  &	  Halby,	  BioTek	  Instruments	  Inc.,	  DK-­‐2605,	  model:	  138	   ELX808IU)	  with	  OD	  (600nm)	  readings	  every	  20	  minutes	  until	  all	  isolates	  had	  reached	  139	   stationary	  phase.	  The	  growth	  rates	  were	  calculated	  from	  the	  exponential	  part	  of	  the	  growth	  140	   curves,	  and	  all	  isolates	  were	  assayed	  with	  a	  minimum	  of	  three	  replicates	  and	  a	  maximum	  of	  141	   seven.	  142	   	  143	  
Motility	  assays	  144	  
Motility	  assays	  were	  performed	  on	  soft	  agar	  plates	  of	  LB	  medium	  (Twitching:	  1%	  agar,	  145	   Swimming:	  0.3%	  agar).	  Plates	  were	  inoculated	  from	  single	  colonies	  using	  sterile	  toothpicks	  146	   either	  by	  positioning	  the	  colony	  at	  the	  bottom	  of	  the	  plate	  (twitching)	  or	  in	  the	  middle	  of	  the	  147	   agar	  (swimming),	  both	  were	  incubated	  24	  hours	  at	  37°C.	  The	  swimming	  assay	  was	  carried	  out	  148	   in	  96	  well	  microtitter	  plates.	  A	  positive	  well	  was	  indicated	  by	  a	  turbid	  well,	  whereas	  a	  149	   negative	  was	  not	  turbid.	  All	  isolates	  were	  assayed	  with	  a	  minimum	  of	  three	  replicates	  and	  a	  150	   maximum	  of	  four.	  151	   	  152	  
Protease	  assay	  153	   Secreted	  protease	  production	  was	  assayed	  using	  LB	  agar	  (1%	  agar)	  and	  3%	  (w/vol)	  skimmed	  154	   milk.	  200µl	  agar	  was	  added	  to	  each	  well	  of	  a	  96	  well	  plate	  and	  after	  drying,	  a	  hole	  was	  made	  in	  155	   each	  well,	  where	  10µl	  supernatant	  of	  an	  overnight	  liquid	  culture	  (also	  grown	  in	  LB	  at	  37°C)	  156	   was	  deposited.	  After	  24h,	  wells	  were	  read	  as	  positive	  if	  the	  agar	  had	  become	  clear	  and	  157	   negative	  if	  not.	  All	  isolates	  were	  assayed	  with	  a	  minimum	  of	  five	  replicates	  and	  a	  maximum	  of	  158	   eight.	  159	   	  160	  
Attachment	  assay	  (Biofilm)	  161	   An	  overnight	  culture	  (also	  grown	  in	  LB	  at	  37°C)	  was	  diluted	  1:100	  wherefrom	  150µl	  was	  162	   added	  to	  each	  well	  in	  a	  96	  well	  plate	  and	  a	  start	  OD	  (600nm)	  was	  measured.	  The	  plates	  were	  163	   incubated	  at	  37°C,	  150rpm	  for	  24h	  and	  an	  end	  point	  OD	  (600nm)	  was	  measured.	  The	  culture	  164	   was	  removed	  and	  the	  plates	  washed	  three	  times	  in	  tab	  water,	  where	  after	  200µl	  0.01%	  crystal	  165	   violet	  was	  added	  to	  each	  well.	  After	  20	  min	  at	  room	  temperature	  (RT)	  the	  crystal	  violet	  was	  166	   removed	  and	  the	  plates	  was	  washed	  three	  times	  in	  tab	  water.	  200µl	  96%	  ethanol	  was	  added	  167	   to	  the	  wells	  and	  left	  for	  20	  min	  at	  240rpm	  at	  RT,	  where	  after	  the	  OD	  (620nm)	  was	  measured.	  	  168	   For	  all	  plates,	  none	  of	  the	  outer	  wells	  were	  used	  for	  isolate	  growth,	  and	  all	  plates	  had	  six	  169	   technical	  replicates	  of	  each	  isolate	  and	  six	  blanks	  (not	  counting	  the	  outer	  wells).	  All	  isolates	  170	   were	  assayed	  with	  a	  minimum	  of	  three	  biological	  replicates	  and	  a	  maximum	  of	  seven.	  	  171	   	  172	  
Accession	  codes	  173	   Sequence	  reads	  from	  all	  P.	  aeruginosa	  isolates	  have	  been	  deposited	  in	  the	  Sequence	  Read	  174	   Archive	  (SRA)	  under	  accession:	  Not	  deposited	  yet.	  	  175	   	  176	   	  177	  
RESULTS	  178	  
PCD	  isolate	  collection	  179	   In	  this	  study	  we	  have	  investigated	  41	  P.	  aeruginosa	  isolates	  longitudinally	  collected	  from	  12	  180	   PCD	  patients	  with	  chronic	  lung	  infections	  [15,16].	  	  The	  median	  age	  at	  the	  PCD	  diagnosis	  was	  181	   7.4	  years	  (range:	  0.0	  -­‐	  29.4).	  The	  median	  age	  of	  the	  patients	  at	  the	  time	  of	  diagnosis	  of	  chronic	  182	   lung	  infection	  was	  15.5	  years	  (range	  9	  –	  59	  years),	  and	  the	  median	  age	  at	  which	  we	  analysed	  183	   the	  first	  P.	  aeruginosa	  isolate	  was	  17.5	  years	  (range	  10-­‐	  62	  years).	  On	  average	  the	  patients	  184	   included	  in	  this	  study	  had	  the	  first	  P.	  aeruginosa	  cultured	  at	  12	  years	  of	  age	  (range	  4	  -­‐	  45).	  185	  
	  186	   To	  gain	  insight	  into	  the	  adaptation	  of	  P.	  aeruginosa	  to	  the	  airways	  of	  PCD	  patients,	  35	  187	   longitudinal	  isolates	  were	  whole	  genome	  sequenced	  and	  41	  longitudinal	  isolates	  were	  188	   phenotypically	  characterised.	  On	  average,	  we	  genome	  sequenced	  2.9	  isolates	  (range	  2-­‐5)	  per	  189	   patient	  with	  an	  average	  timespan	  of	  2.0	  years	  (range	  0.4-­‐3.6)	  (Figure	  1A),	  and	  phenotypically	  190	   analysed	  3.4	  isolates	  (range	  2-­‐6)	  per	  patient	  with	  an	  average	  timespan	  of	  2.4	  years	  (range	  0.4-­‐191	   4.8)	  (Figure	  1B).	  192	   	  193	  
Phylogeny	  of	  the	  PCD	  isolates	  194	   From	  the	  genomic	  analysis	  of	  the	  35	  isolates	  we	  were	  able	  to	  identify	  14	  distinct	  clone	  types,	  195	   five	  of	  these	  have	  previously	  been	  identified	  in	  CF	  patients:	  DK06,	  DK08,	  DK19,	  DK21,	  and	  196	   DK51	  [13].	  This	  suggests	  that	  there	  is	  no	  single	  clone	  type(s)	  specifically	  responsible	  for	  the	  197	   infections	  seen	  in	  either	  CF	  or	  PCD	  patients.	  It	  has	  previously	  been	  documented	  that	  clone	  198	   types	  can	  be	  transmitted	  between	  CF	  patients	  [13,25],	  and	  since	  the	  Copenhagen	  CF	  clinic	  is	  199	   located	  at	  the	  same	  hospital	  as	  the	  Danish	  PCD	  Centre	  this	  close	  proximity	  increases	  the	  risk	  200	   of	  patients	  being	  exposed	  to	  the	  same	  P.	  aeruginosa	  clone	  types:	  This	  may	  be	  caused	  by	  (1)	  201	   direct	  patient-­‐to-­‐patient	  transmission,	  (2)	  indirect	  transmission	  via	  environmental	  reservoirs	  202	   or	  reservoirs	  at	  the	  hospital,	  or	  (3)	  clone	  types	  common	  in	  the	  environment	  [26,27].	  	  203	   We	  investigated	  the	  possibility	  of	  direct	  patient-­‐to-­‐patient	  transmission	  by	  measuring	  the	  204	   genetic	  distance	  between	  the	  earliest	  isolates	  sequenced	  from	  CF	  [13]	  and	  PCD	  patients	  with	  205	   shared	  clone	  types,	  (Supplementary	  Table	  1).	  In	  all	  cases	  68	  SNPs	  or	  more	  separated	  the	  206	   isolate	  with	  shared	  clones	  making	  a	  recent	  transmission	  between	  patients,	  included	  in	  the	  207	   study,	  unlikely	  to	  have	  occurred,	  taking	  into	  account	  a	  within-­‐patient	  mutation	  rate	  of	  P.	  208	  
aeruginosa	  of	  around	  2.6	  SNPs/year,	  as	  found	  in	  CF	  [11].	  	  	  209	   The	  PCD	  patients	  included	  in	  this	  study	  have	  previously	  been	  shown	  to	  be	  infected	  with	  210	   independent	  clone	  types	  assessed	  by	  Pulsed-­‐field-­‐gel-­‐electrophoresis	  (PFGE),	  and	  10	  of	  the	  211	   12	  patients	  were	  found	  to	  be	  infected	  by	  a	  single	  primary	  clone	  type,	  whereas	  two	  patients	  212	   (P01	  and	  P06)	  have	  a	  possible	  clone	  type	  switch	  during	  the	  time	  of	  infection	  covered	  [5].	  The	  213	   whole	  genome	  sequencing	  of	  the	  same	  isolates	  supports	  these	  observations	  (Figure	  1A).	  214	   	  215	  
Genetic	  adaptation	  216	  
P.	  aeruginosa	  is	  known	  for	  its	  genetic	  and	  phenotypic	  plasticity	  as	  a	  microbe,	  as	  it	  can	  be	  217	   found	  in	  watery	  environments,	  soil,	  and	  human	  airways.	  Despite	  this	  large	  repertoire,	  the	  218	   roads	  of	  genotypic	  adaptation	  to	  the	  human	  airways	  of	  CF	  patients	  seem	  to	  be	  relatively	  219	   uniform.	  Previously,	  lists	  of	  genes	  that	  have	  been	  hit	  by	  mutation	  as	  a	  result	  of	  positive	  220	   selection	  during	  adaptive	  evolution,	  referred	  to	  here	  as	  “pathoadaptive	  genes”	  [11-­‐13,28]	  221	   have	  been	  published.	  Pathoadaptation	  is	  the	  adaptation	  of	  micro-­‐organisms	  to	  a	  host	  222	   environment	  through	  mutations,	  and	  includes	  both	  alterations	  and	  destructions	  of	  gene	  223	   functions.	  In	  CF	  it	  appears	  that	  bacteria	  with	  multiple	  mutations	  in	  “pathoadaptive	  genes”	  are	  224	   more	  resilient	  and	  more	  likely	  to	  persist	  in	  the	  host	  [11].	  225	  
	  226	   Since	  the	  mucociliary	  clearance	  is	  defective	  in	  both	  PCD	  and	  CF,	  many	  properties	  of	  the	  PCD	  227	   and	  CF	  airway	  environment	  are	  similar,	  including	  the	  slow	  sputum	  transportation	  [29],	  the	  228	   intensive	  antibiotic	  treatment,	  and	  the	  surrounding	  bacterial	  flora	  [5].	  Therefore,	  we	  would	  229	   expect	  the	  same	  genes	  to	  be	  hit	  by	  mutation	  during	  the	  course	  of	  colonisation	  and	  infection	  by	  230	  
P.	  aeruginosa	  in	  PCD	  and	  CF	  [11-­‐13,28].	  	  231	   To	  identify	  pathoadaptive	  genes	  in	  P.	  aeruginosa	  isolated	  from	  the	  PCD	  patients,	  we	  compared	  232	   the	  genomes	  of	  isolates	  from	  the	  PCD	  patients	  with	  the	  same	  clone	  type,	  a	  strategy	  reviewed	  233	   in	  [30],	  and	  identified	  mutations	  that	  had	  accumulated	  since	  the	  earliest	  isolate,	  in	  this	  case	  234	   representing	  the	  most	  recent	  common	  ancestor	  (MRCA).	  This	  was	  only	  possible	  for	  clone	  235	   types	  that	  were	  represented	  in	  the	  PCD	  collection	  with	  more	  than	  one	  isolate,	  thus	  excluding	  236	   clone	  type	  DK06,	  DK21,	  and	  DK54	  from	  this	  analysis.	  237	   	  238	   Pathoadaptive	  genes	  239	   In	  total	  we	  found	  417	  non-­‐synonymous	  mutations	  that	  accumulated	  in	  the	  recent	  240	   evolutionary	  history	  of	  the	  11	  clone	  types.	  To	  identify	  mutations	  relevant	  for	  the	  adaptation	  241	   to	  the	  PCD	  airways	  we	  sought	  to	  find	  genes	  mutated	  in	  parallel	  between	  the	  clone	  types.	  242	   These	  genes	  were	  identified	  using	  an	  extended	  method	  of	  that	  previously	  described	  [13].	  The	  243	   number	  of	  non-­‐synonymous	  mutations	  accumulated	  in	  each	  clonal	  lineage	  was	  used	  to	  244	   estimate	  the	  expected	  number	  of	  mutations	  to	  be	  found	  in	  each	  individual	  gene,	  depending	  on	  245	   the	  size	  of	  the	  gene.	  	  246	   We	  identified	  eight	  genes	  to	  be	  mutated	  more	  often	  than	  would	  be	  expected	  by	  random	  247	   distribution	  of	  mutations	  (Figure	  2	  A,	  Supplementary	  Table	  2).	  Of	  these	  eight	  genes,	  six	  have	  248	   previously	  been	  identified	  as	  pathoadaptive	  in	  the	  CF	  airways	  [11-­‐13]	  (Figure	  2	  B).	  The	  genes	  249	   found	  to	  be	  advantageously	  mutated	  in	  both	  CF	  and	  PCD	  are:	  mucA,	  algU,	  lasR,	  mexZ,	  mexS,	  250	   and	  mexA.	  The	  two	  genes	  not	  identified	  in	  the	  above	  mentioned	  pathoadaptive	  gene	  lists	  from	  251	   previous	  CF	  studies	  are:	  pilG	  and	  pscP.	  However,	  both	  genes	  have	  been	  identified	  as	  mutated	  252	   in	  CF	  populations	  of	  P.	  aeruginosa	  [13],	  and	  though	  pilG	  is	  not	  identified	  as	  pathoadaptive,	  253	   other	  pili-­‐processing	  genes	  such	  as	  pilQ	  and	  pilD	  have	  been	  recorded	  as	  pathoadaptive	  [13].	  254	   It	  should	  also	  be	  noted,	  that	  even	  though	  the	  genes	  lasR	  and	  mucA	  are	  not	  on	  the	  255	   pathoadaptive	  gene	  list	  of	  Marvig	  et	  al.	  [11],	  they	  were	  found	  to	  have	  been	  mutated	  in	  all	  256	   isolates;	  however,	  the	  mutations	  had	  happened	  decades	  before	  sampling	  of	  the	  first	  isolate.	  	  257	   It	  is	  important	  to	  note	  that	  of	  the	  eight	  pathoadaptive	  genes	  three	  are	  mutations	  in	  mex	  genes.	  258	   The	  mex	  genes	  encode	  efflux	  pumps	  that	  have	  been	  found	  to	  be	  important	  for	  the	  resistance	  259	   towards	  many	  antibiotics	  [31-­‐33].	  In	  20	  out	  of	  the	  35	  isolates	  we	  find	  mutations	  in	  one	  or	  260	   more	  of	  these	  mex	  genes.	  This	  indicates,	  like	  in	  CF,	  that	  a	  primary	  selection	  force	  is	  the	  261	   antibiotic	  pressure.	  	  262	   Two	  of	  the	  other	  pathoadaptive	  genes	  have	  previously	  been	  shown	  to	  be	  constrained	  by	  263	   historic	  contingency	  [13],	  which	  led	  us	  to	  investigate	  whether	  this	  is	  also	  the	  case	  in	  PCD.	  Six	  264	   isolates	  were	  found	  to	  carry	  mutations	  in	  both	  or	  one	  of	  the	  genes,	  and	  in	  only	  one	  case	  did	  265	   we	  find	  a	  mutation	  in	  algU	  without	  finding	  mutations	  in	  mucA	  (Supplementary	  Table	  3),	  and	  266	  
in	  this	  case	  it	  was	  a	  silent	  mutation.	  Otherwise	  four	  isolates	  had	  mutations	  in	  both	  genes,	  and	  267	   one	  had	  a	  mutation	  in	  only	  mucA.	  268	   	  269	  
Phenotypic	  adaptation	  270	   To	  investigate	  whether	  the	  genotypic	  overlap	  extended	  to	  a	  phenotypic	  overlap,	  we	  tested	  the	  271	   properties	  of	  the	  PCD	  isolates	  with	  regard	  to	  mucoidity,	  protease	  production,	  swimming	  and	  	  272	   twitching	  motility,	  generation	  time,	  and	  attachment	  (i.e.	  biofilm	  formation)	  (Figure	  1B,	  Figure	  273	   3,	  and	  Figure	  4).	  We	  found	  that	  none	  of	  the	  longitudinal	  isolates	  showed	  a	  clear	  pattern	  of	  274	   becoming	  mucoid,	  and	  only	  four	  out	  of	  the	  12	  patients	  seem	  to	  have	  populations	  that	  loose	  275	   swimming	  motility	  and	  the	  ability	  to	  produce	  protease.	  	  276	   With	  regard	  to	  biofilm	  we	  find	  that	  the	  earliest	  isolates	  from	  each	  patient	  compared	  to	  the	  277	   latest	  isolates	  remain	  equally	  capable	  of	  attachment	  and	  biofilm	  formation,	  only	  two	  patients’	  278	   isolates	  show	  significant	  change	  in	  this	  trait,	  towards	  an	  increase	  in	  biofilm	  production	  279	   (p<0.01	  and	  R2>0.8),	  Figure	  3.	  	  280	   Overall,	  the	  generation	  time	  does	  not	  seem	  to	  increase	  and	  we	  find	  a	  median	  generation	  time	  281	   of	  36.33	  (range:	  22-­‐104	  min)	  similar	  to	  wild	  type	  PAO1,	  found	  in	  this	  study	  to	  have	  a	  282	   generation	  time	  of	  29.69	  (1.82	  Standard	  deviation).	  Four	  patients	  showed	  significant	  changes	  283	   in	  generation	  time	  over	  the	  time	  of	  infection	  two	  increased	  (P05	  and	  P12)	  and	  two	  decreased	  284	   (P06	  and	  P07),	  p<0.05,	  R2>0.7.	  	  285	   These	  results	  are	  opposed	  to	  what	  has	  been	  shown	  for	  P.	  aeruginosa	  populations	  in	  CF	  286	   airways,	  where	  the	  hallmarks	  of	  advanced	  CF	  lung	  infection	  are:	  Increased	  mucoidity,	  287	   increased	  generation	  time,	  loss	  of	  protease	  production,	  loss	  of	  motility	  as	  well	  as	  loss	  of	  the	  288	   ability	  to	  attach	  to	  polystyrene[6,9,14,15,34,35],	  Table	  1.	  	  289	   	  290	   	  291	  
DISCUSSION	  292	   We	  hypothesised	  that	  if	  the	  main	  selective	  pressures	  in	  CF	  and	  PCD	  airways	  were	  the	  same,	  293	   we	  would	  see	  no	  difference	  between	  the	  genes	  mutated	  or	  in	  the	  phenotypic	  adaptive	  traits.	  294	   The	  main	  difference	  between	  the	  two	  environments	  is	  the	  composition	  of	  the	  airway	  mucus,	  295	   which	  is	  where	  the	  bacteria	  are	  known	  to	  be	  situated	  and	  proliferate.	  In	  CF	  the	  mucus	  has	  a	  296	   low	  NaCl	  osmolarity	  and	  high	  viscosity	  compared	  to	  the	  normal	  mucus	  in	  the	  PCD	  airway.	  	  By	  297	   genome	  sequencing	  35	  and	  phenotypically	  characterizing	  41	  P.	  aeruginosa	  isolates	  from	  PCD	  298	   patients,	  we	  have	  been	  able	  to	  identify	  both	  similarities	  and	  dissimilarities	  in	  the	  genotypic	  299	   and	  phenotypic	  adaptations	  between	  the	  two	  diseases.	  	  300	   We	  have	  found	  evidence	  of	  convergent	  molecular	  evolution	  in	  eight	  genes	  in	  isolates	  from	  301	   PCD	  patients,	  where	  all	  have	  previously	  been	  identified	  as	  mutated	  in	  P.	  aeruginosa	  isolates	  302	   from	  CF	  airways	  [13],	  and	  six	  have	  been	  found	  specifically	  important	  for	  the	  adaptation	  in	  CF	  303	   airways[11-­‐13].	  Thus,	  the	  genome	  sequences	  reflect	  similarity	  of	  the	  selective	  pressures	  304	   acting	  on	  the	  evolution	  and	  adaptation	  of	  P.	  aeruginosa	  in	  the	  airways	  of	  the	  two	  patient	  305	   groups.	  It	  is	  also	  important	  to	  note	  the	  absence	  of	  specific	  “PCD	  pathoadaptive	  genes”	  in	  this	  306	  
study,	  supporting	  the	  method	  used	  for	  the	  identification	  of	  pathoadaptive	  genes,	  as	  well	  as	  307	   underlines	  the	  similarities	  of	  selective	  pressures	  found	  in	  the	  two	  diseases.	  308	   This	  similarity	  of	  the	  genetic	  adaptation,	  together	  with	  the	  difference	  in	  sputum	  composition	  309	   indicates	  that	  the	  primary	  selective	  forces	  for	  the	  evolution	  of	  P.	  aeruginosa	  in	  the	  CF	  and	  PCD	  310	   airways	  are:	  (1)	  the	  pressure	  from	  the	  immune	  system,	  (2)	  competition	  with	  other	  microbes	  311	   in	  the	  airways,	  or	  (3)	  antibiotic	  treatments,	  since	  these	  are	  the	  common	  factors	  of	  the	  two	  312	   environments.	  	  313	   Surprisingly,	  and	  despite	  the	  similar	  genomic	  adaptation,	  the	  phenotypic	  traits	  of	  the	  PCD	  314	   isolates	  retained	  most	  of	  the	  P.	  aeruginosa	  wild	  type	  traits,	  such	  as	  being	  motile,	  producing	  315	   proteases,	  maintaining	  and	  in	  some	  cases	  increasing	  the	  ability	  to	  attach	  (producing	  biofilm),	  316	   and	  retain	  the	  growth	  rate	  as	  compared	  to	  PAO1,	  and	  what	  is	  found	  in	  CF[6].	  317	   This	  is	  consistent	  with	  a	  lower	  viscosity	  of	  the	  mucus	  of	  PCD	  patients	  compared	  to	  the	  CF	  318	   patients,	  making	  it	  possible	  for	  P.	  aeruginosa	  to	  move.	  This	  indicates	  that	  the	  loss	  of	  motility,	  319	   found	  in	  CF	  isolates	  over	  time,	  is	  not	  only	  an	  effect	  of	  the	  selective	  pressure	  from	  the	  host	  320	   immune	  defence	  [8],	  but	  also	  a	  question	  of	  the	  selective	  pressures	  from	  an	  environment	  of	  321	   highly	  viscous	  sputum	  that	  strongly	  inhibits	  the	  use	  of	  pili	  and	  flagella.	  The	  difference	  in	  322	   viscosity	  of	  the	  mucus	  is	  also	  a	  plausible	  explanation	  for	  the	  increased	  biofilm	  production,	  323	   where	  the	  mucus	  viscosity	  in	  CF	  might	  not	  require	  P.	  aeruginosa	  to	  produce	  its	  own	  324	   extracellular	  matrix;	  whereas	  in	  PCD,	  the	  lower	  degree	  of	  viscosity	  of	  the	  mucus	  necessitates	  325	  
P.	  aeruginosa	  to	  produce	  its	  own	  extracellular	  matrix.	  	  326	   This	  is	  also	  reflected	  by	  the	  results	  of	  attachment	  where	  the	  PCD	  isolates	  either	  remain	  status	  327	   quo	  or	  increase	  the	  biofilm	  formation	  over	  time,	  which	  is	  in	  opposition	  to	  the	  results	  found	  by	  328	   Lee	  et	  al.	  [14]	  for	  CF	  isolates	  which	  show	  decreased	  biofilm	  formation	  over	  the	  time	  of	  329	   infection.	  	  330	   To	  further	  support	  our	  theory,	  we	  find	  only	  a	  few	  patients	  with	  bacterial	  populations	  that	  331	   loose	  motility.	  According	  to	  O’Tool	  [36]	  loss	  of	  motility	  is	  linked	  to	  a	  decreased	  ability	  to	  332	   attach	  as	  compared	  to	  motile	  isolates,	  explaining	  the	  differences	  of	  attachment	  seen	  for	  PCD	  333	   and	  CF	  isolates.	  334	   It	  could	  be	  argued	  that	  the	  progression	  of	  chronic	  infection	  in	  PCD	  inhibits	  us	  from	  detecting	  335	   the	  adaptive	  change	  of	  phenotypic	  traits,	  as	  has	  been	  observed	  over	  time	  from	  initial	  336	   colonisation	  to	  chronic	  infection	  in	  CF	  patients.	  If	  this	  is	  the	  case,	  the	  lack	  of	  change	  cannot	  be	  337	   compared	  with	  the	  presence	  of	  change	  which	  has	  been	  found	  in	  CF.	  Still,	  with	  a	  median	  338	   generation	  time	  of	  36.33	  minutes	  this	  differs	  significantly	  (p<0.01,	  T-­‐test)	  from	  the	  63.11	  339	   minutes	  found	  by	  Markussen	  et	  al.	  [6]	  in	  CF	  patients	  chronically	  infected	  with	  the	  DK2	  clone	  340	   type	  (excluding	  early	  isolates	  from	  before	  1973),	  Figure	  4.	  	  341	   Also,	  with	  regard	  to	  protease	  production,	  bearing	  in	  mind	  the	  long	  persistence	  of	  chronic	  342	   infection	  in	  the	  included	  PCD	  patients,	  the	  isolates	  still	  produce	  protease.	  Whereas	  this	  trait	  343	   has	  been	  shown	  to	  be	  lost	  in	  CF	  [6,15].	  344	   A	  reason	  for	  the	  observed	  differences	  in	  growth	  rate	  and	  protease	  production	  between	  CF	  and	  345	   PCD	  isolates	  might	  be	  the	  ability	  to	  move	  within	  the	  environment,	  which	  affect	  these	  346	   properties.	  Due	  to	  preserved	  motility	  the	  bacteria	  are	  not	  limited	  to	  the	  nutrients	  in	  close	  347	  
proximity,	  but	  can	  “invade”	  new	  niches	  when	  necessary.	  In	  this	  way	  they	  increase	  the	  348	   available	  nutrients	  and	  thus	  do	  not	  limit	  the	  growth	  in	  the	  same	  degree	  as	  in	  CF	  airways,	  349	   where	  the	  bacteria	  probably	  are	  more	  stationary.	  This	  “re-­‐infection”	  of	  new	  niches	  might	  also	  350	   be	  what	  causes	  the	  ability	  to	  produce	  proteases	  to	  linger.	  This	  ability	  is	  known	  to	  be	  present	  351	   and	  possibly	  advantageous	  in	  newly	  infecting	  isolates	  of	  P.	  aeruginosa	  [16]	  and	  thereby	  might	  352	   aid	  the	  invasion	  of	  new	  niches	  of	  the	  PCD	  airways.	  353	   It	  is	  worth	  noticing,	  that	  PCD	  patients	  in	  many	  cases	  can	  clear	  the	  chronic	  P.	  aeruginosa	  354	   infection	  [5].	  This	  stands	  in	  contrast	  to	  CF,	  where	  clearance	  is	  rarely	  achieved.	  Clearance	  may	  355	   favour	  re-­‐colonisation	  with	  wild	  type	  environmental	  isolates	  and	  thus	  explain	  the	  phenotypic	  356	   differences	  found	  in	  this	  study	  between	  PCD	  and	  CF	  isolates.	  However,	  this	  is	  contradictory	  to	  357	   the	  genetic	  adaptations	  identified	  in	  this	  study	  suggesting	  that	  the	  phenotypic	  changes	  found	  358	   in	  the	  PCD	  isolates	  are	  primarily	  caused	  by	  genotypic	  adaptation	  and	  mutation	  accumulation	  359	   rather	  than	  phenotypic	  acclimation,	  indicating	  that	  sufficient	  time	  for	  genetic	  adaptation	  has	  360	   passed.	  361	   	  362	   	  363	  
CONCLUSION	  364	   Our	  results	  indicate	  that	  while	  in	  the	  CF	  airways	  the	  isolates	  quickly	  adapt	  to	  the	  lung	  365	   environment	  by	  losing	  several	  phenotypic	  traits	  the	  isolates	  from	  PCD	  airways,	  seemingly,	  366	   have	  an	  advantage	  if	  they	  retain	  their	  wild	  type-­‐like	  phenotype,	  this	  despite	  of	  the	  similarity	  367	   of	  genes	  that	  are	  mutated	  and	  identified	  as	  important	  for	  the	  colonisation	  and	  infection	  in	  368	   both	  disease	  entities.	  	  369	   These	  similarities	  and	  specifically	  the	  dissimilarities	  between	  the	  two	  environments	  are	  370	   important	  for	  the	  understanding	  of	  the	  evolution	  of	  P.	  aeruginosa.	  The	  discontinuity	  of	  371	   genotype	  -­‐	  phenotype,	  reveals	  a	  gap	  in	  the	  understanding	  of	  the	  evolution	  of	  P.	  aeruginosa	  to	  372	   the	  human	  airways,	  and	  speaks	  of	  an	  evolution	  that	  in	  particular	  is	  characterised	  by	  a	  373	   complex	  web	  of	  adaptational	  roads	  towards	  a	  common	  goal,	  -­‐chronic	  infection	  of	  the	  airways.	  374	   However,	  the	  convergence	  of	  genotypic	  adaptation	  found	  between	  CF	  and	  PCD	  reveals	  a	  375	   common	  selective	  pressure	  of	  antibiotic	  treatments,	  which	  might	  by	  further	  investigations	  376	   reveal	  new	  possibilities	  for	  treatment	  of	  P.	  aeruginosa	  infections.	  377	   	  378	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Figure	  1:Patient	  and	  isolate	  overview.	  (A)	  Genotypic	  characterisation.	  ”First	  PA”	  shows	  the	  491	   year	  the	  patients	  had	  the	  first	  culture	  of	  P.	  aeruginosa.	  When	  a	  year	  is	  noted	  on	  the	  grey	  bar	  492	   (indicating	  chronicity	  of	  the	  patients)	  this	  is	  the	  year	  when	  the	  patient	  was	  diagnosed	  as	  493	   chronically	  infected.	  Isolates	  denoted	  by	  ”X”	  was	  not	  sequenced.	  (B)	  Phenotypic	  494	   characterisation.	  Here	  the	  phenotypic	  characters	  are	  shown	  for	  41	  isolates	  sampled	  at	  the	  495	   same	  time	  points	  as	  indicated	  by	  isolates	  in	  (A).	  When	  phenotypic	  boxes	  are	  close	  together	  496	   they	  were	  sampled	  from	  the	  same	  sputum	  sample	  (se	  sub-­‐figure	  (A)).	  A	  grey	  box	  indicates	  an	  497	   uncharacterisable	  phenotype	  (N/A),	  white	  indicates	  the	  absense	  of	  a	  phenotype,	  and	  coloured	  498	   boxes	  indicate	  the	  presence	  of	  a	  phenotype.	  	  499	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Figure	  2:	  Genes	  mutated	  in	  more	  clones	  than	  would	  be	  expected	  by	  genetic	  drift	  (p-­‐501	  
values	  <	  0.0001).	  (A)	  Overview	  of	  the	  number	  of	  clones	  observed	  to	  be	  mutated	  in	  each	  gene,	  502	   and	  the	  enrichment	  of	  clones	  mutated	  in	  relation	  to	  expected	  	  (B)	  Overlap	  of	  the	  genes	  found	  503	   important	  for	  the	  adaptation	  of	  P.	  aeruginosa	  to	  the	  PCD	  airways,	  and	  gees	  found	  important	  504	   for	  the	  adaptation	  to	  CF	  airways	  in	  three	  other	  studies:	  Smith	  (2006),	  Marvig	  (2013),	  and	  505	   Marvig	  (2015).	  506	   	  507	   	  508	  
	  509	  
Figure	  3:	  Attachement	  assay.	  (A)	  Barplot	  of	  the	  first	  and	  last	  isolate	  from	  each	  patient	  510	   (Figure	  1),	  including	  PAO1	  as	  control,	  *	  p<0.01	  and	  R2>0.8,	  Linear	  regression	  with	  Bonferroni	  511	   correction	  for	  multiple	  testing.	  Errorbars:	  Standard	  error	  of	  the	  mean	  (SEM)	  (SD/sqrt(n),	  n=	  512	   number	  of	  samples).	  (B)	  Overall	  view	  of	  the	  tendency	  of	  the	  isolates	  to	  either	  remains	  status	  513	   quo	  with	  regard	  to	  biofilm	  production	  or	  increase.	  	  514	   	  515	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Figure	  4:	  Generation	  time.	  Growth	  data	  from	  the	  twelve	  PCD	  patients.	  *	  and	  red	  bold	  patient	  517	   IDs	  denote	  p<0.05	  and	  R2	  >0.69,	  Linear	  regression	  with	  Bonferroni	  	  correction	  for	  multiple	  518	   testing.	  	  519	   	  520	  
Table	  1:	  Phenotypic	  hallmarks	  of	  chronic	  lung	  infection	  with	  P.	  aeruginosa	  in	  patients	  with	  521	   cystic	  fibrosis	  compared	  with	  primary	  ciliary	  dyskinesia.	  	  522	   	  523	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Supplementary	  Table	  S1
DK06 Patient P44F5 P21F4 P99F4 P77F4
Patient Isolate	  êè 35 294 390 398
P1 PCD-­‐25 1322 102 109 102
DK08 Patient P88M4 P73M4
Patient Isolate	  êè 66 351
P08 PCD-­‐03 534 220
DK19 Patient P41M3 P70F4 P72F4 P55M4
Patient Isolate	  êè 156 338 346 415
P2 PCD-­‐05 68 509 573 575
DK21 Patient P22M4
Patient Isolate	  êè 182
P06 PCD-­‐01 107
DK51 Patient P99F4
Patient Isolate	  êè 388
P05 PCD-­‐08 165
DK60 Patient P07
Patient Isolate	  êè PCD-­‐33
P06 PCD-­‐31 882
Minimum	  distance	  between	  shared	  clones	  (#	  SNPs)
68
Maximum	  distance	  between	  shared	  clones	  (#	  SNPs)
1322
Average	  distance	  between	  shared	  clones	  (#	  SNPs)
405.2
Distance	  (number	  of	  SNPs)	  between	  initial	  isolates	  of	  shared	  clone	  types,	  from	  both	  PCD	  and	  CF	  
patients.
Supplementary	  Table	  S2
Genes	  of	  PAO1,	  the	  number	  of	  clones	  observed	  to	  be	  mutated	  and	  expected	  number	  of	  clones	  mutated,	  for	  significantly	  mutated	  genes.
Gene_ID PA2020 PA0762 PA0763 PA0425 PA1695 PA0408 PA1430 PA2491
Gene	  name mexZ algU mucA mexA pscP pilG lasR mexS
Observed	  number	  of	  clones	  mutated	  in	  gene 6 4 4 4 3 2 2 2
Expected	  number	  of	  clones	  mutated	  in	  gene	  (minimum) 0 0 0 0 0 0 0 0
Expected	  number	  of	  clones	  mutated	  in	  gene	  (maximum) 1 1 2 2 2 1 1 1
Expected	  number	  of	  clones	  mutated	  in	  gene	  (variance) 2.35 1.41 1.89 5.70 5.85 1.26 2.97 5.85
Expected	  number	  of	  clones	  mutated	  in	  gene	  (average) 0.05 0.04 0.04 0.08 0.08 0.04 0.06 0.08
Average	  enrichment 122 105 91 53 39 56 36 26
Probality	  of	  observation	  if	  random	  drift	  [P(Z≥Y)	  ~	  pois(Z;	  Y)] 1.29E-­‐13 6.40E-­‐10 1.32E-­‐09 1.98E-­‐08 1.38E-­‐06 7.57E-­‐06 2.66E-­‐05 7.18E-­‐05
Function
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Suplementary	  Table	  S3:
Historic	  contingencies	  of	  mutations	  in	  mucA	  and	  algU.
Patient Isolate	  No. Internal	  ref.	  Number Date	  of	  isolation mucA algU
P01 25 1809_11 10/01/11
P01 14 3517_12 16/01/12
P01 13 312_1_14 20/01/14
P02 36 44994_09 30/08/09
P02 33 2806_11 16/01/11
P03 31 54878B_10 26/10/10 1(nonsense) 1(missense)
P03 3 54878A_10 26/10/10
P03 5 9983_2_11 22/02/11
P03 4 13713_12 07/03/12
P04 29 6704B_09 01/02/09
P04 23 6704A_09 01/02/09
P04 41 66002B_11 07/12/11 1 1
P04 6 66002A_11 07/12/11 1
P04 34 45477_12 20/08/12
P05 1 2141_11 28/08/11
P05 2 2764_12 11/01/12
P05 7 3541_13 23/08/13
P06 10 57224_11 26/10/11
P06 11 12277_12 28/02/12
P06 35 13904_12 07/03/12
P07 40 10118_10 22/02/10
P07 9 18506_12 28/03/12
P08 37 3149_09 16/01/09
P08 22 56781_10 06/11/10
P08 18 8523_1_11 18/02/11
P08 26 8523_2_11 18/02/11
P08 27 10624_12 19/02/12 1(missense) 1(missense)
P09 32 53051_09 15/10/09 1* 1(missense)
P09 8 60945_10 26/11/10
P09 15 51838_3_11 04/10/11
P09 17 22943_3_11 18/04/12 1(silent)
P09 39 22943_1_11 18/04/12
P09 16 3228_14 20/08/14
P10 38 55545_11 17/10/11
P10 30 18012_12 26/03/12
P11 12 59511_10 18/11/10
P11 21 37392_12 02/07/12
P11 19 3649_14 16/09/14
P12 28 4223_09 21/01/09
P12 20 1037_11 06/01/11
P12 24 3362_12 06/01/12
1	  =	  mutation	  found	  in	  gene,	  if	  not	  insertion	  or	  deletion	  the	  mutation	  is	  written	  in	  parenthesis,	  
mis=missense,	  non=nonsense,	  and	  silent.	  *=also	  contains	  a	  silent	  SNP.
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